



**EMORY UNIVERSITY**  
Consolidated Financial Statements, and OMB Circular A-133 Reports and  
Related Information

August 31, 2015

(With Independent Auditors' Reports Thereon)

# EMORY UNIVERSITY

## Table of Contents

	<b>Page(s)</b>
Independent Auditors' Report	1–2
Consolidated Financial Statements and Supplementary Schedules – Years ended August 31, 2015 and 2014	3–50
Supplementary Schedule of Expenditures of Federal Awards – Year ended August 31, 2015	51–78
Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards – Year ended August 31, 2015	79
Notes to Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards	80–81
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	82–83
Independent Auditors' Report on Compliance for Each Major Program; Report on Internal Control Over Compliance; and Report on Schedules of Expenditures of Federal Awards Required by OMB Circular A-133	84–85
Schedule of Findings and Questioned Costs	86



**KPMG LLP**  
Suite 2000  
303 Peachtree Street, N.E.  
Atlanta, GA 30308-3210

## **Independent Auditors' Report**

The Board of Trustees  
Emory University:

### **Report on the Consolidated Financial Statements**

We have audited the accompanying consolidated financial statements of Emory University and subsidiaries (Emory University), which comprise the consolidated statements of financial position as of August 31, 2015 and 2014, the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the consolidated financial statements.

### ***Management's Responsibility for the Consolidated Financial Statements***

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

### ***Auditors' Responsibility***

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### ***Opinion***

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Emory University as of August 31, 2015 and 2014, and the changes in its net assets and its cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.



### ***Supplementary Information***

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The supplementary information included in Schedules 1 through 3 is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

### ***Other Reporting Required by Government Auditing Standards***

In accordance with *Government Auditing Standards*, we have also issued our report dated December 18, 2015 on our consideration of Emory University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Emory University's internal control over financial reporting and compliance.

**KPMG LLP**

December 18, 2015

**EMORY UNIVERSITY**  
**CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**  
*August 31, 2015 and August 31, 2014*  
*(Dollars in thousands)*

	<u>August 31, 2015</u>	<u>August 31, 2014</u>
<b>ASSETS:</b>		
Cash and cash equivalents	\$ 607,163	\$ 557,248
Patient accounts receivable, net	367,433	342,011
Student accounts receivable, net	46,715	51,220
Loans receivable, net	28,411	28,467
Contributions receivable, net	92,724	135,667
Other receivables, net	241,639	240,351
Prepaid expenses, deferred charges and other assets	264,591	241,942
Investments	6,842,183	7,031,316
Interests in perpetual funds held by others	1,071,531	1,130,063
Property and equipment, net	2,883,412	2,852,580
<b>Total assets</b>	<b>\$ 12,445,802</b>	<b>\$ 12,610,865</b>
<b>LIABILITIES AND NET ASSETS:</b>		
Accounts payable and accrued liabilities	\$ 473,188	\$ 416,835
Liability for derivative instruments	176,791	150,495
Interest payable	28,955	29,817
Annuities payable	17,073	17,821
Bonds, notes and mortgages payable	1,914,808	1,955,399
Accrued liabilities for benefit obligations and professional liabilities	515,625	456,447
Deferred tuition and other revenue	440,272	426,661
Funds held in trust for others	645,996	643,902
Government advances for federal loan programs	17,834	17,802
<b>Total liabilities</b>	<b>4,230,542</b>	<b>4,115,179</b>
Unrestricted net assets:		
Net assets controlled by Emory	3,428,363	3,506,297
Net assets related to noncontrolling interests	78,344	66,580
<b>Total unrestricted net assets</b>	<b>3,506,707</b>	<b>3,572,877</b>
Temporarily restricted net assets	2,807,376	3,005,261
Permanently restricted net assets	1,901,177	1,917,548
<b>Total net assets</b>	<b>8,215,260</b>	<b>8,495,686</b>
<b>Total liabilities and net assets</b>	<b>\$ 12,445,802</b>	<b>\$ 12,610,865</b>

See accompanying notes to consolidated financial statements.

# EMORY UNIVERSITY

## CONSOLIDATED STATEMENT OF ACTIVITIES

Year Ended August 31, 2015 (with summarized financial information for the year ended 2014)

(Dollars in thousands)

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total August 31, 2015	Total August 31, 2014
<b>OPERATING REVENUES:</b>					
Tuition and fees	\$ 617,826	-	-	\$ 617,826	\$ 592,385
Less: Scholarship allowances	(221,694)	-	-	(221,694)	(215,434)
Net tuition and fees	396,132	-	-	396,132	376,951
Endowment spending distribution	165,880	-	-	165,880	157,174
Distribution from perpetual funds	32,490	-	-	32,490	29,979
Other investment income designated for current operations	41,266	-	-	41,266	37,477
Gifts and contributions	49,520	-	-	49,520	50,606
Grants and contracts	372,791	-	-	372,791	365,653
Indirect cost recoveries	113,945	-	-	113,945	110,516
Net patient service revenue	2,706,682	-	-	2,706,682	2,549,902
Medical services	267,327	-	-	267,327	234,855
Sales and services of auxiliary enterprises	71,743	-	-	71,743	68,850
Independent operations	22,006	-	-	22,006	20,543
Other revenue	167,254	-	-	167,254	124,509
Net assets released from restrictions	11,371	(5,030)	-	6,341	3,648
<b>Total operating revenues</b>	<b>4,418,407</b>	<b>(5,030)</b>	<b>-</b>	<b>4,413,377</b>	<b>4,130,663</b>
<b>OPERATING EXPENSES:</b>					
Salaries and fringe benefits	2,687,359	-	-	2,687,359	2,543,034
Student financial aid	11,699	-	-	11,699	11,297
Supplies and pharmaceuticals	657,482	-	-	657,482	595,640
Professional fees and purchased services	408,839	-	-	408,839	361,610
Other operating expenses	275,563	-	-	275,563	298,802
Interest on indebtedness	79,490	-	-	79,490	78,267
Depreciation	232,401	-	-	232,401	226,052
<b>Total operating expenses</b>	<b>4,352,833</b>	<b>-</b>	<b>-</b>	<b>4,352,833</b>	<b>4,114,702</b>
<b>NET OPERATING REVENUES/(EXPENSES):</b>	<b>65,574</b>	<b>(5,030)</b>	<b>-</b>	<b>60,544</b>	<b>15,961</b>
<b>NONOPERATING ACTIVITIES:</b>					
Investment return (less than) in excess of spending distribution for current operations	(136,661)	(171,080)	1,934	(305,807)	733,610
Change in undistributed income from perpetual funds held by others	-	-	(58,532)	(58,532)	95,939
Gifts and contributions	552	21,978	40,435	62,965	110,110
Net assets released from restrictions	36,298	(42,639)	-	(6,341)	(3,648)
Loss on disposal of property and equipment	(4,230)	-	-	(4,230)	(4,346)
Change in fair value of derivative instruments	(26,296)	-	-	(26,296)	(49,673)
Pension and postretirement benefit plans	(23,064)	-	-	(23,064)	(34,092)
Other nonoperating items, net	21,657	(1,114)	(208)	20,335	18,465
<b>Total nonoperating activities</b>	<b>(131,744)</b>	<b>(192,855)</b>	<b>(16,371)</b>	<b>(340,970)</b>	<b>866,365</b>
<b>CHANGE IN NET ASSETS</b>	<b>(66,170)</b>	<b>(197,885)</b>	<b>(16,371)</b>	<b>(280,426)</b>	<b>882,326</b>
Less change in net assets related to noncontrolling interests	11,764	-	-	11,764	2,615
<b>CHANGE IN NET ASSETS CONTROLLED BY EMORY</b>	<b>\$ (77,934)</b>	<b>\$ (197,885)</b>	<b>\$ (16,371)</b>	<b>\$ (292,190)</b>	<b>\$ 879,711</b>

See accompanying notes to consolidated financial statements

**EMORY UNIVERSITY**  
**CONSOLIDATED STATEMENT OF ACTIVITIES**

Year ended August 31, 2014

(Dollars in thousands)

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total August 31, 2014
<b>OPERATING REVENUES:</b>				
Tuition and fees	\$ 592,385	-	-	\$ 592,385
Less: Scholarship allowances	(215,434)	-	-	(215,434)
Net tuition and fees	376,951	-	-	376,951
Endowment spending distribution	157,174	-	-	157,174
Distribution from perpetual funds	29,979	-	-	29,979
Other investment income designated for current operations	37,477	-	-	37,477
Gifts and contributions	50,606	-	-	50,606
Grants and contracts	365,653	-	-	365,653
Indirect cost recoveries	110,516	-	-	110,516
Net patient service revenue	2,549,902	-	-	2,549,902
Medical services	234,855	-	-	234,855
Sales and services of auxiliary enterprises	68,850	-	-	68,850
Independent operations	20,543	-	-	20,543
Other revenue	124,509	-	-	124,509
Net assets released from restrictions	7,412	(3,764)	-	3,648
<b>Total operating revenues</b>	<b>4,134,427</b>	<b>(3,764)</b>	<b>-</b>	<b>4,130,663</b>
<b>OPERATING EXPENSES:</b>				
Salaries and fringe benefits	2,543,034	-	-	2,543,034
Student financial aid	11,297	-	-	11,297
Supplies and pharmaceuticals	595,640	-	-	595,640
Professional fees and purchased services	361,610	-	-	361,610
Other operating expenses	298,802	-	-	298,802
Interest on indebtedness	78,267	-	-	78,267
Depreciation	226,052	-	-	226,052
<b>Total operating expenses</b>	<b>4,114,702</b>	<b>-</b>	<b>-</b>	<b>4,114,702</b>
<b>NET OPERATING REVENUES/(EXPENSES):</b>	<b>19,725</b>	<b>(3,764)</b>	<b>-</b>	<b>15,961</b>
<b>NONOPERATING ACTIVITIES:</b>				
Investment return in excess of spending distribution for current operations	332,560	389,415	11,635	733,610
Change in undistributed income from perpetual funds held by others	-	-	95,939	95,939
Gifts and contributions	5,160	73,250	31,700	110,110
Net assets released from restrictions	28,305	(31,953)	-	(3,648)
Loss on disposal of property and equipment	(4,346)	-	-	(4,346)
Change in fair value of derivative instruments	(49,673)	-	-	(49,673)
Pension and postretirement benefit plans	(34,092)	-	-	(34,092)
Other nonoperating items, net	18,134	540	(209)	18,465
<b>Total nonoperating activities</b>	<b>296,048</b>	<b>431,252</b>	<b>139,065</b>	<b>866,365</b>
<b>CHANGE IN NET ASSETS</b>	<b>315,773</b>	<b>427,488</b>	<b>139,065</b>	<b>882,326</b>
Less change in net assets related to noncontrolling interests	2,615	-	-	2,615
<b>CHANGE IN NET ASSETS CONTROLLED BY EMORY</b>	<b>\$ 313,158</b>	<b>\$ 427,488</b>	<b>\$ 139,065</b>	<b>\$ 879,711</b>

See accompanying notes to consolidated financial statements

**EMORY UNIVERSITY**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**

Years Ended August 31, 2015 and 2014

(Dollars in thousands)

	<u>2015</u>	<u>2014</u>
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Change in net assets	\$ (280,426)	\$ 882,326
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Net assets acquired in formation of Emory Rehabilitation Hospital	-	(4,125)
Gain on formation of the Emory Rehabilitation Hospital	-	(949)
Capital contributions from noncontrolling interests	(13,677)	(20,550)
Gifts and contributions for endowment and capital projects	3,794	(33,850)
Net realized gains on sale of investments	(281,593)	(416,749)
Net unrealized loss (gains) on investments	437,738	(531,231)
Loss on disposal of property and equipment	4,230	4,346
Interests in perpetual funds held by others	58,532	(95,939)
Depreciation and amortization	231,744	225,422
Provision for uncollectible patients accounts receivable	189,154	138,148
Accretion/amortization of bond discounts/premiums	(1,878)	(3,411)
Actuarial adjustments for retiree pension and benefit plans	23,064	24,892
Change in fair value of derivative instruments	26,296	49,673
Gifts of securities and other assets	(7,910)	(19,785)
Increase in operating assets, net of effects from FY 2014 formation of Emory Rehabilitation Hospital:		
Accounts and other receivables, net	(211,359)	(167,457)
Contributions receivable for operations	(10,068)	(45,512)
Prepaid expenses, deferred charges and other assets	(15,293)	(13,248)
Increase in operating liabilities:		
Accounts payable, accrued liabilities and interest payable	40,268	5,636
Accrued liabilities for benefit obligations and professional liabilities	36,114	30,385
Deferred tuition and other revenue	13,611	19,794
<b>Net cash provided by operating activities</b>	<u><b>242,341</b></u>	<u><b>27,816</b></u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Disbursements for loans to students	(4,863)	(6,239)
Repayment of loans from students	4,919	4,494
Proceeds from sales and maturities of investments	22,494,607	15,185,014
Purchases of investments	(22,453,709)	(15,047,139)
Cash received in formation of Emory Rehabilitation Hospital	-	1,083
Purchases of property, plant and equipment	(252,240)	(304,098)
Increase in deposits held in custody for others	2,094	112,366
<b>Net cash used in investing activities</b>	<u><b>(209,192)</b></u>	<u><b>(54,519)</b></u>

(Continued)



**EMORY UNIVERSITY**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**

*Years Ended August 31, 2013 and 2012*

*(Dollars in thousands)*

	<u>2015</u>	<u>2014</u>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Gifts and contributions for endowment and capital projects	49,218	134,687
Proceeds from bonds and mortgages payable	-	28,300
Principal repayments of bonds and mortgages payable	(38,713)	(62,497)
Required posting of collateral	(6,700)	(600)
(Decrease) increase in annuities payable	(748)	120
Increase in government advances for federal loan programs	32	38
Capital contributions from noncontrolling interests	13,677	20,550
	<hr/>	<hr/>
<b>Net cash provided by financing activities</b>	<b>16,766</b>	<b>120,598</b>
	<hr/>	<hr/>
<b>Net increase in cash and cash equivalents</b>	<b>49,915</b>	<b>93,895</b>
<b>Cash and cash equivalents at beginning of year</b>	<b>557,248</b>	<b>463,353</b>
	<hr/>	<hr/>
<b>Cash and cash equivalents at end of year</b>	<b><u>\$ 607,163</u></b>	<b><u>\$ 557,248</u></b>
Supplemental disclosure:		
Cash paid for interest	\$ 82,769	\$ 79,263
Accounts payable attributable to property, plant and equipment purchases	15,223	13,352
Income taxes paid, net	368	242
Pledge payments received in form of securities and immediately sold	28,000	80,000

See accompanying notes to consolidated financial statements.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

#### (1) Organization

Emory University (the University or Emory) is a private, coeducational, not-for-profit institution, located in Atlanta, Georgia. Founded in 1836, Emory owns and operates educational, research and healthcare facilities to support its mission. Emory provides educational services to approximately 7,800 undergraduate students and 6,700 graduate and professional students within its nine schools and colleges. Included within the University is the Emory Healthcare system, Emory Medical Care Foundation (EMCF) and Emory Innovations, LLC.

The Emory Healthcare system (Emory Healthcare) consists of Emory Healthcare, Inc. (EHC), Emory University Hospital Midtown (EUHM), Emory University Hospital (EUH), EHCA Johns Creek Hospital, LLC (EJCH), Emory Saint Joseph's Hospital (ESJH), Saint Joseph's Translational Research Institute (SJTRI) d/b/a T3 Laboratories (T3), The Emory Clinic, Inc. (TEC), Emory Specialty Associates, LLC (ESA), Emory Specialty Associates – Joint Operating Company (ESA-JOC), Wesley Woods Center of Emory University, Inc. (WWC), Emory Rehabilitation Hospital (ERH) and Clifton Casualty Insurance Company, Ltd. (CCIC). Emory Healthcare is in the process of legally dissolving WWC and expects that process to be completed during fiscal 2016.

The consolidated financial statements include the University and all other entities in which Emory has significant financial interest and control. All significant interentity accounts and transactions have been eliminated in consolidation.

Emory University Hospital, Emory University Hospital Midtown, EHCA Johns Creek Hospital, LLC, and Emory Saint Joseph's Hospital are sometimes referred to herein as "the Hospitals."

Effective July 1, 2014, Emory Healthcare contributed certain assets and liabilities to a limited liability company under the name of ES Rehabilitation, LLC (ES Rehab), formed together with Select Medical Corporation (SMC), in exchange for a 51% controlling membership interest in ES Rehab. ES Rehab is also known as Emory Rehabilitation Hospital (ERH).

#### (2) Summary of Significant Accounting Policies

The following significant accounting policies are used in the preparation of the accompanying consolidated financial statements:

The consolidated financial statements have been prepared on the accrual basis in conformity with U.S. generally accepted accounting principles (GAAP).

Net assets and revenues, gains and losses are classified based on the existence or absence of externally imposed restrictions. Accordingly, net assets of the University are classified and reported as follows:

*Unrestricted Net Assets* – Net assets that are not subject to donor imposed stipulations. Certain unrestricted net assets are designated for specific purposes or uses under various internal operating and administrative arrangements of the University.

*Temporarily Restricted Net Assets* – Net assets that are subject to donor imposed stipulations that will be met either by actions of the University and/or the passage of time.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

*Permanently Restricted Net Assets* – Net assets that are subject to donor imposed restrictions that the University maintains permanently. Generally, the donors of these assets permit the University to use all or part of the income earned and net appreciation on related investments for general or specific purposes.

Revenues are reported as increases in unrestricted net assets unless their use is limited by donor-imposed restrictions. Expenses are reported as decreases in unrestricted net assets. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in unrestricted net assets unless their use is restricted by explicit donor stipulation or by law. Expirations of restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from restrictions and shown as reclassifications between the applicable classes of net assets.

Income and realized and unrealized gains on investments of permanently donor-restricted endowment net assets are reported as follows:

- As increases in permanently restricted net assets if the terms of the gift require that they be added to the principal of a permanent endowment fund.
- As increases in temporarily restricted net assets until appropriated for expenditure by the University and/or donor restrictions are met.

**(a) *Cash Equivalents***

Cash equivalents consist primarily of short-term money market mutual funds and treasury bills with original maturities of 90 days or less that are not invested as part of the long-term investment assets. These amounts are carried at cost, which approximates fair value. Cash and cash equivalents that are part of the long-term pool are shown within investments as those funds generally are not used for daily operating purposes.

**(b) *Contributions Receivable***

Contributions of assets other than cash are recorded at their estimated fair value at the date of the gift. Contributions to be received after one year, net of an allowance for uncollectible amounts, are discounted to their present value at a risk-adjusted rate. Amortization of discounts is recorded as additional contribution revenue. An allowance for uncollectible contributions receivable is provided based upon management's judgment, considering such factors as prior collection history, type of contribution, relationship with donor, and other relevant factors.

**(c) *Loans Receivable, Net***

Emory-funded loans to students are carried at estimated net realizable value. Loans receivable from students under certain governmental loan programs, carried at cost, can only be assigned to the federal government or its designees. In addition to Federal Direct Loans which are not reported in the financial statements, loans to qualified students are funded principally with government advances to Emory under the Perkins, Nursing and Health Professions Student Loan Programs.

**(d) *Other Receivables, Net***

Other receivables are recorded at net realizable value and include receivables under grants and contracts, medical services provided to other organizations and losses recoverable from reinsurers.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

(e) **Investments**

Investments are reported at fair value and net asset value (NAV).

Investments in securities include U.S. and non-U.S. equities and fixed income instruments, both publicly traded and privately held. Fair value for these investments is measured based upon quoted prices in active markets, if available. If the market is inactive, fair value is determined by underlying managers and reviewed by the University after considering various sources of information. Due to variations in trading volumes and the lack of quoted market prices for fixed maturities, the fair value of fixed maturities is normally derived through recent reported trades for identical or similar securities, making adjustments through the reporting date based upon available market observable data described above.

Investments in funds primarily include investments in commingled equity and fixed income funds and other investments in funds (hedged strategies, private market investments, real estate partnerships and natural resources) and are reported at fair value as determined by the University in accordance with the University's valuation policies and procedures. The University has estimated the fair value of the majority of its investments in investment funds on the basis of the net asset value (NAV) per share of the investment (or its equivalent), as a practical expedient, if a) the underlying investment manager's calculation of NAV is fair value based, and b) the NAV has been calculated by the fund manager as of the University's fiscal year end date. If the reported NAV is not as of the University's fiscal year end date or is not fair value based, the University will adjust the NAV, if deemed necessary. If the University determines it is not practicable to calculate an adjusted NAV as of the University's fiscal year end date, the practical expedient will not be utilized and other valuation methodologies will be used. Typically, real estate partnerships and funds are valued based on appraisals of underlying properties held and conducted by third party appraisers retained by the general partner or investment manager. General partners of oil and gas partnerships also use third party appraisers to value properties. Valuations provided by the general partners and investment managers are evaluated by the Emory Investment Management Office and are believed to present reasonable estimates of fair value at August 31, 2015 and 2014.

The University's investments in investment funds are subject to the terms of the respective funds' agreements, private placement memoranda, and other governing agreements of such funds. These terms are typical for hedge fund and private equity arrangements. The University's investments are also subject to management and performance fees as specified in such funds' agreements. Additionally, such funds in which the University invests may restrict both the transferability of the University's interest and the University's ability to withdraw. In light of such restrictions imposed, an investment in these funds is illiquid and subject to liquidity risk.

Investment transactions are accounted for on the trade date basis. Dividend income is recognized on the ex-dividend date and interest income is recognized on the accrual basis. Realized gains and losses are determined by the specific identification method for investments in investment funds and average cost for investments in securities. Additionally, gains and losses from realized and unrealized changes in the fair value of investments are reported in the consolidated statements of activities, as increases or decreases in unrestricted net assets, where there are no donor restrictions, or temporarily restricted net assets, until amounts have been appropriated and the donor-imposed time restrictions have elapsed.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

(f) ***Fair Value Measurements***

Fair value measurements reflected in the consolidated financial statements conceptually represent the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP provides a hierarchy that prioritizes the inputs to fair value measurements based on the extent to which inputs to valuation techniques are observable in the marketplace. The hierarchy assigns a higher priority to observable inputs that reflect verifiable information obtained from independent sources, and a lower priority to unobservable inputs that would reflect the University's assumptions about how market participants would value an asset or liability based on the best information available. Fair value measurements must maximize the use of observable inputs and minimize the use of unobservable inputs.

Assets and liabilities measured and reported at fair value are classified and disclosed within one of the following categories:

**Level 1** – Valuations for assets and liabilities traded in active exchange markets as of the reporting date. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

**Level 2** – Valuations are determined through direct or indirect observations other than quoted market prices. The type of investments in Level 2 also includes certain positions in which the University is a unit of account holder within a fund or account that holds underlying assets that are traded in active exchange markets with readily available pricing.

**Level 3** – Valuations for assets and liabilities that are unobservable and derived from other valuation methodologies including discounted cash flow models and similar techniques, and not based on market exchange, dealer, or broker-traded transactions. Level 3 valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.

The majority of the University's investments is held through limited partnerships and commingled funds for which fair value is estimated using the NAVs reported by the investment managers as a practical expedient. Such investments have not been categorized within the fair value hierarchy due to early adoption by the University of ASU 2015-07, as discussed in (s) below.

(g) ***Split Interest Agreements***

The University's split-interest agreements with donors consist primarily of gift annuity agreements and irrevocable charitable remainder trusts for which the University serves as trustee. Assets held in the trusts are included in investments. Contribution revenues are recognized when trusts (or annuity agreements) are established, after recording liabilities for the present value of the estimated future payments to be made to beneficiaries. The liabilities are adjusted annually for changes in the value of assets, accretion of the discount, and other changes in the estimates of future benefits.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

**(h) *Interests in Perpetual Funds Held by Others***

The University is also the beneficiary of certain perpetual funds held and administered by others. The value of the funds' assets (or Emory's share when there are other beneficiaries) is considered a reasonable estimate of the present value of the estimated future cash flows from these funds and is recognized in beneficial interest in perpetual funds and as contribution revenue at the date such funds are established. The largest fund of this type consists primarily of shares of common stock of The Coca-Cola Company. The carrying value of Emory's interest is adjusted annually for changes in fair value. The fair value of these perpetual funds is recorded in the consolidated statements of financial position on August 31, 2015 and 2014 at \$1,071.5 million and \$1,130.1 million, respectively.

**(i) *Property and Equipment***

Land, buildings, and equipment are recorded at cost at the date of acquisition or fair value at the date of gift to the University. Depreciation expense is based on the straight-line method over the estimated useful lives of the assets. Useful lives are as follows: buildings – 10 to 60 years; land improvements and infrastructure – 5 to 40 years; moveable equipment – 3 to 20 years; fixed equipment – 3 to 30 years; software and enterprise systems – 5 to 10 years; leasehold improvements – term of the lease; and library books – 10 years. Certain assets totaling \$90.0 million and \$84.6 million, such as art, museum assets and rare books, are included in property and equipment on August 31, 2015 and August 31, 2014, respectively, but are not depreciated.

**(j) *Bond Issuance Costs***

Costs related to the registration and issuances of bonds are being amortized over the life of the bonds. The costs, net of accumulated amortization, are included in prepaid expenses, deferred charges and other assets in the consolidated statements of financial position and were \$8.4 million and \$9.1 million for August 31, 2015 and 2014, respectively.

**(k) *Tuition and Fees***

Tuition and fee revenues are recognized in the fiscal year during which the academic services are rendered. Student tuition and fees received in advance of services to be rendered are reported as deferred revenue. Student aid provided by the University for tuition and fees is reflected as a reduction of gross tuition and fee revenue.

**(l) *Contributions Revenue***

Contributions, including unconditional promises to give, are recognized as revenues in the period received. Contributions restricted for capital projects, endowment funds, and contributions under split-interest agreements or perpetual funds held by others are reported as nonoperating revenue. All other contributions are recorded as operating revenues. Unconditional promises to give, with payments due in future periods, are recorded as increases in temporarily or permanently restricted assets at the estimated present value of future cash flows, net of an allowance for uncollectible pledges.

Donor-restricted contributions are reported as temporarily restricted or permanently restricted revenue that increases those net asset classes. Expirations of temporary restrictions on net assets, such as the donor stipulation being met or the passage of time, are reported as net assets released from restrictions and reflect reclassifications from temporarily restricted net assets to unrestricted net assets. If the donor

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

stipulation for a temporarily restricted contribution is met in the year of the gift, the contribution is reflected in the unrestricted net asset class. Temporary restrictions on gifts to acquire long-lived assets are considered met in the period when the asset is placed in service. Conditional promises to give are not recognized until they become unconditional, that is, when the conditions on which they depend are met.

**(m) *Grants and Contracts Revenue and Indirect Cost Recoveries***

Indirect cost recoveries and grants and contracts revenue are reported at the estimated net realizable amounts due from sponsoring agencies. These grants and contract awards generally specify the purpose for which the funds are to be used. Revenues from sponsored grants and contracts are recognized when allowable expenditures are incurred under such agreements. These revenues, primarily from the federal government, are recorded as unrestricted support. Amounts recorded in grants and contracts receivable are for grant expenditures incurred in advance of the receipt of funds.

Indirect cost recoveries are based on negotiated rates and represent recoveries of facilities and administrative costs incurred under grants and contracts agreements.

**(n) *Net Patient Service Revenue***

Net patient service revenue is reported at the estimated net realizable amounts due from patients, third-party payors, and others for services rendered, including estimated retroactive adjustments due to future audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenues on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews, and investigations. Emory Healthcare's estimates in this area may differ from actual experience, and those differences may be material.

**(o) *Auxiliary Enterprises and Independent Operations***

Auxiliary enterprises include residence halls, food service, bookstore and parking operations which provide services to students, faculty and staff. Fee charges are directly related to the costs of services provided. Independent operations include an externally managed conference center, hotel, and a fitness center. Fee charges are based on market rates for the services provided.

**(p) *Income Taxes***

The University is recognized as a tax-exempt organization as defined in Section 501(c)(3) of the U.S. Internal Revenue Code (the Code) and is generally exempt from the federal income taxes on related income pursuant to Section 501(a) of the Code. Accordingly, no provision for income taxes is made in the consolidated financial statements. Unrelated business income of the University is reported on Form 990-T. As of August 31, 2015 and 2014, there were no material uncertain tax positions.

**(q) *Derivative Instruments***

Certain investment strategies used by the University and its investment managers incorporate various derivative financial instruments in order to reduce volatility, manage market risk, and enhance investment returns. Changes in the fair value of these instruments are recognized as nonoperating investment gains or losses in the consolidated statements of activities.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

The University will from time to time utilize interest rate exchanges to hedge interest rate market exposure of variable rate debt. The University uses the accrual method to account for the interest rate exchanges in connection with the underlying bonds. The difference between amounts paid and received under such agreements is reported in interest expense in the consolidated statements of activities. Changes in the fair value of these exchanges are recognized as nonoperating changes in net assets in the consolidated statements of activities.

**(r) Pension and Postretirement Benefits**

The University recognizes the funded status of its defined benefit pension and postretirement benefit plans as an asset or liability and recognizes changes in funded status during the year in which the changes occur as changes in unrestricted net assets.

**(s) New Accounting Pronouncements**

In May 2015, the FASB issued Accounting Standards Update (ASU) 2015-07, Fair Value Measurement (Topic 820): *Disclosures for Investments in Certain Entities that Calculate Net Asset Value per Share (or its Equivalent)*. ASU 2015-07 removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using net asset value per share as a practical expedient. The University elected to adopt ASU 2015-07 as of and for the year ended August 31, 2015 and all prior periods presented in the notes to the consolidated financial statements (note 9).

In December 2011, the FASB issued ASU 2011-11 (Topic 210): *Disclosures about Offsetting Assets and Liabilities*. This ASU requires an entity to disclose information about offsetting and related arrangements to enable users of its financial statements to understand the effects of those arrangements on its financial position. The adoption of ASU 2011-11 during fiscal 2014 had no material impact on the University's consolidated financial statements.

In October 2012, the FASB issued ASU 2012-05 (Topic 230): *Not-for-Profit Entities: Classification of the Sale Proceeds of Donated Financial Assets in the Statement of Cash Flows*. This ASU requires a not-for-profit (NFP) to classify cash receipts from the sale of donated financial assets consistently with cash donations received in the statement of cash flows if those cash receipts were from the sale of donated financial assets that upon receipt were directed without any NFP-imposed limitations for sale and were converted nearly immediately into cash. The adoption of ASU 2012-05 during fiscal 2014 had no material impact on the University's consolidated financial statements.

**(t) Use of Estimates**

The preparation of the consolidated financial statements in conformity with GAAP requires that management make estimates and assumptions affecting the reported amounts of assets, liabilities, revenues, and expenses, as well as disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Significant items in the University's consolidated financial statements subject to such estimates and assumptions include valuations for certain investments without readily determinable fair values, the determination of the allowances for uncollectible accounts and contractual adjustments, reserves for employee healthcare and workers' compensation claims, accrued professional and general liability



## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

costs, estimated third-party settlements, and actuarially determined benefit liabilities related to the University's pension and other postretirement benefit plans. Depreciation expense is based on the estimated useful lives of the related assets. The carrying value of contributions to be received after one year is estimated by discounting the expected future cash flows at a risk-free rate which could have been obtained at the date of the gift.

#### (u) *Conflict of Interest Policies*

University trustees, directors, principal officers and key employees may periodically be directly or indirectly associated with companies doing business with the University. The University requires annual disclosure of significant financial interests in, or employment or board service with, entities doing business with the University. The annual disclosures cover these key officials and their immediate family members. When such relationships exist, measures are taken to appropriately manage the actual or perceived conflict. Written conflict of interest policies for the University require, among other things, that no member of a governing board may participate in any decision in which he or she (or an immediate family member) has a material financial interest. Each board member is required to certify compliance with the conflict of interest policy on an annual basis and indicate whether the University does business with an entity in which that member (or an immediate family member) has a material financial interest or is employed or serves as a director or officer. When such relationships exist, measures are taken to mitigate any actual or perceived conflict, including requiring that such transactions be conducted at arm's length, for good and sufficient consideration, based on terms that are fair and reasonable to the University, and in accordance with applicable conflict of interest laws.

#### (3) **Contributions Receivable**

Contributions receivable as of August 31 consist of the following (in thousands):

	<u>2015</u>	<u>2014</u>
Unconditional promises expected to be collected in:		
Less than one year	\$ 50,523	91,929
One year to five years	49,677	52,311
Over five years	350	3,126
	<u>100,550</u>	<u>147,366</u>
Less:		
Allowance for uncollectible amounts	(2,961)	(4,358)
Discount to present value	(4,865)	(7,341)
	<u>\$ 92,724</u>	<u>135,667</u>

At August 31, 2015 and 2014, the five largest outstanding donor pledge balances represented 63.7% and 61.6%, respectively, of Emory's gross contributions receivable. Contributions receivable are discounted at rates ranging from 1.46% to 9.24%.

**EMORY UNIVERSITY**

Notes to Consolidated Financial Statements

August 31, 2015 and 2014

As of August 31, 2015, the University had received bequest intentions of approximately \$55.8 million. These intentions to give are not recognized as assets or revenues and, if received, will generally be restricted for purposes stipulated by the donor.

**(4) Business and Credit Concentrations**

Emory Healthcare grants credit to patients, substantially all of whom reside in the southeastern United States. Emory Healthcare generally does not require collateral or other security in extending credit to patients; however, it routinely obtains assignment of (or is otherwise entitled to receive) patients' benefits payable under their health programs, plans, or policies (e.g., Medicare, Medicaid, Blue Cross, and other preferred provider arrangements and commercial insurance policies). The composition of net receivables from patients and third-party payors follows:

	<b>2015</b>	<b>2014</b>
Managed care and other third-party payors	58%	57%
Medicare	31	32
Patients	7	7
Medicaid	4	4
	100%	100%

**(5) Net Patient Service Revenue**

Emory Healthcare has agreements with governmental and other third-party payors that provide for reimbursement to Emory Healthcare at amounts different from established rates. Contractual adjustments under third-party reimbursement programs represent the difference between Emory Healthcare's billings at established rates for services and amounts reimbursed by third-party payors. A summary of the basis of reimbursement with major third-party payors follows:

- Medicare – Substantially all acute care and professional services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to patient classification systems that are based on clinical, diagnostic, and other factors. Revenue from the Medicare program accounted for approximately 41% and 37% of Emory Healthcare's net patient service revenue for each of the years ended August 31, 2015 and 2014, respectively.
- Medicaid – Inpatient and professional services rendered to Medicaid program beneficiaries are paid at prospectively determined rates. Outpatient services are generally paid based upon cost reimbursement methodologies. Emory Healthcare's cost reports have been audited and substantially settled for all fiscal years through August 31, 2008. Revenue from the Medicaid program accounted for approximately 5% of Emory Healthcare's net patient service revenue for both years ended August 31, 2015 and 2014.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

Emory Healthcare has also entered into other reimbursement arrangements providing for payment methodologies which include prospectively determined rates per discharge, discounts from established charges, and prospectively determined per diem rates.

The composition of net patient service revenue (excluding charity care) follows (in thousands):

	<u>2015</u>	<u>2014</u>
Gross patient service revenue	\$ 7,637,741	6,906,797
Less provisions for contractual and other adjustments	(4,741,905)	(4,218,747)
Less provisions for uncollectible accounts	<u>(189,154)</u>	<u>(138,148)</u>
Net patient service revenue	<u>\$ 2,706,682</u>	<u>2,549,902</u>

Emory Healthcare recognizes patient service revenue associated with services provided to patients with third-party payor coverage on the basis of contractual rates for the services rendered. For uninsured patients who do not qualify for financial assistance in accordance with Emory Healthcare's established charity/indigent care policy, Emory Healthcare recognizes revenue on the basis of its discounted rates for services provided. On the basis of historical experience, a significant portion of Emory Healthcare's uninsured patients are unable or unwilling to pay for the services provided. Thus, Emory Healthcare records a significant provision for uncollectible accounts related to uninsured patients in the period the services are provided.

Patient service revenue, net of contractual allowances and discounts (but before the provision for uncollectible accounts), recognized during the years ended August 31, 2015 and 2014 from these major payor sources is as follows (in thousands):

	<u>2015</u>	<u>2014</u>
Third-party payors	\$ 2,766,246	2,609,538
Self-pay	<u>129,590</u>	<u>78,511</u>
Total	<u>\$ 2,895,836</u>	<u>2,688,049</u>

The impact of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively, the Health Care Acts) is complicated and difficult to predict, but Emory Healthcare anticipates its reimbursement in the future will be affected by major elements of the Health Care Acts. Emory Healthcare continues to monitor developments in healthcare reform and participates actively in contemplating and designing new programs that are encouraged and/or required by the Health Care Acts.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

#### (6) Investments

The following table summarizes the fair value of investments as of August 31 (in thousands):

	2015	2014
Short-term investments and cash equivalents <sup>(a)</sup>	\$ 260,208	249,197
Investments in securities:		
Global equity securities		
U.S. equity securities	422,283	363,230
Non-U.S. equity securities	191,480	194,239
Fixed income securities		
U.S. government securities	429,777	659,476
Domestic bonds and long-term notes <sup>(b)</sup>	158,758	239,750
International bonds and long-term notes <sup>(c)</sup>	42,297	78,677
Investments in private securities <sup>(d)</sup>	11,257	6,000
Commingled funds - equity <sup>(e)</sup>	677,404	692,701
Commingled funds - fixed income <sup>(e)</sup>	641,090	756,409
Investments in funds:		
Hedged strategies <sup>(f)</sup>	2,089,483	1,771,544
Private market investments <sup>(g)</sup>	1,208,804	1,316,490
Natural resources <sup>(h)</sup>	444,844	522,089
Real estate partnerships <sup>(i)</sup>	239,992	165,413
Derivatives <sup>(j)</sup>	10,278	9,679
Marketable real estate investments <sup>(k)</sup>	8,206	3,381
Oil and gas properties	2,255	2,195
Miscellaneous investments <sup>(l)</sup>	3,203	648
Total investments at fair value	6,841,619	7,031,118
Joint ventures (equity method)	564	198
Total investments	\$ 6,842,183	7,031,316

(a) Includes short-term U.S. Treasury securities with maturities of less than one year, as well as funds that invest in these types of investments. At August 31, 2015 and 2014, \$31.4 million and \$30.1 million, respectively, was posted as collateral (primarily related to derivatives' trading agreements) and thus not readily available for use.

(b) Includes investments in non-government debt securities. Investments consist primarily of credit-oriented securities including U.S. investment-grade and below investment-grade debt securities. Other investments include mortgage-backed securities, asset-backed securities, repurchase agreements, senior loans, and bank loans.

(c) Includes fixed income investments in non-U.S. debt securities such as government bonds, corporate bonds, bank loans, and asset backed securities.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

- (d) Includes investments in private securities not held through a traditional fund or commingled vehicle.
- (e) Includes professionally managed pooled investment funds registered with the Securities and Exchange Commission or the Comptroller of the Currency (i.e., mutual funds and collective trusts).
- (f) Includes investments in fund structures that pursue multiple strategies to diversify risks and reduce volatility. Fund managers have the ability to shift investments across a wide variety of sectors, geographies, and strategies and from a net long position to a net short position. Certain investments in hedged strategies may be subject to restrictions that limit the University's ability to withdraw capital until i) a certain "lock-up period" has expired or ii) until certain underlying investments designated as "illiquid" in "sidepockets" are sold. In addition, this class includes investments that may be subject to restrictions that limit the amount that the University is able to withdraw as of a given redemption date.
- (g) Includes illiquid investments in venture capital, growth equity, buyout, mezzanine, distressed debt and reinsurance held in commingled vehicles in which Emory is typically a limited partner or shareholder. The nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds. It is estimated that underlying assets of the funds will be liquidated over the next 10 years.
- (h) Includes investments in timber, mining, energy, farmland, commodities and related services businesses held through liquid and illiquid fund structures. The nature of the investments in this category is largely such that distributions are received through liquidation of the underlying assets of the funds; however, certain liquid investments in natural resources may be subject to restrictions that limit the University's ability to withdraw capital until a certain "lock-up period" has expired. It is estimated that the underlying assets of the funds will be liquidated over the next 10 years.
- (i) Includes illiquid investments in real estate assets, projects, or land held in commingled funds. The fair value of these investments is calculated from the net asset value of Emory's ownership interests in these funds. The nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds. It is estimated that the underlying assets of the funds will be liquidated over the next 9 years.
- (j) Includes investments in derivative instruments including both exchange traded and over the counter futures, forwards, swaps, options, rights and warrants valued at the fair market value of each underlying instrument.
- (k) Includes miscellaneous investments in real estate such as land gifts.
- (l) Includes other investments in mutual funds not included in the endowment and other similar funds.

At August 31, 2015 and 2014, cash equivalents of \$260.2 million and \$230.1 million, respectively, are included in investments and are restricted for use by endowments and special projects.

The University's investment policies allow certain fund managers to use foreign exchange contracts, currency hedges, and other derivative transactions in order to reduce the volatility and manage market risk involved in its investment portfolio. These financial instruments are included in investments at fair value in the accompanying consolidated statements of financial position with the related gain or loss recognized as

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

investment income and gains (losses) in excess of spending distributions for current operations in the accompanying consolidated statements of activities.

The University may hold investments denominated in currencies other than the U.S. dollar. Thus, there is exposure to currency risk because the value of the investments denominated in other currencies may fluctuate due to changes in currency exchange rates, and this can have an effect on the reported value of these investments.

The value of securities held by the University may decline in response to certain economic events, including those events impacting entities whose securities are owned and included in the investment portfolio. Those events impacting valuation may include (but are not limited to) economic changes, market fluctuations, regulatory changes, global and political instability, and currency, interest rate, and commodity price fluctuations. The University attempts to manage this risk through diversification, ongoing due diligence of fund managers, and monitoring of economic conditions.

As of August 31, 2015, the related unfunded commitments of the University's alternative investments and limitations and restrictions on the University's ability to redeem or sell are summarized as follows (in thousands):

	<b>Unfunded commitments</b>	<b>Redemption frequency (if currently eligible)</b>	<b>Redemption notice period</b>
Private market investments	\$ 367,687	not eligible	not eligible
Real estate partnerships	246,169	not eligible	not eligible
Natural resources	193,603	30 - 90 days and not eligible	30 - 90 days and not eligible
	\$ 807,459		

Over the next five years, approximately 87% of the unfunded commitments are expected to be called by the general partners. Although the University is obligated to fund these commitments, many of these agreements allow resale. Funds to meet these commitments will be required over future years and are expected to be generated from existing endowment assets.

#### (7) **Endowment Net Assets**

The University's Endowment (Endowment) consists of over 1,500 individual funds established for a variety of purposes including both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments. The Endowment provides stable financial support to a wide variety of programs and activities in perpetuity, playing a critical role in enabling the university to achieve its mission. Net assets associated with these endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

**(a) Interpretation of Relevant Law**

The Board of Trustees of the University has approved the University's adoption of the State of Georgia Uniform Prudent Management of Institutional Funds Act (UPMIFA) which provides standards for managing investments of institutional funds and spending from endowments. The University classifies as permanently restricted net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditures by the University in a manner consistent with the standard of prudence prescribed by the Act. In accordance with the Act, the University considers several factors in making a determination to appropriate or accumulate donor-restricted endowment funds, including the duration and preservation of the fund, the purposes of the fund, general economic conditions, the possible effect of inflation and deflation, the expected total return from income and the appreciation of investments, other resources of the University and the investment policies of the University.

The endowment funds subject to UPMIFA are true endowments and do not include perpetual funds held by others, long-term investments, annuity funds, and deposits held in custody and miscellaneous investments. Approximately 69.7% of the investments described in note 6 are classified as endowed net assets. Endowment funds are categorized in the following net asset classes as of August 31 (in thousands):

	2015			2014		
	Donor- Restricted	Board- Designated	Total	Donor- Restricted	Board- Designated	Total
Unrestricted	\$ (12,561)	1,416,626	1,404,065	(4,062)	1,458,865	1,454,803
Temporarily restricted	2,557,777	—	2,557,777	2,727,955	—	2,727,955
Permanently restricted	806,288	—	806,288	731,633	—	731,633
Total endowment funds	\$ 3,351,504	1,416,626	4,768,130	3,455,526	1,458,865	4,914,391

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

Changes in endowment funds by net asset classification for the years ended August 31 are summarized as follows (in thousands):

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
Balance as of August 31, 2013	\$ 1,261,435	2,342,859	671,611	4,275,905
Investment return:				
Investment income	13,917	43,342	—	57,259
Realized and unrealized gain	232,281	508,716	—	740,997
Total investment return	<u>246,198</u>	<u>552,058</u>	<u>—</u>	<u>798,256</u>
Cash contributions	654	3	51,915	52,572
Withdrawal of board-designated funds for strategic initiatives	(3,927)	—	—	(3,927)
Appropriations for expenditure	(40,257)	(144,538)	—	(184,795)
Appropriations for capital purposes	(5,583)	(18,037)	—	(23,620)
Other	<u>(3,717)</u>	<u>(4,390)</u>	<u>8,107</u>	<u>—</u>
Balance as of August 31, 2014	\$ 1,454,803	2,727,955	731,633	4,914,391
Investment return:				
Investment income	14,058	18,936	—	32,994
Realized and unrealized loss	<u>(11,833)</u>	<u>(63,020)</u>	<u>—</u>	<u>(74,853)</u>
Total investment return	2,225	(44,084)	—	(41,859)
Cash contributions	675	9	71,312	71,996
Additions of institutional funds for quasi endowments	51,864	—	—	51,864
Withdrawal of board-designated funds for strategic initiatives	(15,366)	—	—	(15,366)
Appropriations for expenditure	(79,259)	(113,936)	—	(193,195)
Appropriations for capital purposes	(6,086)	(13,615)	—	(19,701)
Other	<u>(4,791)</u>	<u>1,448</u>	<u>3,343</u>	<u>—</u>
Balance as of August 31, 2015	\$ <u>1,404,065</u>	<u>2,557,777</u>	<u>806,288</u>	<u>4,768,130</u>

**(b) Funds with Deficiencies**

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level of the donor's original contribution. Deficiencies of this nature that are reported in unrestricted net assets were \$12.6 million and \$4.0 million as of August 31, 2015 and 2014, respectively. Subsequent gains that restore the fair value of the assets of the endowment fund to book value will be classified as an increase in unrestricted net assets.

**(c) Return Objectives and Risk Parameters**

The University has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of the endowment assets. Under this policy, as approved by the Board of Trustees, the endowment assets are invested in a manner to attain a total return of at least 8% (including inflation) over the long term. Over shorter time periods, the endowment assets performance will be measured versus a policy benchmark. The policy benchmark represents the weighted average



## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

of benchmark returns to each asset class in the policy asset allocation. The performance objective is to outperform the policy benchmark by at least 50 basis points net of fees, on average. It is not expected that the performance target will be met for every three-year period.

**(d) *Strategies Employed for Achieving Objectives***

To satisfy its long-term rate-of-return objectives, the University relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The University employs a diversified asset allocation strategy across global equities, fixed income, marketable alternatives, and private investments to achieve its long-term return objectives within prudent risk constraints. The Endowment's long-term target asset allocation is approved by the Investment Committee of the Board of Trustees. The portfolio is periodically rebalanced to the target weightings for each asset class.

**(e) *Relationship between Investment Objectives and Spending Policy***

The University's Board of Trustees has established a spending policy that determines how endowment distributions are made. The University employs a total return endowment spending policy that establishes the amount of endowment investment return available to support current operating and capital needs. The distribution of endowment income in 2015 and 2014 was based on 4.75% of the average fair value of the endowment over the previous 12 months ending on December 31. The University considers the expected return on its endowment, including the effect of inflation in setting the annual appropriation amount. Accordingly, the University expects the current spending policy to allow its endowment to maintain its purchasing power if projected growth rates are achieved. Additional real growth will be provided through new gifts and any excess investment return. The payout rate is approved annually by the Board of Trustees as part of the budget process.

**(8) *Derivative Instruments and Hedging Activities***

**Investments**

The University has executed derivative financial instruments in the normal course of its business. Investment strategies employed by Emory and investment managers retained by Emory may incorporate the use of various derivative financial instruments with valuation risk. Emory uses these instruments for a number of investment purposes, including hedging or altering exposure to certain asset classes and cost-effectively adding exposures to portions of the portfolio. Futures, options and other derivative instruments are used to adjust elements of investment exposures to various securities, markets and currencies without actually taking a position in the underlying asset.

These instruments expose Emory to risk of an unexpected movement in the fair value of the underlying security, a counterparty failing to meet its obligations, and, in certain circumstances, not being able to unwind a position at current fair value due to market illiquidity. Emory has established procedures to monitor and manage these risks. The purchase and sale of exchange traded derivatives require collateral deposits with a Futures Commission Merchant (FCM). In the event of an FCM's insolvency, recovery may be limited to Emory's pro rata share of segregated customer funds available. It is possible that the recovery amount could be less than the total of cash and other equity deposited. Management does not consider the underlying

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

counterparty risk from these arrangements to have a material impact on the financial position of the University.

Emory's net investment related derivative exposures, categorized by primary underlying risk, as of August 31, 2015 (in thousands):

	<b>Gross Notional Amount</b> <sup>(1)</sup>	<b>Derivative Assets</b> <sup>(2)</sup>	<b>Derivative Liabilities</b> <sup>(2)</sup>	<b>Gains (Losses)</b> <sup>(3)</sup>
Interest-rate contracts	\$ 138,589	109	(313)	4,930
Foreign exchange contracts	424,491	17,208	(1,825)	34,161
Equity contracts	643,643	3,380	(8,469)	785
Credit contracts	39,057	526	(338)	(75)
<b>Total</b>	<b>\$ 1,245,780</b>	<b>21,223</b>	<b>(10,945)</b>	<b>39,801</b>

Emory's net investment related derivative exposures, categorized by primary underlying risk, as of August 31, 2014 (in thousands):

	<b>Gross Notional Amount</b> <sup>(1)</sup>	<b>Derivative Assets</b> <sup>(2)</sup>	<b>Derivative Liabilities</b> <sup>(2)</sup>	<b>Gains (Losses)</b> <sup>(3)</sup>
Interest-rate contracts	\$ 286,403	1,359	(1,418)	(835)
Foreign exchange contracts	113,400	1,020	(137)	298
Equity contracts	844,333	11,255	(3,944)	123,312
Credit contracts	57,891	1,740	(196)	(28)
<b>Total</b>	<b>\$ 1,302,027</b>	<b>15,374</b>	<b>(5,695)</b>	<b>122,747</b>

- (1) The notional amount is representative of the absolute value of the open contracts on August 31, 2015 and 2014
- (2) Derivative assets less derivative liabilities for investment-related activities are presented as net in Note 6.
- (3) Gains (losses) on derivatives are included in the Statements of Activities in "investment return (less than) in excess of spending distribution for current operations" in "non-operating activities".

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

Emory's investment related derivative assets and liabilities at August 31, 2015, by counterparty, are as follows (in thousands):

	<u>Assets</u>	<u>Liabilities</u>	<u>Cash Collateral Held (Pledged)</u>	<u>Net Amount</u>
Counterparty A	\$ 16,409	(335)	—	16,074
Counterparty B	3,377	(4,550)	—	(1,173)
Counterparty C	353	(347)	(360)	(354)
Counterparty D	318	(593)	(1,528)	(1,803)
All other	766	(5,120)	(29,489)	(33,843)
Total	<u>\$ 21,223</u>	<u>(10,945)</u>	<u>(31,377)</u>	<u>(21,099)</u>

Emory's investment related derivative assets and liabilities at August 31, 2014, by counterparty, are as follows (in thousands):

	<u>Assets</u>	<u>Liabilities</u>	<u>Cash Collateral Held (Pledged)</u>	<u>Net Amount</u>
Counterparty A	\$ 5,489	(105)	(28,260)	(22,876)
Counterparty B	3,383	(22)	—	3,361
Counterparty C	1,642	(3,947)	(367)	(2,672)
Counterparty D	1,147	(188)	254	1,213
All other	3,713	(1,433)	(1,767)	513
Total	<u>\$ 15,374</u>	<u>(5,695)</u>	<u>(30,140)</u>	<u>(20,461)</u>

### Debt

As a component of the debt portfolio, the University entered into interest rate swap agreements that effectively convert a portion of variable rate debt to fixed rates and are used to manage interest rate risk. The University's exchange arrangements are exposed to credit loss in the event of nonperformance by the counterparty and to interest rate risk driven by factors influencing the spread between the taxable and tax-exempt market interest rates on its basis exchange. Certain University derivative instruments contain provisions requiring long-term, unsecured debt to be maintained at specified credit ratings from Moody's Investors Service and Standard and Poor's Ratings Service. If the ratings of the University's debt were to fall below certain benchmarks, the counterparty could request immediate payment on derivatives in net liability positions. At August 31, 2015, the University's long term debt ratings exceeded these benchmarks.

At August 31, 2015, Emory had nine interest rate swap agreements expiring on various dates ranging from November 15, 2028 through December 1, 2042. These agreements require Emory to pay fixed interest rates to the counterparties varying from 3.238% to 4.388% in exchange for variable rate payments from the counterparties based on a percentage of the Three Month London Interbank Offered Rate (LIBOR).

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

Net settlement transactions related to the agreements described above resulted in interest expense totaling \$20.9 million and \$21.0 million during 2015 and 2014, respectively. The fair value of each exchange agreement is estimated based on pricing models that utilize significant observable inputs, such as relevant current interest rates, that reflect assumptions on the amount the University would receive or pay to terminate the agreement at the reporting date. As such, the University's exchange agreements are categorized as Level 2 in the fair value hierarchy.

The aggregate fair value of all derivative instruments with credit-risk related contingent features that are in a liability position was \$176.8 million and \$150.5 million on August 31, 2015 and 2014, respectively, for which Emory University had a requirement to post collateral in the amount of \$6.7 million and \$0.6 million for 2015 and 2014, respectively. During 2015, Emory replaced a swap counterparty in an interest rate exchange agreement to another counterparty to maintain a diversified portfolio. Collateral postings are reported in prepaid expenses, deferred charges and other assets in the consolidated statements of financial position.

The following table summarizes the debt-related derivatives as of August 31 (in thousands):

<b>Interest Rate Swaps</b>		<b>2015</b>		<b>2014</b>	
<b>Inception</b>	<b>Maturity</b>	<b>Liability Fair Value</b>	<b>Loss</b>	<b>Liability Fair Value</b>	<b>Loss</b>
August 4, 2005	September 1, 2035	\$ (28,688)	(4,566)	(24,123)	(8,681)
August 4, 2005	September 1, 2035	—	—	(24,114)	(8,678)
August 25, 2005	September 1, 2035	(9,576)	(1,521)	(8,055)	(2,896)
August 25, 2005	September 1, 2035	—	—	(8,055)	(2,896)
April 19, 2007	November 15, 2028	(1,795)	(30)	(1,765)	(226)
December 1, 2007	September 1, 2035	(21,616)	(2,780)	(18,836)	(5,471)
May 1, 2008	September 1, 2038	(24,746)	(3,294)	(21,452)	(6,124)
December 1, 2008	December 1, 2042	(30,095)	(5,232)	(24,863)	(9,216)
December 1, 2009	September 1, 2035	(22,013)	(2,781)	(19,232)	(5,485)
June 23, 2015	September 1, 2035	(28,689)	(4,574)	—	—
June 23, 2015	September 1, 2035	(9,573)	(1,518)	—	—
Total		<u>\$ (176,791)</u>	<u>(26,296)</u>	<u>(150,495)</u>	<u>(49,673)</u>

Emory is exposed to financial loss in the event of nonperformance by counterparty to any of the financial instruments described above. General market conditions could impact the credit standing of the counterparties and, therefore, potentially impact the value of the instruments on Emory's consolidated statement of financial position. Emory management, with consultation from third party financial advisors, controls this counterparty credit risk by considering the credit rating, business risk, and reputation of any counterparty before entering into a transaction, monitoring for any change in the credit standing of its counterparty during the life of the transaction, and requiring collateral be posted when predetermined

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

thresholds are crossed. Emory has additional counterparty arrangements managed by funds in which Emory invests, which are included in the general investment and fund manager monitoring activities for the funds.

Emory's debt-related derivative liabilities at August 31, 2015, by counterparty, are as follows (in thousands):

	<u>Liabilities</u>	<u>Cash Collateral Held (Pledged)</u>	<u>Net Amount</u>
Counterparty A	\$ (21,616)	—	(21,616)
Counterparty B	(30,095)	—	(30,095)
Counterparty C	(38,265)	—	(38,265)
Counterparty D	(46,759)	(6,700)	(53,459)
Counterparty E	—	—	—
Counterparty F	(38,262)	—	(38,262)
All other	(1,794)	—	(1,794)
Total	<u>\$ (176,791)</u>	<u>(6,700)</u>	<u>(183,491)</u>

Emory's debt-related derivative liabilities at August 31, 2014, by counterparty, are as follows (in thousands):

	<u>Liabilities</u>	<u>Cash Collateral Held (Pledged)</u>	<u>Net Amount</u>
Counterparty A	\$ (18,836)	—	(18,836)
Counterparty B	(24,863)	—	(24,863)
Counterparty C	(32,177)	—	(32,177)
Counterparty D	(40,685)	(600)	(41,285)
Counterparty E	(32,170)	—	(32,170)
All other	(1,764)	—	(1,764)
Total	<u>\$ (150,495)</u>	<u>(600)</u>	<u>(151,095)</u>

#### (9) Fair Values of Assets and Liabilities

The carrying values for cash and cash equivalents, patient receivables, short term receivables, and short term payables approximate fair value because of the terms and relative short maturity of these financial instruments. Current year additions to contributions receivable and annuity and other split interest obligations carrying amounts approximate fair value because these instruments are recorded at estimated net present value and are categorized as Level 3 assets. Long term investments and deposits held in custody for others are reflected in the accompanying consolidated financial statements at fair value. It is not practicable to determine the fair value of loans receivable, comprised primarily of federally sponsored student loans, and government advances for federal loan programs due to significant government restrictions as to marketability, interest rates, and repayment terms of these loans. The estimated fair value of the University's long term debt, based on the quoted market prices for issues with similar terms and maturities, is approximately \$1.9 billion at both August 31, 2015 and 2014 and categorized as Level 2 liabilities. The

# EMORY UNIVERSITY

## Notes to Consolidated Financial Statements

August 31, 2015 and 2014

carrying value of long term debt reflected in the accompanying consolidated statements of financial position is approximately \$1.9 billion and \$2.0 billion for August 31, 2015 and 2014, respectively.

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2015 (in thousands):

	Total fair value	Fair value hierarchy			
		Investments measured at NAV <sup>(3)</sup>	Level 1	Level 2	Level 3
Financial assets:					
Short-term investments and cash equivalents	\$ 260,208	—	251,535	8,673	—
Investments in securities:					
Global equity securities					
U.S. equity securities	422,283	—	421,786	494	3
Non-U.S. equity securities	191,480	—	185,342	6,138	—
Fixed income securities:					
U.S. government securities	429,777	—	166	429,611	—
Domestic bonds and long-term notes	158,758	—	1,716	156,642	400
International bonds and long-term notes	42,297	—	35	41,477	785
Investments in private securities	11,257	—	—	—	11,257
Commingled funds - equity	677,404	547,212	43,664	86,528	—
Commingled funds - fixed income	641,090	143,364	431,223	66,503	—
Investments in funds:					
Hedged strategies	2,089,483	2,089,483	—	—	—
Private market investments	1,208,804	1,208,125	—	—	679
Natural resources	444,844	444,844	—	—	—
Real estate partnerships	239,992	239,992	—	—	—
Derivatives					
Derivatives - options	10,278	—	11,389	(1,111)	—
Marketable real estate investments	8,206	—	234	7,972	—
Oil and gas properties	2,255	—	—	—	2,255
Miscellaneous investments	3,203	—	3,203	—	—
Total investments at fair value <sup>(1)</sup>	6,841,619	4,673,020	1,350,293	802,927	15,379
Interest in perpetual funds held by others <sup>(2)</sup>	1,071,531	—	—	—	1,071,531
Total assets at fair value	\$ 7,913,150	4,673,020	1,350,293	802,927	1,086,910
Financial liabilities:					
Derivative instruments - interest rate swaps	(176,791)	—	—	(176,791)	—
Deposits held in custody for others	(645,996)	—	—	(645,996)	—
Total liabilities at fair value	\$ (822,787)	—	—	(822,787)	—

(1) Certain investments in joint ventures carried under the equity method of accounting are not reported at fair value and thus not included in the table above (see note 6).

(2) Primarily invested in The Coca Cola Company.

(3) Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the statement of financial position.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2014 (in thousands):

	Total fair value	Fair value hierarchy			
		Investments measured at NAV <sup>(3)</sup>	Level 1	Level 2	Level 3
Financial assets:					
Short-term investments and cash equivalents	\$ 249,197	—	167,194	82,003	—
Investments in securities:					
Global equity securities					
U.S. equity securities	363,230	—	363,211	16	3
Non-U.S. equity securities	194,239	—	187,236	7,003	—
Fixed income securities:					
U.S. government securities	659,476	—	157	659,319	—
Domestic bonds and long-term notes	239,750	—	1,745	238,005	—
International bonds and long-term notes	78,677	—	—	78,092	585
Investments in private securities	6,000	—	—	—	6,000
Commingled funds - equity	692,701	565,202	48,802	78,697	—
Commingled funds - fixed income	756,409	141,730	554,858	59,821	—
Investments in funds:					
Hedged strategies	1,771,544	1,771,544	—	—	—
Private market investments	1,316,490	1,315,731	—	—	759
Natural resources	522,089	521,881	—	208	—
Real estate partnerships	165,413	165,218	—	—	195
Derivatives					
Derivatives - options	9,679	—	5,687	3,992	—
Marketable real estate investments	3,381	—	—	3,381	—
Oil and gas properties	2,195	—	—	—	2,195
Miscellaneous investments	648	—	648	—	—
Total investments at fair value <sup>(1)</sup>	<u>7,031,118</u>	<u>4,481,306</u>	<u>1,329,538</u>	<u>1,210,537</u>	<u>9,737</u>
Interest in perpetual funds held by others <sup>(2)</sup>	<u>1,130,063</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>1,130,063</u>
Total assets at fair value	<u>\$ 8,161,181</u>	<u>4,481,306</u>	<u>1,329,538</u>	<u>1,210,537</u>	<u>1,139,800</u>
Financial liabilities:					
Derivative instruments - interest rate swaps	(150,495)	—	—	(150,495)	—
Deposits held in custody for others	<u>(643,902)</u>	<u>—</u>	<u>—</u>	<u>(643,902)</u>	<u>—</u>
Total liabilities at fair value	<u>\$ (794,397)</u>	<u>—</u>	<u>—</u>	<u>(794,397)</u>	<u>—</u>

- (1) Certain investments in joint ventures carried under the equity method of accounting are not reported at fair value and thus not included in the table above (see note 6).
- (2) Primarily invested in The Coca Cola Company.
- (3) Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the statement of financial position.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

Investments made directly by the University whose values are based on quoted market prices in active markets, and are therefore classified within Level 1, include actively traded common and preferred stock, U.S. government fixed income instruments and non-U.S. government fixed income instruments. Level 1 investments may also include commingled funds such as listed mutual funds, futures contracts, and exchange traded funds (ETFs).

Investments that trade in markets that are considered to be active, but are based on dealer quotations or alternative pricing sources supported by observable inputs or investments that trade in markets that are not considered to be active, but are valued based on quoted market prices, dealer quotations or alternative pricing sources supported by observable inputs are classified within Level 2. Alternative pricing sources include quotations from market participants and pricing models which are based on accepted industry modeling techniques. These investments include U.S. investment-grade and below investment-grade debt securities, international corporate bonds, mortgage-backed securities, asset-backed securities, money market funds, senior loans and bank loans, most derivative contracts other than futures, and commingled structures with quoted market prices.

Investments that do not trade in active markets and for which values are instead derived from significant unobservable inputs are classified within Level 3. However, as of August 31, 2015 and August 31, 2014, approximately \$4.7 billion and \$4.5 billion, respectively, of the University's investments are held through limited partnerships and commingled vehicles for which fair value is estimated using NAVs reported by the fund managers as a practical expedient.

Typically, such funds are structured as limited partnership or limited liability vehicles. Funds with hedged strategies generally offer redemption terms and often hold marketable securities in addition to certain illiquid investments. The determination of NAV by managers of private market, real estate and natural resources funds, which generally do not have redemption terms, requires the use of significant unobservable inputs because the underlying investments trade infrequently or not at all. Such investments may include, for example, private placements, distressed securities, and properties and other real interests. Inputs used by the fund managers may include the original transaction price, recent transactions in the same or similar market, completed or pending third party transactions in the underlying investment or comparable issuers, and subsequent rounds of financing. When observable prices are not available these investments are valued using one or more valuation techniques described below.

- **Market Approach:** This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.
- **Income Approach:** This approach determines a valuation by discounting future cash flows.
- **Cost Approach:** This approach is based on the principle of substitution and the concept that a market participant would not pay more than the amount that would currently be required to replace the asset.

Due to inherent uncertainty of fair value, such estimates of fair value may differ from values that would have been applied had a readily available market existed and those differences could be material. Although a secondary market exists for these investments, the market is not active and individual transactions are typically not observable. When transactions do occur in this limited secondary market, they may occur at discounts to the reported net asset value. It is therefore reasonably possible that if the University were to sell



## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

these investments in the secondary market, a buyer may require a discount to the reported net asset value, and that discount could be significant.

The categorization or omission of an investment within the hierarchy does not necessarily correspond to the perceived risk of that investment. The funds and the University use inputs in applying various valuation techniques that are assumptions which market participants use to make valuation decisions, including assumptions about risk. Inputs may include price information, volatility statistics, operating statistics, specific and broad credit data, liquidity statistics, recent transactions, earnings forecasts, future cash flows, market multiples, discount rates and other factors.

The following tables summarize the University's Level 3 reconciliation as of August 31, 2015 and 2014 (in thousands):

	Balance as of August 31, 2014	Net gains (losses)	Purchases	Sales	Transfer out of Level 3	Balance as of August 31, 2015
Investments in U.S. equity securities	\$ 3	—	—	—	—	3
Domestic bonds & long-term notes	—	2	400	(2)	—	400
International bonds & long terms notes	585	(183)	390	(7)	—	785
Investments in private securities	6,000	257	5,000	—	—	11,257
Investment in funds:						
Private market investments	759	(228)	185	(37)	—	679
Real estate partnerships	195	4	—	(199)	—	—
Oil and gas properties	2,195	—	60	—	—	2,255
Total investments	9,737	(148)	6,035	(245)	—	15,379
Interest in perpetual funds held by others	1,130,063	(58,532)	—	—	—	1,071,531
Total assets	\$ 1,139,800	(58,680)	6,035	(245)	—	1,086,910

	Balance as of August 31, 2013	Net gains (losses)	Purchases	Sales	Transfer out of Level 3	Balance as of August 31, 2014
Investments in U.S. equity securities	\$ 3	—	—	—	—	3
International bonds & long terms notes	—	166	419	—	—	585
Investments in private securities	—	—	6,000	—	—	6,000
Investment in funds:						
Private market investments	587	(93)	265	—	—	759
Real estate partnerships	—	—	195	—	—	195
Oil and gas properties	2,100	95	—	—	—	2,195
Total investments	2,690	168	6,879	—	—	9,737
Interest in perpetual funds held by others	1,034,124	95,939	—	—	—	1,130,063
Total assets	\$ 1,036,814	96,107	6,879	—	—	1,139,800

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

#### (10) Property and Equipment

Property and equipment at August 31 are summarized as follows (in thousands):

	<u>2015</u>	<u>2014</u>
Land and land improvements	\$ 174,774	174,689
Buildings and improvements	3,006,988	2,933,440
Equipment	2,066,387	1,958,375
Library and museum assets	382,075	359,492
Construction in progress	<u>229,659</u>	<u>187,914</u>
	5,859,883	5,613,910
Less accumulated depreciation	<u>(2,976,471)</u>	<u>(2,761,330)</u>
	<u>\$ 2,883,412</u>	<u>2,852,580</u>

Property and equipment is reviewed for recoverability whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss shall be recognized only if the carrying amount of a long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. There were no asset impairments for fiscal 2015.

The University has identified asset retirement obligations primarily from commitments to remove asbestos and lead paint in University facilities at the time of major renovation or demolition. The liability was estimated using an inflation rate of 5.00% and discount rate of 4.74%. The liability for asset retirement obligations at August 31, 2015 and 2014 is \$57.6 million and \$55.4 million, respectively, and is included in accounts payable and accrued liabilities in the accompanying consolidated statements of financial position.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

#### (11) Long-Term Debt

Bonds, notes and mortgages payable, including unamortized premiums and discounts, consisted of the following at August 31 (dollars in thousands):

	<u>Interest rate average</u>	<u>Final maturity</u>	<u>Outstanding principal</u>	
			<u>2015</u>	<u>2014</u>
Tax-exempt fixed-rate revenue bonds:				
2013 Series A	4.93%	October 1, 2043	\$ 209,412	214,578
2011 Series A <sup>(1)</sup>	4.95	September 1, 2041	233,170	234,440
2009 Series B <sup>(2)</sup>	4.78	September 1, 2035	217,051	221,986
2009 Series C	4.90	September 1, 2039	99,335	99,410
2008 Series C	4.96	September 1, 2038	124,027	123,346
2005 Series A	5.06	September 1, 2025	50,440	71,591
Total tax-exempt fixed-rate revenue bonds			<u>933,435</u>	<u>965,351</u>
Tax-exempt variable-rate revenue bonds:				
2013 Series B <sup>(3)</sup>	0.59	October 1, 2039	135,100	135,100
2013 Series C <sup>(3)</sup>	0.69	October 1, 2039	57,865	57,865
2007 Series A	0.98	November 15, 2028	7,453	7,271
2005 Series B	0.04	September 1, 2035	250,000	250,000
2005 Series C	0.04	September 1, 2036	124,150	124,150
Total tax-exempt variable-rate revenue bonds			<u>574,568</u>	<u>574,386</u>
Taxable fixed-rate revenue bonds:				
2009 Series A	5.63	September 1, 2019	249,438	249,297
1994 Series C	8.00	October 1, 2024	5,915	6,285
Series 1991	8.87	April 1, 2022	851	1,351
Total taxable fixed-rate revenue bonds			<u>256,204</u>	<u>256,933</u>
Taxable variable-rate revenue bonds:				
1999 Series B	0.11	November 1, 2029	9,955	10,355
1995 Series B	0.10	November 1, 2025	3,990	5,710
1994 Series B	0.18	October 1, 2024	9,355	9,975
Total taxable variable-rate revenue bonds			<u>23,300</u>	<u>26,040</u>
Commercial paper:				
2010 Program 1 - Tax-exempt	0.08	August 1, 2050	2,834	2,834
2008 Program 1 - Taxable	0.18	April 1, 2047	123,900	128,300
Total commercial paper			<u>126,734</u>	<u>131,134</u>
Other long term debt <sup>(4)</sup>	Various		567	1,555
Total bonds, notes and mortgages payable			<u>\$ 1,914,808</u>	<u>1,955,399</u>

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

- (1) Included in the 2011 Series Bonds is a 5 year maturity of \$92.2 million due on September 1, 2016 at an average interest rate of 4.88%.
- (2) Included in the 2009 Series Bonds is a medium-term maturity of \$43.0 million due on September 1, 2019 at an average interest rate of 4.68%.
- (3) Series 2013B and 2013C bonds are floating rate notes and interest rates are based on a spread to SIFMA.
- (4) Included in other long term debt are the St. Joseph's capital leases.

The University incurred interest expense of \$79.5 million and \$78.3 million in 2015 and 2014, respectively, net of capitalized interest of \$3.5 million in 2015 and 2014. During 2015, the average interest rate on University tax exempt and taxable variable rate demand bonds (VRDB) was 0.04% and 0.17%, respectively. Related indices for this period were 0.04% for tax exempt debt (The Securities Industry and Financial Markets Association Index – SIFMA) and 0.17% for taxable debt (London Interbank Offered Rate – LIBOR).

At August 31, 2015 the aggregate annual maturities of bonds, notes and mortgages payable for the next five years and thereafter are as follows (in thousands):

Payable in fiscal year:	
2016	\$ 30,660
2017	113,628
2018	22,362
2019	22,133
2020	302,693
Thereafter	<u>1,387,231</u>
	1,878,707
Unamortized net premium	<u>36,101</u>
	<u>\$ 1,914,808</u>

In 2010, the University established a \$400 million tax exempt Commercial Paper program. The primary purpose of the program is to meet interim financing needs related to capital projects. As of August 31, 2015 and 2014, the University had outstanding balances of \$2.8 million under this program.

In 2008, the University established a \$100 million taxable Commercial Paper program. In 2014, the University increased the program to \$150 million. As of August 31, 2015 and 2014, the University had an outstanding balance of \$123.9 and \$128.3 million, respectively, under this program.

The University has standby credit facilities to enable the University to purchase tendered variable rate debt in the event of a failed remarketing. Currently, it has two diversified facilities totaling \$200 million that are committed for this sole purpose and cannot be used for operating needs of the University. As of August 31, 2015 and 2014, there were no draws against these lines of credit.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

The University also has a \$75 million line of credit and the Emory Clinic has a \$15 million line of credit at August 31, 2015. There were no balances outstanding as of August 31, 2015. There were no draws on either line of credit for 2015 and 2014.

The University has two letters of credit with a commercial bank totaling \$1.7 million. There were no draws against these letters of credit as of August 31, 2015 and 2014.

During fiscal year 2014, Emory Healthcare and Emory-Adventist Health System, made the decision to close Emory Adventist Hospital and sell the related real estate property during fiscal year 2015 due to sustainability issues. The closure process was completed during fiscal year 2015. As a result, the university's obligation to guarantee \$6.3 million of an \$18.1 million outstanding loan payable to Adventist Health System is no longer in place.

The terms of the University's long term debt provide for certain financial and nonfinancial covenants, including provisions as to the use of the proceeds, limits as to arbitrage and bond issue costs, and various other administrative requirements. At August 31, 2015, management believes that the University was in compliance with these covenants.

#### (12) Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets consist of the following as of August 31 (in thousands):

	<b>2015</b>	<b>2014</b>
Appreciation on endowments restricted until appropriated	\$ 2,432,747	2,603,231
Term endowments	125,030	124,724
Contributions receivable, time and purpose restricted	74,787	85,192
Capital projects and other donor designations	168,970	183,643
Annuity and life income agreements	5,842	8,471
	\$ 2,807,376	3,005,261

Permanently restricted net assets include endowment funds subject to UPMIFA (note 7) as well as perpetual trusts and endowments held by others. Permanently restricted net assets as of August 31 are comprised of (in thousands):

	<b>2015</b>	<b>2014</b>
Donor-restricted endowments	\$ 806,288	731,633
Interests in perpetual funds held by others	1,071,531	1,130,063
Contributions receivable, restricted for endowment	17,937	50,475
Annuity and life income agreements	1,874	2,215
Split interest trusts	3,547	3,162
	\$ 1,901,177	1,917,548

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

Generally, the donors of these restricted gifts permit the University to use all or part of the income earned and net appreciation on related investments for general or specific purposes, such as scholarships, faculty salaries or other operational and administrative support.

#### (13) Investment Return

Investment return, including interest on perpetual funds, as reflected in the accompanying consolidated statements of activities, for August 31 is as follows (in thousands):

	<u>2015</u>	<u>2014</u>
Endowment spending distribution for current operations	\$ 165,880	157,174
Distributions from perpetual funds	32,490	29,979
Other investment income designated for current operations	41,266	37,477
Total operating return	<u>239,636</u>	<u>224,630</u>
Realized gains on investments	281,593	416,749
Unrealized (losses) gains on investments, net	(587,400)	316,861
Change in undistributed income from perpetual funds held by others	(58,532)	95,939
Total nonoperating (loss) gain	<u>(364,339)</u>	<u>829,549</u>
Total investment return	<u>\$ (124,703)</u>	<u>1,054,179</u>

In addition to a core internal group of investment professionals dedicated to the management of Emory's investments, the University also employs external investment managers. External management fees paid directly (i.e., segregated investment account fees, custody fees, internal staff expenses and consulting reviews) totaled \$28.7 million and \$25.9 million for fiscal 2015 and 2014, respectively. Fees and expenses paid to investment managers related to investments in funds which are not segregated from earnings are recorded on the accrual basis and are netted against either the investment income or net asset values of the funds themselves.

#### (14) Retirement and Deferred Compensation Plans

The University has a defined contribution plan under Internal Revenue Code (IRC) Section 403(b) covering certain employees and teaching staff. The University contributes an amount equal to 6% of each eligible employee's compensation to the plan as well as a supplemental contribution of 3% based on a 1.5 to 1 match of employee contributions of up to 2% of compensation. Emory Healthcare sponsors a retirement plan, covering most full time employees, under which annuities are purchased with contributions by Emory Healthcare and its employees. The benefits are vested only to the extent of the annuities purchased. The Emory Clinic (TEC) sponsors The Emory Clinic, Inc. Retirement Savings Plan (the Plan), covering all its employees, except those considered leased employees or those covered under collective bargaining agreements, as defined. The Plan provides for employees to make salary reduction contributions and for TEC to make discretionary contributions for employees who have attained the age of 21 and are employees at the date the contribution is made. The Plan provides for contributions at an annual determined percentage of compensation and employees cliff vest in employer contributions after five years of service. Retirement

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

expense totaled \$118.9 million and \$118.5 million during 2015 and 2014, respectively, and is included in operating expense in the accompanying consolidated statements of activities.

The University sponsors an IRC Section 457(b) Deferred Compensation Plan primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees who are eligible for participation and elect to make salary deferrals under the Deferred Compensation Plan. These assets are fully vested and available to the participating employees at the point of termination of employment from the University. As of August 31, 2015 and 2014, respectively, the University held other assets of \$86.0 million and \$82.5 million under the plan. These assets are included in other assets, which are designated by the University to pay future Salary Deferral Plan payments. The assets are held in separate investment funds for which \$83.1 million and \$79.6 million are classified as Level 1 as of August 31, 2015 and 2014, respectively, and \$2.9 million are classified as Level 2 as of both August 31, 2015 and 2014. Associated liabilities for the obligations of \$86.0 million and \$82.5 million as of August 31, 2015 and 2014, respectively, are included in accrued liabilities for benefit obligations and professional liabilities.

#### (15) Pension Plan

Emory Healthcare sponsors a defined benefit pension plan (the Plan). The plan was curtailed, effective December 31, 2011. The terms of the curtailment generally provide that no further benefit accrual under the Plan is provided for service after the effective date nor will new entrants into the Plan be permitted after the effective date.

The JOC assumed certain defined benefit pension liabilities covering certain employees of the entities contributed to the JOC by SJHS (SJHS Pension Plan). The Plan was curtailed, effective December 31, 2011, and the JOC has agreed to provide for funding of the plan, generally over 10 years, beginning in fiscal 2015, subject to certain terms and conditions.

At the time of the formation of the JOC and assumption of control over the JOC by Emory Healthcare, Emory Healthcare recognized as part of the business combination a liability representing the unfunded status of the SJHS Pension Plan, in accordance with FASB ASC 805-20, *Business Combinations – Identifiable Assets, Liabilities, and Any Noncontrolling Interest*. The SJHS Pension Plan is accounted for by Emory Healthcare as a multiple-employer plan in accordance with FASB ASC 715-30, *Defined Benefit Plans – Pension*.

The changes in the projected benefit obligations as of August 31 follow (in thousands):

	2015		2014	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Projected benefit obligation, beginning of year	\$ 286,612	140,614	242,941	119,060
Interest cost	12,291	5,947	12,446	5,995
Actuarial loss (gain)	3,273	(2,357)	35,830	19,267
Benefits paid	(15,788)	(4,137)	(4,605)	(3,708)
Projected benefit obligation, end of year	\$ 286,388	140,067	286,612	140,614

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

Given the fiscal 2012 curtailment of the plans, the accumulated benefit obligations at August 31, 2015 and 2014 are the same as the projected benefit obligations.

The changes in the fair value of plan assets, funded status of the plans, and the status of amounts recognized in the accompanying consolidated statements of financial position as of August 31 follow (in thousands):

	2015		2014	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Fair value of plan assets, beginning of year	\$ 215,453	93,874	180,815	85,220
Actual return on plan assets	(9,782)	(3,718)	37,292	12,362
Employer contributions	2,623	2,912	1,951	—
Benefits paid	(15,788)	(4,137)	(4,605)	(3,708)
Fair value of plan assets, end of year	<u>\$ 192,506</u>	<u>88,931</u>	<u>215,453</u>	<u>93,874</u>
Funded status - accrued pension cost recognized in the consolidated statements of financial position	<u>\$ (93,882)</u>	<u>(51,136)</u>	<u>(71,159)</u>	<u>(46,740)</u>

The components of net periodic pension cost as of August 31 follow (in thousands):

	2015		2014	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Interest cost	\$ 12,291	5,947	12,446	5,995
Expected return on plan assets	(15,349)	(6,484)	(13,930)	(6,243)
Amortization of prior service cost	—	(438)	—	(438)
Recognized actuarial loss	6,881	1,592	4,254	1,231
Net periodic pension cost	<u>\$ 3,823</u>	<u>617</u>	<u>2,770</u>	<u>545</u>

The amounts accumulated in unrestricted net assets for net unrecognized actuarial loss totaled \$84.9 million and \$63.4 million as of August 31, 2015 and 2014, respectively, for Emory Healthcare and \$53.2 million and \$46.6 million as of August 31, 2015 and 2014, respectively, for SJHS Pension Plan.

Emory Healthcare's net loss of \$6.3 million and SJHS Pension Plan's net loss of \$1.3 million are expected to be amortized from unrestricted net assets into net periodic pension cost in fiscal 2016.



**EMORY UNIVERSITY**

Notes to Consolidated Financial Statements

August 31, 2015 and 2014

Weighted average assumptions used to determine benefit obligations in the accompanying consolidated statements of financial position for 2015 and 2014 follow:

	2015		2014	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Discount rate	4.67%	4.62%	4.33%	4.30%
Expected long-term rate of return on plan assets	8.00	7.50	8.00	7.50

Weighted average assumptions used to determine net periodic pension cost for 2015 and 2014 follow:

	2015		2014	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Discount rate	4.33%	4.30%	5.17%	5.12%
Expected return on plan assets	8.00	7.50	8.00	7.50

***Emory Healthcare Plan Assets***

The Plan's investment objectives are to protect long-term asset value by applying prudent, low-risk, high-quality investment disciplines and to enhance the values by maximizing investment returns through active security management within the framework of the Plan's investment policy. Asset allocation strategies and investment management structure are designed to meet the Plan's investment objectives.

The Plan's expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the Plan's target asset allocation.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

The following table summarizes the Plan's assets which are recorded at fair value as of August 31 (in thousands):

		2015						
		Total fair value	NAV	Fair value hierarchy		Target allocation	Total asset allocation	
				Level 1	Level 2			
Investments:								
Short-term investments and cash equivalents	\$	(220)	47	(267)	—	—%	—%	
Commingled funds - equity		135,078	135,078	—	—	70	70	
Commingled funds - fixed income		57,648	57,648	—	—	30	30	
Total investments	\$	192,506	192,773	(267)	—	100%	100%	
		2014						
		Total fair value	NAV	Fair value hierarchy		Target allocation	Total asset allocation	
				Level 1	Level 2			
Investments:								
Short-term investments and cash equivalents	\$	319	—	319	—	—%	—%	
Commingled funds - equity		149,560	149,560	—	—	70	70	
Commingled funds - fixed income		65,574	65,574	—	—	30	30	
Total investments	\$	215,453	215,134	319	—	100%	100%	

### ***SJHS Pension Plan Assets***

Under the terms of the agreement forming the JOC, the assets of the SJHS Pension Plan formally remain assets of SJHS and the plan assets remain invested in the CHE Trinity Health Pension Investment Program. Accordingly, neither the JOC nor Emory Healthcare has discretion over the management of the plan assets. However, the plan assets related to the entities contributed to the JOC (and certain other employees leased to the JOC) are contractually required to be clearly separated from the plan assets of the other entities participating in the CHE Trinity Health Employee Pension Program. The SJHS Pension Plan's investment objectives are to protect long-term asset value by applying prudent, low-risk, high-quality investment disciplines and to enhance the values by maximizing investment returns through active security management within the framework of the plan's investment policy. Asset allocation strategies and investment management structure are designed to meet the plan's investment objectives.

The SJHS Pension Plan's expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the plan's target asset allocation.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

The following table summarizes the Plan's assets which are recorded at fair value as of August 31 (in thousands):

	2015					
	Total	NAV	Fair value hierarchy		Target allocation	Total asset allocation
	fair value		Level 1	Level 2		
Investments:						
Short-term investments and cash equivalents	\$ 1,531	—	1,531	—	—%	2%
Commingled funds - equity	44,072	24,308	17,878	1,886	50	50
Commingled funds - fixed income	34,374	2,057	—	32,317	40	38
Managed funds	8,954	3,106	5,848	—	10	10
Total investments	<u>\$ 88,931</u>	<u>29,471</u>	<u>25,257</u>	<u>34,203</u>	<u>100%</u>	<u>100%</u>
	2014					
	Total	NAV	Fair value hierarchy		Target allocation	Total asset allocation
	fair value		Level 1	Level 2		
Investments:						
Short-term investments and cash equivalents	\$ 2,214	—	2,214	—	—%	3%
Commingled funds - equity	47,188	20,355	26,833	—	50	50
Commingled funds - fixed income	31,024	31,024	—	—	40	33
Managed funds	13,448	13,420	28	—	10	14
Total investments	<u>\$ 93,874</u>	<u>64,799</u>	<u>29,075</u>	<u>—</u>	<u>100%</u>	<u>100%</u>

### ***Cash Flows***

Emory Healthcare does not expect to contribute to the Emory Healthcare Pension Plan in fiscal 2016 and expects to contribute \$5.7 million to the SJHS Pension Plan in fiscal 2016.

### ***Expected Future Benefit Payments***

Emory Healthcare annual future benefit payments, excluding lump sum settlements, are expected to range from \$6.6 million to \$11.5 million, for the next five years. SJHS Pension Plan annual future benefit payments, excluding lump sum settlements, are expected to range from \$4.8 million to \$6.2 million, for the next five years.

### ***Other Items***

Emory Healthcare uses the straight-line method to amortize prior service cost for both plans.

## **(16) Postretirement Healthcare and Life Insurance Benefits**

The University and Emory Healthcare each fund a separate trust (VEBA Trust) for retiree health and life benefits. The assets of the VEBA Trust are invested primarily in equity and fixed income securities. The University funds these benefits only to the extent of current retiree claims. The University measures its participation in the VEBA Trust at August 31.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

The changes in the accumulated postretirement benefit obligation (APBO) as of August 31 are as follows (in thousands):

	<b>2015</b>			<b>2014</b>
	<b>Emory University</b>	<b>Emory Healthcare</b>	<b>Total</b>	<b>Total</b>
APBO, beginning of year	\$ 83,494	46,803	130,297	108,178
Service cost	1,531	678	2,209	1,936
Interest cost	3,551	1,991	5,542	5,517
Plan changes	—	—	—	263
Actuarial loss (gain)	(255)	(1,897)	(2,152)	19,378
Benefits paid	(2,982)	(1,620)	(4,602)	(5,645)
Retiree drug subsidy paid	—	—	—	670
APBO, end of year	<u>\$ 85,339</u>	<u>45,955</u>	<u>131,294</u>	<u>130,297</u>

The changes in the fair value of plan assets, funded status of the plan and the status of the accrued postretirement benefit obligation recognized in the accompanying consolidated statements of financial position as of August 31 are as follows (in thousands):

	<b>2015</b>			<b>2014</b>
	<b>Emory University</b>	<b>Emory Healthcare</b>	<b>Total</b>	<b>Total</b>
Fair value of plan assets, beginning of year	\$ 59,853	22,136	81,989	71,158
Actual return on plan assets	(1,172)	(743)	(1,915)	12,577
Benefits paid by Emory	—	(1,482)	(1,482)	(1,947)
Retiree drug subsidy	—	—	—	201
Fair value of plan assets, end of year	<u>\$ 58,681</u>	<u>19,911</u>	<u>78,592</u>	<u>81,989</u>
Funded status - accrued postretirement benefit cost recognized in the consolidated statements of financial position	<u>\$ (26,658)</u>	<u>(26,044)</u>	<u>(52,702)</u>	<u>(48,308)</u>

Actuarial assumptions used to determine the values of the APBO and the benefit costs for years ended August 31, 2015 and 2014 included a discount rate of 4.67% and 4.33%, respectively. Since the plan was amended on April 11, 2002 to limit the University's liability for future medical care cost increases to 4.00%, the per capita cost increase of healthcare benefits is capped at 4.00%. The estimated long-term rate of return on plan assets was 8.00% for the University and Emory Healthcare for both years ended August 31, 2015 and 2014. During fiscal year 2014, the University's Health Plan Steering Committee approved a change in the postretirement benefits plan whereby it will convert to a Medicare exchange model. The model will use a concierge service to assist participants with plan selection and will include a Health Reimbursement Account (HRA) of \$100 per month for each participant to help pay for the coverage. It will also provide

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

coverage of drug costs for participants in a Part D drug plan who have catastrophic, as defined, expenses. The effective date for this change is September 1, 2014.

The components of net periodic postretirement benefit cost for years ended August 31 were as follows (in thousands):

	2015			2014
	Emory University	Emory Healthcare	Total	Total
Service cost of benefits earned	\$ 1,531	678	2,209	1,936
Interest cost on APBO	3,551	1,991	5,542	5,517
Expected return on plan assets	(4,669)	(1,706)	(6,375)	(5,472)
Recognized net actuarial loss	1,903	1,523	3,426	2,683
Net periodic postretirement benefit cost	\$ 2,316	2,486	4,802	4,664

The amounts accumulated in unrestricted net assets follow (in thousands):

	2015			2014
	Emory University	Emory Healthcare	Total	Total
Net unrecognized actuarial loss	\$ 36,349	17,171	53,520	50,735
Prior service cost	(236)	426	190	263
Total	36,113	17,597	53,710	50,998

In fiscal 2016, net unrecognized actuarial losses of \$2.3 million for Emory University and \$1.4 million for Emory Healthcare are expected to be amortized from unrestricted net assets into net periodic postretirement benefit cost.

#### ***Plan Assets***

The Investment Committee of the Emory University Board of Trustees approves the investment guidelines and asset allocation targets for the pension benefits and postretirement benefits plans. The primary objective of the investments is to ensure the solvency of the plans over time to meet plan obligations. The secondary objective is to meet or exceed the plans' actuarial assumed rate of return over time, without taking excess risk. The funds are diversified by asset class in accordance with established allocation targets and rebalanced as needed. Specific investments are apportioned to a combination of institutional pooled funds and mutual funds.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

The following tables summarize the University's VEBA Trust assets as of August 31 (in thousands):

	2015					
	Total fair value	Fair value hierarchy			Target allocation	Total asset allocation
		NAV	Level 1	Level 2		
Investments:						
Commingled funds - equity	44,138	26,880	17,258	—	75%	75%
Commingled funds - fixed income	14,543	6,209	8,334	—	25	25
Total investments	\$ 58,681	33,089	25,592	—	100%	100%
	2014					
	Total fair value	Fair value hierarchy			Target allocation	Total asset allocation
		NAV	Level 1	Level 2		
Investments:						
Commingled funds - equity	45,502	27,642	17,860	—	75%	76%
Commingled funds - fixed income	14,351	6,116	8,235	—	25	24
Total investments	\$ 59,853	33,758	26,095	—	100%	100%

The following tables summarize Emory Healthcare's VEBA Trust assets as of August 31 (in thousands):

	2015					
	Total fair value	Fair value hierarchy			Target allocation	Total asset allocation
		NAV	Level 1	Level 2		
Investments:						
Commingled funds - equity	\$ 14,796	7,693	7,103	—	75%	74%
Commingled funds - fixed income	5,115	1,784	3,331	—	25	26
Total investments	\$ 19,911	9,477	10,434	—	100%	100%
	2014					
	Total fair value	Fair value hierarchy			Target allocation	Total asset allocation
		NAV	Level 1	Level 2		
Investments:						
Commingled funds - equity	\$ 16,609	8,533	8,076	—	75%	77%
Commingled funds - fixed income	5,527	1,922	3,605	—	25	23
Total investments	\$ 22,136	10,455	11,681	—	100%	100%

### *Cash Flows*

Emory Healthcare plans to fund future retiree claims from VEBA Trust assets.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

#### *Expected Future Benefit Payments*

Annual future benefit payments are expected to range from \$3.1 million to \$3.9 million for Emory University and from \$1.7 million to \$2.1 million for Emory Healthcare, for the next five years.

#### **(17) Charity Care and Community Benefits**

Emory Healthcare provides care to patients who meet certain criteria under their charity care policies without charge or at amounts less than their established rates. Because such operating companies do not pursue collection of amounts determined to qualify as charity care, such amounts are not included in net patient service revenue.

Records are maintained to identify and monitor the level of charity care provided. These records include the amount of charges foregone and actual costs for services furnished under its charity and indigent care policies. The cost of charity care provided totaled approximately \$66.5 million and \$88.0 million for the years ended August 31, 2015 and 2014, respectively. Emory Healthcare estimated these costs by applying a ratio of cost to gross charges to the gross uncompensated charges associated with providing care to the charity patients.

#### **(18) Functional Expenses**

The Consolidated Statements of Activities include the following functional expenses for the years ended August 31 (in thousands):

	<u>2015</u>	<u>2014</u>
Instruction	\$ 403,378	377,491
Research	418,929	400,182
Public service	89,810	82,469
Academic support	152,928	131,113
Student services	83,202	76,848
Institutional support	203,567	178,765
Scholarships and fellowships	16,055	15,659
Medical services	231,519	244,016
Healthcare services	2,687,532	2,547,754
Auxiliary enterprises	45,113	41,790
Independent operations	<u>20,800</u>	<u>18,615</u>
Total operating expenses	<u>\$ 4,352,833</u>	<u>4,114,702</u>

Costs related to the University's operation and maintenance of property, including depreciation of property and equipment and interest on related debt, are allocated to program and supporting activities based upon information reported in the space study, conducted the second half of calendar year 2014, and debt financing records. Total amounts allocated in 2015 and 2014 were \$183.4 million and \$181.5 million, respectively. Fundraising costs, measured by the operating budgets for the function, were approximately \$23.3 million and \$18.2 million in 2015 and 2014, respectively.

## EMORY UNIVERSITY

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

#### **(19) Medical Professional and General Liability Insurance Coverage**

CCIC, Emory Healthcare's wholly owned off-shore captive insurer, provides claims-made primary medical professional and general liability coverage for the University, the Hospitals, Emory Clinic, Emory Specialty Associates, and Wesley Woods Center.

As of August 31, 2015 and 2014, the University has recorded an accrual for estimated losses associated with all retained CCIC risks of approximately \$124.9 million (discounted at 2%) and \$107.6 million (discounted at 2%), respectively.

Emory has purchased layered excess and umbrella reinsurance coverage beyond the amounts retained by CCIC, through various reinsurance carriers, for a total of \$125.0 million per claim and in the aggregate.

The estimated liability for professional and general liability claims will be significantly affected if current and future claims differ from historical trends. While the University monitors reported claims closely and considers potential outcomes as estimated by its actuaries when determining its professional and general liability accruals, the complexity of the claims, the extended period of time to settle the claims and the wide range of potential outcomes complicate the estimation. The University management believes adequate provision has been made for the related risk.

#### **(20) Related-Party Transactions**

The Carter Center, Inc. (CCI) is a nonprofit organization founded by former United States President Jimmy Carter which sponsors various domestic and international programs. The board of trustees of CCI is comprised of 22 members, including the University President and 9 other members appointed by the University's board of trustees. The University's board of trustees has the authority to approve amendments to CCI's articles of incorporation and bylaws and to approve the annual and capital budgets of CCI. The University provides minor administrative support to CCI and has an economic interest in CCI but does not exercise control over the organization.

Funds held in trust for others include \$609.9 million and \$603.5 million representing CCI's investment in the University's long-term investment portfolio of August 31, 2015 and 2014, respectively.

#### **(21) Commitments and Contingencies**

The University is in the process of constructing, renovating and equipping certain facilities for which the outstanding commitments at August 31, 2015 totaled \$34.3 million.

Lawsuits and claims have been filed against the University in the ordinary course of business. As one of the nation's largest research universities and academic medical centers, the University has active litigation that takes several forms. The University's policy is to accrue for litigation and claims when such amounts are probable and can be reasonably estimated based on consultation with external legal counsel and Emory General Counsel review. In addition, the University is subject to many federal and state regulations and, as a result, there may be one or more pending government investigations ongoing at any time. While the outcome of many of these actions is not presently determinable, it is the opinion of management that any resulting liability from these actions will not have a material adverse effect on the consolidated financial position or operating results of the University. The University also has a comprehensive program of primary and excess insurance, if a final judgment were entered in any action in excess of its insurance coverage; the



## **EMORY UNIVERSITY**

### Notes to Consolidated Financial Statements

August 31, 2015 and 2014

University would be liable for the excess. Management of the University believes any current pending lawsuit subjecting the University to liability would not have a materially adverse effect on the University's consolidated financial position.

#### **(22) Subsequent Events**

Emory has evaluated subsequent events after the statement of position date of August 31, 2015 through December 18, 2015, the date the consolidated financial statements were issued. No additional matters were identified for recognition or disclosure.

**SUPPLEMENTARY INFORMATION**

**EMORY UNIVERSITY (excluding Emory Healthcare)**  
**STATEMENTS OF FINANCIAL POSITION - SUPPLEMENTARY INFORMATION**  
*August 31, 2015 and 2014*  
*(Dollars in thousands)*

Schedule 1

	<u>August 31, 2015</u>	<u>August 31, 2014</u>
<b>ASSETS:</b>		
Cash and cash equivalents	\$ 401,168	\$ 433,966
Student accounts receivable, net	46,715	51,150
Loans receivable, net	28,411	28,467
Contributions receivable, net	92,724	135,667
Other receivables, net	156,462	151,471
Prepaid expenses, deferred charges and other assets	200,324	212,315
Investments	6,534,779	6,697,802
Interests in perpetual funds held by others	1,071,531	1,130,063
Property and equipment, net	1,920,761	1,915,843
Due from affiliates	316,747	490,004
<b>Total assets</b>	<b>\$ 10,769,622</b>	<b>\$ 11,246,748</b>
<b>LIABILITIES AND NET ASSETS:</b>		
Accounts payable and accrued liabilities	\$ 179,447	\$ 166,197
Liability for derivative instruments	174,996	148,731
Interest payable	28,828	29,690
Annuities payable	17,073	17,821
Bonds, notes and mortgages payable	1,906,788	1,946,573
Accrued liabilities for benefit obligations and professional liabilities	122,271	145,113
Deferred tuition and other revenue	438,434	422,780
Funds held in trust for others	645,996	643,902
Government advances for federal loan programs	17,834	17,802
<b>Total liabilities</b>	<b>3,531,667</b>	<b>3,538,609</b>
Unrestricted net assets	2,682,463	2,795,319
Temporarily restricted net assets	2,657,818	2,998,775
Permanently restricted net assets	1,897,674	1,914,045
<b>Total net assets</b>	<b>7,237,955</b>	<b>7,708,139</b>
<b>Total liabilities and net assets</b>	<b>\$ 10,769,622</b>	<b>\$ 11,246,748</b>

See accompanying independent auditors' report.

**EMORY UNIVERSITY (excluding Emory Healthcare)**
**Schedule 2**
**STATEMENT OF ACTIVITIES - SUPPLEMENTARY INFORMATION**
*Year ended August 31, 2015 ( with summarized financial information for the year ended 2014)*
*(Dollars in thousands)*

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total August 31, 2015	Total August 31, 2014
<b>OPERATING REVENUES:</b>					
Tuition and fees	\$ 617,826	-	-	\$ 617,826	\$ 592,385
Less: Scholarship allowances	(221,694)	-	-	(221,694)	(215,434)
Net tuition and fees	396,132	-	-	396,132	376,951
Endowment spending distribution	165,880	-	-	165,880	157,174
Distributions from perpetual funds	32,490	-	-	32,490	29,979
Other investment income designated for current operations	39,882	-	-	39,882	34,804
Gifts and contributions	36,945	-	-	36,945	41,348
Grants and contracts	372,791	-	-	372,791	365,653
Indirect cost recoveries	113,945	-	-	113,945	110,516
Medical services	267,327	-	-	267,327	234,855
Sales and services of auxiliary enterprises	71,743	-	-	71,743	68,850
Independent operations	22,006	-	-	22,006	20,543
Other revenue	85,130	-	-	85,130	67,360
Net assets released from restrictions	11,371	(5,030)	-	6,341	3,648
<b>Total operating revenues</b>	<b>1,615,642</b>	<b>(5,030)</b>	<b>-</b>	<b>1,610,612</b>	<b>1,511,681</b>
<b>OPERATING EXPENSES:</b>					
Salaries and fringe benefits	1,184,140	-	-	1,184,140	1,112,192
Student financial aid	11,699	-	-	11,699	11,297
Other operating expenses	286,667	-	-	286,667	269,364
Interest on indebtedness	58,321	-	-	58,321	53,912
Depreciation	124,474	-	-	124,474	120,184
<b>Total operating expenses</b>	<b>1,665,301</b>	<b>-</b>	<b>-</b>	<b>1,665,301</b>	<b>1,566,949</b>
<b>NET OPERATING REVENUES/(EXPENSES):</b>	<b>(49,659)</b>	<b>(5,030)</b>	<b>-</b>	<b>(54,689)</b>	<b>(55,268)</b>
<b>NONOPERATING ACTIVITIES:</b>					
Investment return (less than) in excess of spending distribution for current operations	(132,828)	(171,080)	1,934	(301,974)	715,875
Change in undistributed income from perpetual funds held by others	-	-	(58,532)	(58,532)	95,939
Gifts and contributions	(2,291)	21,977	40,435	60,121	107,762
Net assets released from restrictions	36,298	(42,639)	-	(6,341)	(3,648)
Loss on disposal of property and equipment	(4,485)	-	-	(4,485)	(3,606)
Change in fair value of derivative instruments	(26,265)	-	-	(26,265)	(49,449)
Pension and postretirement benefit plans	3,237	-	-	3,237	(9,200)
Other nonoperating items, net	8,522	(144,185)	(208)	(135,871)	(6,364)
<b>Total nonoperating activities</b>	<b>(117,812)</b>	<b>(335,927)</b>	<b>(16,371)</b>	<b>(470,110)</b>	<b>847,309</b>
Net transfers from affiliates	54,615	-	-	54,615	56,569
<b>CHANGE IN NET ASSETS</b>	<b>(112,856)</b>	<b>(340,957)</b>	<b>(16,371)</b>	<b>(470,184)</b>	<b>848,610</b>
<b>BEGINNING NET ASSETS</b>	<b>2,795,319</b>	<b>2,998,775</b>	<b>1,914,045</b>	<b>7,708,139</b>	<b>6,859,529</b>
<b>ENDING NET ASSETS</b>	<b>\$ 2,682,463</b>	<b>\$ 2,657,818</b>	<b>\$ 1,897,674</b>	<b>\$ 7,237,955</b>	<b>\$ 7,708,139</b>

See accompanying independent auditors' report.

## STATEMENTS OF CASH FLOWS - SUPPLEMENTARY INFORMATION

Years Ended August 31, 2015 and 2014

(Dollars in thousands)

	<u>2015</u>	<u>2014</u>
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Change in net assets	\$ (470,184)	\$ 848,610
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:		
Noncash equity transfer to affiliate	137,425	-
Gifts and contributions for endowment and capital projects	3,794	(33,850)
Net realized gain on sale of investments	(280,859)	(408,602)
Net unrealized loss (gains) on investments	434,871	(520,845)
Loss on disposal of property and equipment	4,485	3,606
Interests in perpetual funds held by others	58,532	(95,939)
Depreciation and amortization	123,817	119,554
Accretion/amortization of bond discounts/premiums	(2,060)	(3,592)
Change in fair value of derivative instruments	26,265	49,449
Gifts of securities and other assets	(7,910)	(19,785)
(Increase) decrease in:		
Accounts receivable, net	(556)	(15,740)
Contributions receivable for operations	(10,068)	(45,512)
Prepaid expenses, deferred charges and other assets	19,347	(16,711)
Increase (decrease) in:		
Accounts payable and interest payable	(2,837)	4,029
Accrued liabilities for benefit obligations and professional liabilities	(22,842)	24,431
Deferred tuition and other revenue	15,654	19,367
<b>Net cash provided (used in) by operating activities</b>	<b><u>26,874</u></b>	<b><u>(91,530)</u></b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Disbursements of loans to students	(4,863)	(6,239)
Repayment of loans from students	4,919	4,494
Proceeds from sales and maturities of investments	22,441,599	15,174,832
Purchases of investments	(22,424,678)	(14,950,116)
Purchases of property, plant and equipment	(118,652)	(172,645)
Increase in deposits held in custody for others	2,094	112,366
Decrease in investments held for affiliate	-	(185,646)
<b>Net cash used in investing activities</b>	<b><u>(99,581)</u></b>	<b><u>(22,954)</u></b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Gifts and contributions for endowment and capital projects	49,218	134,687
Proceeds from bonds and mortgages payable	-	28,300
Principal repayments of bonds and mortgages payable	(37,725)	(61,259)
Decrease (increase) in affiliate debt, net	35,832	82,528
Required posting of collateral	(6,700)	(600)
(Decrease) increase in annuities payable	(748)	120
Increase in government advances for federal loan programs	32	38
<b>Net cash provided by financing activities</b>	<b><u>39,909</u></b>	<b><u>183,814</u></b>
<b>Net (decrease) increase in cash and cash equivalents</b>	<b><u>(32,798)</u></b>	<b><u>69,330</u></b>
<b>Cash and cash equivalents at beginning of year</b>	<b><u>433,966</u></b>	<b><u>364,636</u></b>
<b>Cash and cash equivalents at end of year</b>	<b><u>\$ 401,168</u></b>	<b><u>\$ 433,966</u></b>
Supplemental disclosure:		
Cash paid for interest	\$ 61,600	\$ 55,967
Accounts payable attributable to property, plant and equipment purchases	15,223	13,352
Income taxes paid, net	368	242
Pledge payments received in form of securities and immediately sold	28,000	80,000

See accompanying independent auditors' report.

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS**

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
<b>Student Financial Assistance Cluster:</b>			
U.S. Department of Education:			
Federal Work Study		84.033	\$ 2,010,487
Federal Supplemental Education Opportunity Grant Program		84.007	791,876
Federal Pell Grant		84.063	7,324,011
Federal Direct Stafford Loan Program		84.268	82,988,265
Federal Direct PLUS Loan Program		84.268	34,859,953
Federal Perkins Loan Program		84.038	16,431,621
Total U.S. Department of Education			144,406,213
Total Student Financial Assistance Cluster			144,406,213
<b>Research and Development Cluster:</b>			
U.S. Department of Agriculture:			
Agriculture and Food Research Initiative (AFRI)	2010-85212-20608	10.310	12,284
Agriculture and Food Research Initiative (AFRI)	2011-67013-30090	10.310	3,509
Agriculture and Food Research Initiative (AFRI)	2011-6701330131	10.310	30,379
Agriculture and Food Research Initiative (AFRI)	2013-67011-21133	10.310	32,709
Agriculture and Food Research Initiative (AFRI)	2015-67017-23080	10.310	24,778
Pass-through Childrens Hospital & Research Center	12.7814_Emory_02	10.310	(57)
Pass-through North Carolina A and T State University	2011-0494-12 Mod. 7	10.310	164,040
Pass-through University of Florida	UF12245	10.310	81,283
Total CFDA No. 10.310			348,925
U.S. Department of Agriculture Total			348,925
U.S. Department of Commerce:			
Sea Grant Support			
Pass-through Georgia Sea Grant, University of Georgia	RR746-075/4945466	11.417	52,951
Total CFDA No. 11.417			52,951
Climate and Atmospheric Research			
Total CFDA No. 11.431	NA130AR4310059	11.431	197,537
U.S. Department of Commerce Total			250,488
U.S. Department of Defense:			
Basic and Applied Scientific Research	N00014-09-1-0912	12.300	171
Basic and Applied Scientific Research	N00014-13-1-0253	12.300	299,883
Basic and Applied Scientific Research	N00014-13-1-0864 PO1	12.300	52,886
Basic and Applied Scientific Research	W81XWH-12-1-0564	12.300	379,663
Total CFDA No. 12.300			732,603
Basic Scientific Research – Combating Weapons of Mass Destruction			
Total CFDA No. 12.351		12.351	79,986
Total CFDA No. 12.351			79,986
Military Medical Research and Development			
Military Medical Research and Development	W81XWH0810494	12.420	1,392
Military Medical Research and Development	W81XWH-11-1-0816	12.420	320,216
Military Medical Research and Development	W81XWH-13-1-0495	12.420	138,041
Military Medical Research and Development	W81XWH-12-0255	12.420	168,974
Military Medical Research and Development	W81XWH-12-10138	12.420	59,799
Military Medical Research and Development	W81XWH-12-1-0407	12.420	11,982
Military Medical Research and Development	W81XWH-12-1-0436	12.420	268,404
Military Medical Research and Development	W81XWH-13-1-0269	12.420	5,034
Military Medical Research and Development	W81XWH-13-1-0334	12.420	88,287
Military Medical Research and Development	W81XWH-14-1-0616	12.420	189,884
Pass-through Atlanta Research and Education Foundation	HRTDoD	12.420	32,388
Pass-through Atlanta Research and Education Foundation	M14050	12.420	46,848
Pass-through M D Anderson Cancer Center	PO# 29315-2000 Chen	12.420	369
Pass-through New York University	11-01935	12.420	35
Pass-through New York University	13-A0-00-001212	12.420	65,915
Total CFDA No. 12.420			1,397,568
Basic Scientific Research			
Basic Scientific Research	W911NF0510200/P00011	12.431	(3,828)
Basic Scientific Research	W911NF-11-1-0477-003	12.431	5,789
Basic Scientific Research	W911NF-12-1-0136 P00	12.431	174,753
Basic Scientific Research	W911NF-13-1-0100P003	12.431	180,920
Basic Scientific Research	W911NF-13-1-0182	12.431	56,311
Basic Scientific Research	W911NF-13-1-0247	12.431	20,432
Basic Scientific Research	W911NF1410208-P00003	12.431	125,054
Basic Scientific Research	W911NF-14-1-0471	12.431	125,054
Pass-through University of California Los Angeles	1000GSA786	12.431	26,194
Total CFDA No. 12.431			710,679
Basic, Applied, and Advanced Research in Science and Engineering			
Total CFDA No. 12.630	FA9550-13-1-0002	12.630	496,918
Total CFDA No. 12.630			496,918
Uniformed Services University Medical Research Projects			
Pass-through Geneva Foundation	S-1254-02	12.750	20,712
Pass-through Geneva Foundation	S-1263-01	12.750	25,763
Pass-through Geneva Foundation	S-1348-01	12.750	40,118
Pass-through Henry M Jackson Foundation	2407795400	12.750	(209,969)
Pass-through Henry M Jackson Foundation	HT9404-13-0030	12.750	241,337
Total CFDA No. 12.750			117,961
Air Force Defense Research Sciences Program			
Air Force Defense Research Sciences Program	FA9550-07-1-0575	12.800	(727)
Air Force Defense Research Sciences Program	FA9550-12-1-0084-02	12.800	55,718
Air Force Defense Research Sciences Program	FA9550-12-1-0233-002	12.800	39,424
Air Force Defense Research Sciences Program	FA9550-12-1-0240 P00	12.800	91,250
Passed-through Georgia Institute of Technology	R0668-G1 AMD 9	12.800	9,343
Passed-through University Of Illinois	2012-03966-02(A0076)	12.800	93,923
Passed-through University Of Southern California	34438627	12.800	50,421
Passed-through Yale University	C13L11587(L00124)	12.800	232,019
Total CFDA No. 12.800			571,371

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Research and Technology Development:	W31P4Q-14-1-0010	12.910	\$ 1,441,957
Pass-through University of Pennsylvania	564000	12.910	196,162
Total CFDA No. 12.910			1,638,119
Contract	HDTRA-13-C-0072	12.RD	1,583
Contract	W81XWH-12-1-0217	12.RD	333,642
Contract	W81XWH-12-C-0203	12.RD	952,424
Contract	1406-04-09-GT-21447	12.RD	1,050
Contract	N62645-11-C-4008	12.RD	657,285
Contract	PATRIOT LIFESAVER 20	12.RD	3,879
Pass-through University of Southern California	PO# 57169635	12.RD	55,811
Pass-through Henry M Jackson Foundation	760515	12.RD	15,505
Total CFDA No. 12.RD			2,021,179
U.S. Department of Defense Total			7,766,384
U.S. Department of State:			
Academic Exchange Programs – Humphrey Fellowship Program:			
Pass-through Institute Of International Education	2014-2015	19.010	19,789
Total CFDA No. 19.010			19,789
Academic Exchange Programs – English Language Programs:			
Pass-through Institute Of International Education	SECAAS07CA019(CS)	19.421	(25,090)
Total CFDA No. 19.421			(25,090)
U.S. Department of State Total			(5,301)
National Aeronautics and Space Administration:			
Science	NNX08BA08G	43.001	2,243
Science	NNX11A107G	43.001	2,627
Science	NNX11A153G S08	43.001	157,834
Science	NNX14A01G	43.001	87,097
Science	NNX15AH74G	43.001	18,741
Pass-through University Of Georgia	RR185-437/4941956AM5	43.001	82,986
Pass-through University Of Nebraska	25-0514-0171-002	43.001	14,616
Total CFDA No. 43.001			366,144
Aeronautics:			
Passed-through California Institute Of Technology	1363692	43.002	41,235
Total CFDA No. 43.002			41,235
Exploration	NNX11AC30G S16	43.003	1,475,307
Exploration	NNX12AC30G	43.003	42,267
Exploration	NNX15AD63G	43.003	165,874
Total CFDA No. 43.003			1,683,448
Space Operations:			
Pass-through Center For The Advancement Of Science In	GA-2014-126	43.007	130,426
Total CFDA No. 43.007			130,426
Contract:			
Pass-through University Of Nebraska	25-0514-0125-002	43.999	9,818
Total CFDA No. 43.999			9,818
National Aeronautics and Space Administration Total			2,231,071
National Endowment for the Humanities:			
Promotion of the Humanities_Research	RQ-50566-11	45.161	90,727
Total CFDA No. 45.161			90,727
Promotion of the Humanities_Professional Development	AQ-50761-12	45.163	957
Total CFDA No. 45.163			957
National Endowment for the Humanities Total			91,684
National Science Foundation:			
Engineering Grants	CBET-1150235	47.041	29,049
Engineering Grants	CBET-1159434	47.041	136,843
Engineering Grants	CBET-1249250	47.041	3,214
Engineering Grants	CBET-1336401	47.041	64,619
Engineering Grants	CMMI-1250235	47.041	59,386
Engineering Grants	ECCS 1503878	47.041	6,861
Engineering Grants	ECCS 1218419	47.041	(3,883)
Engineering Grants	ECCS-1305586	47.041	100,110
Engineering Grants	EFR1-1137229	47.041	285,788
Engineering Grants	1135345	47.041	4,514
Pass-through Council Of Graduate Schools	E67A01G1/TASK 013	47.041	(22,546)
Pass-through Georgia Institute of Technology	RA414-S1	47.041	1,880
Pass-through Georgia Institute of Technology	RB392-G2	47.041	129,156
Total CFDA No. 47.041			794,991
Mathematical and Physical Sciences	1455086	47.049	79,259
Mathematical and Physical Sciences	CHE – 0956442	47.049	14
Mathematical and Physical Sciences	CHE 1212371	47.049	384
Mathematical and Physical Sciences	CHE_1362249	47.049	138,356
Mathematical and Physical Sciences	CHE-1057350	47.049	1,704
Mathematical and Physical Sciences	CHE-1124862	47.049	(12)
Mathematical and Physical Sciences	CHE-1145227	47.049	79,773
Mathematical and Physical Sciences	CHE-1150492	47.049	122,126
Mathematical and Physical Sciences	CHE-1151304	47.049	509
Mathematical and Physical Sciences	CHE-1205646 Amend 4	47.049	4,264,505
Mathematical and Physical Sciences	CHE-1205646-Supp	47.049	(5,532)
Mathematical and Physical Sciences	CHE-1213246	47.049	81,454
Mathematical and Physical Sciences	CHE-1213904	47.049	80,872



**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Mathematical and Physical Sciences	CHE-1265586	47.049	\$ 129,627
Mathematical and Physical Sciences	CHE-1309817	47.049	187,172
Mathematical and Physical Sciences	CHE-1352040	47.049	135,428
Mathematical and Physical Sciences	CHE-1362113	47.049	246,525
Mathematical and Physical Sciences	CHE-1362281	47.049	211,357
Mathematical and Physical Sciences	CHE-1362502	47.049	80,069
Mathematical and Physical Sciences	CHE-1412580	47.049	129,675
Mathematical and Physical Sciences	CHE-1463552	47.049	57,246
Mathematical and Physical Sciences	CHE-1506405	47.049	37
Mathematical and Physical Sciences	CHE-1507932	47.049	35
Mathematical and Physical Sciences	DMA-112086	47.049	59,177
Mathematical and Physical Sciences	DMR0804174	47.049	2,500
Mathematical and Physical Sciences	DMR-1151646 Amend 4	47.049	114,527
Mathematical and Physical Sciences	DMR-1207431-002	47.049	92,619
Mathematical and Physical Sciences	DMR-1218414	47.049	(423)
Mathematical and Physical Sciences	DMR-1409851	47.049	177,799
Mathematical and Physical Sciences	DMR-1504449	47.049	2,569
Mathematical and Physical Sciences	DMS 1157289	47.049	88,206
Mathematical and Physical Sciences	DMS-1000617	47.049	14,347
Mathematical and Physical Sciences	DMS-1115692	47.049	46,979
Mathematical and Physical Sciences	DMS-1201542	47.049	21,098
Mathematical and Physical Sciences	DMS-1208874	47.049	49,739
Mathematical and Physical Sciences	DMS-1250467-002	47.049	14,806
Mathematical and Physical Sciences	DMS-1301698	47.049	54,258
Mathematical and Physical Sciences	DMS-1301785	47.049	41,596
Mathematical and Physical Sciences	DMS-1401319	47.049	90,831
Mathematical and Physical Sciences	DMS-1412973	47.049	28,276
Mathematical and Physical Sciences	DMS-1418889	47.049	31,810
Mathematical and Physical Sciences	DMS-1419060	47.049	42,818
Mathematical and Physical Sciences	DMS-1463882	47.049	68,951
Mathematical and Physical Sciences	PHY-1410978	47.049	7,341
Pass-through Georgia Institute Of Technology	RB011-G8, AMND 4	47.049	(42,749)
Total CFDA No. 47.049			7,027,658
Geosciences	1360330	47.050	290,970
Geosciences	AGS-1350021	47.050	80,186
Total CFDA No. 47.050			371,156
Computer and Information Science and Engineering	1350885	47.070	47,536
Computer and Information Science and Engineering	CNS-1117763	47.070	115,797
Pass-through Notre Dame University	CNS-1405912	47.070	36,475
Total CFDA No. 47.070			199,808
Biological Sciences	1120572 AM 6	47.074	5,411
Biological Sciences	1146316	47.074	207,936
Biological Sciences	1354829	47.074	128,357
Biological Sciences	1359575	47.074	89,658
Biological Sciences	1456912	47.074	13,934
Biological Sciences	1457291	47.074	370
Biological Sciences	1501928	47.074	4,759
Biological Sciences	DBI-1344208	47.074	124,571
Biological Sciences	DBI-1353939	47.074	499,971
Biological Sciences	DEB-1257160	47.074	51,831
Biological Sciences	IOS-1149829	47.074	161,727
Biological Sciences	IOS-1208126	47.074	77,697
Biological Sciences	IOS-1354998	47.074	230,544
Biological Sciences	MCB-0953714	47.074	22,856
Biological Sciences	MCB-1350829	47.074	196,232
Biological Sciences	MCB-1413062	47.074	163,426
Biological Sciences	ELO18-50	47.074	(21,185)
Pass-through Georgia State University	60036543	47.074	29,466
Pass-through Ohio State University	S-000585	47.074	184,837
Pass-through University Of California Riverside	3001382166	47.074	776
Pass-through University Of Michigan	557585	47.074	48,778
Pass-through University Of Pennsylvania			
Total CFDA No. 47.074			2,221,952
Social, Behavioral, and Economic Sciences	1125756 AMD 02	47.075	129,422
Social, Behavioral, and Economic Sciences	1357497	47.075	28,899
Social, Behavioral, and Economic Sciences	1533260	47.075	1,779
Social, Behavioral, and Economic Sciences	BCS-1225734	47.075	668
Social, Behavioral, and Economic Sciences	BCS-1245803	47.075	1,264
Social, Behavioral, and Economic Sciences	BCS-1260270	47.075	80
Social, Behavioral, and Economic Sciences	BCS-1260640	47.075	1,010
Social, Behavioral, and Economic Sciences	BCS-1354088	47.075	75,620
Social, Behavioral, and Economic Sciences	BCS-1357284	47.075	5,024
Social, Behavioral, and Economic Sciences	BCS-1413395	47.075	15,691
Social, Behavioral, and Economic Sciences	BCS-1430403	47.075	17,856
Social, Behavioral, and Economic Sciences	BCS-1528091	47.075	1,701
Social, Behavioral, and Economic Sciences	SES-1067899	47.075	18,504
Social, Behavioral, and Economic Sciences	SES-1125539	47.075	523
Social, Behavioral, and Economic Sciences	SES-1127665	47.075	19,650
Social, Behavioral, and Economic Sciences	SMA-1306132	47.075	95,610
Social, Behavioral, and Economic Sciences	SMA-1328567	47.075	42,004
Pass-through Columbia University	SES-0951516	47.075	26,894
Total CFDA No. 47.075			482,199
Education and Human Resources	DGE1444932	47.076	914,926
Education and Human Resources	DUE-1068238	47.076	296,922
Pass-through Amer Educational Research Association	DRL-0941014	47.076	12,240
Pass-through Georgia Institute Of Technology	Postdoctoral Fellows	47.076	(1,587)
Pass-through Georgia Institute Of Technology	R5702G3 Amend 10	47.076	1,019
Total CFDA No. 47.076			1,223,520

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Office of Cyberinfrastructure	OCI-1124418	47.080	\$ 72,453
Total CFDA No. 47.080			72,453
National Science Foundation Total			12,393,737
U.S. Department of Veterans Affairs:			
Contract:			
Pass-through Atlanta Research and Education Fdtn	2013 EIP	64.000	(197)
Total CFDA No. 64.000			(197)
Veterans State Hospital Care	508-13-3-3103-0185	64.016	6,653
Total CFDA No. 64.016			6,653
Contract:			
U.S. Dept Of Veteran Affairs	621D45004	64.RD	4,248
U.S. Dept Of Veteran Affairs	PO# 508D35025	64.RD	69,200
U.S. Dept Of Veteran Affairs	V247P1879/SURGERY	64.RD	204,600
U.S. Dept Of Veterans Affairs	508-D40002	64.RD	35,613
U.S. Dept Of Veterans Affairs	508-D27115	64.RD	(1,002)
U.S. Dept Of Veterans Affairs	VA247-12-C-0241	64.RD	(369)
U.S. Dept Of Veterans Affairs	VA247-13-C-0364	64.RD	17,944
Pass-through University of Texas Southwestern	803221-CMO800732	64.RD	(38,224)
Total CFDA No. 64.RD			292,010
U.S. Department of Veterans Affairs Total			298,466
U.S. Environmental Protection Agency:			
Environmental Protection Consolidated Research:			
Pass-through Georgia Institute Of Technology	RD557-G1	66.500	43,362
Total CFDA No. 66.500			43,362
Science to Achieve Results (STAR) Research Program	83479901	66.509	1,294,454
Science to Achieve Results (STAR) Research Program	112514-5080711	66.509	22,906
Pass-through Harvard University			1,317,360
Total CFDA No. 66.509			1,317,360
Office of Research and Development Consolidated Research/Training/Fellowships:			
Pass-through Health Effects Institute	4942-RFA13-1/14-3-2	66.511	236,897
Total CFDA No. 66.511			236,897
U.S. Environmental Protection Agency Total			1,597,619
U.S. Department of Energy:			
Office of Science Financial Assistance Program	DE-FG02-01ER15153	81.049	153,943
Office of Science Financial Assistance Program	DE-FG02-02ER15377	81.049	208,527
Office of Science Financial Assistance Program	DE-FG02-03ER15461	81.049	(17,691)
Office of Science Financial Assistance Program	DEFG0205ER25696A002	81.049	2,350
Office of Science Financial Assistance Program	DE-FG02-07ER15906-00	81.049	436,004
Office of Science Financial Assistance Program	DE-FG02-97ER14782	81.049	140,699
Office of Science Financial Assistance Program	DE-SC0008798-003	81.049	118,924
Office of Science Financial Assistance Program	DE-SC0010271-001	81.049	109,528
Office of Science Financial Assistance Program	DE-SC0012092	81.049	97,418
Total CFDA No. 81.049			1,249,702
Contract:			
Pass-through Battelle	4000091051	81.RD	2,591
Pass-through UT - Battelle	4000078139	81.RD	(6,223)
Total CFDA No. 81.RD			(3,632)
U.S. Department of Energy Total			1,246,070
U.S. Department of Education:			
Overseas Programs - Doctoral Dissertation Research Abroad	P022A130041	84.022	17,772
Total CFDA No. 84.022			17,772
Javits Fellowships	P170B080018-11	84.170	(3,714)
Total CFDA No. 84.170			(3,714)
U.S. Department of Education Total			14,058
U.S. Department of Health and Human Services:			
Innovations in Applied Public Health Research	5P01TP000300-05 REV	93.061	257,629
Pass-through Partnership for Prevention	UPN09021908	93.061	(66,337)
Total CFDA No. 93.061			191,292
Global AIDS	5U14GH001237-02	93.067	1,314,159
Total CFDA No. 93.067			1,314,159
Family Smoking Prevention and Tobacco Control Act Regulatory Research	5R01CA179422-03	93.077	711,952
Total CFDA No. 93.077			711,952
Food and Drug Administration_Research	4R01FD003527-03	93.103	111,881
Food and Drug Administration_Research	5R01FD003440-03S1	93.103	50,129
Food and Drug Administration_Research	5R01FD003539-06REVIS	93.103	133,687
Pass-through Georgia Institute of Technology	RC223-G1	93.103	5,980
Pass-through Georgia Institute of Technology	RE159-G1	93.103	146,731
Pass-through Muscular Dystrophy Association	MDA 10068	93.103	(9,597)
Pass-through Seattle Children's Research Institute	10974SUB	93.103	110
Pass-through Seattle Children's Research Institute	11066SUB	93.103	29,957
Pass-through Seattle Children's Research Institute	11277SUB	93.103	19,202
Pass-through University of Georgia	RR211-393/4940576	93.103	25,597
Total CFDA No. 93.103			513,677
Maternal and Child Health Federal Consolidated Programs	1 T76MC28446-01-01	93.110	9,099
Maternal and Child Health Federal Consolidated Programs	6 T03 MC07651-09-01	93.110	21,013
Total CFDA No. 93.110			30,112

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Environmental Health	1 R01 ES023839-01A1	93.113	\$ 261,111
Environmental Health	1K22ES025418-01 REVI	93.113	41,498
Environmental Health	1K99ES023475-01	93.113	85
Environmental Health	1R21ES025632-01	93.113	26,824
Environmental Health	3P30ES019776-03S1	93.113	1,419,264
Environmental Health	5 R21 ES022795-02REV	93.113	171,213
Environmental Health	5K25ES020355-02	93.113	32,973
Environmental Health	5K99ES024570-02	93.113	66,557
Environmental Health	5R21ES023763-02	93.113	136,891
Environmental Health	5R21ES023927-02	93.113	169,363
Environmental Health	5T32ES012160-10	93.113	128,309
Environmental Health	5T32ES012870-12	93.113	299,264
Environmental Health	5K01ES019877-05	93.113	130,999
Environmental Health	5P01ES011163-10	93.113	(1,719)
Environmental Health	5P01ES016731-05	93.113	7,765
Environmental Health	5R01ES009047-1-4REVIS	93.113	44,845
Environmental Health	5R01ES012014-10	93.113	477,148
Environmental Health	5R01ES012458-08	93.113	622
Environmental Health	5R01ES015317-05	93.113	3,271
Environmental Health	5R01ES015813-05	93.113	166,747
Environmental Health	5R01ES016175-04	93.113	635
Environmental Health	5R01ES023485-02	93.113	202,150
Environmental Health	5R21ES019697-02REVIS	93.113	41,219
Environmental Health	5T32ES012160-07	93.113	(5,334)
Environmental Health	5T32ES012870-10	93.113	1,769
Pass-through Brown University	00000590	93.113	4,689
Pass-through Harvard School Of Public Health	112481-5047201	93.113	44,575
Pass-through Middlebury College	265332EU-4	93.113	46,460
Pass-through University Of California Berkeley	8345/ PO BB00335881	93.113	47,285
Pass-through University Of California Davis	201016645-01	93.113	19,376
Pass-through University Of California Irvine	2012-2844	93.113	68,515
Total CFDA No. 93.113			4,054,369
Project Grants and Cooperative Agreements for Tuberculosis Control Programs			
Pass-through Georgia Dept of Public Health	4050004615151505	93.116	23,574
Total CFDA No. 93.116			23,574
Oral Diseases and Disorders Research			
Pass-through Georgia Institute of Technology	RD249-G2	93.121	35,280
Pass-through University Of Maryland Baltimore	SR00001689	93.121	6,965
Total CFDA No. 93.121			42,245
Grants to Increase Organ Donations	5R39OT26991-02-00	93.134	297,022
Grants to Increase Organ Donations	R390T20066-03-00	93.134	1,360
Total CFDA No. 93.134			298,382
Centers for Research and Demonstration for Health Promotion and Disease Prevention	5U48DP001909-05REVIS	93.135	656,722
Pass-through Dartmouth College	1612	93.135	104,429
Pass-through Morehouse School of Medicine	002-EMORY-260056-01	93.135	81,819
Pass-through New York University	PO M150039217	93.135	10,676
Pass-through University Of Washington	758251	93.135	1,177
Pass-through University Of Washington	764083 [BPO2357]	93.135	43,212
Total CFDA No. 93.135			898,035
Injury Prevention and Control Research and State and Community Based Programs	5R49CE001494-05	93.136	390,514
Total CFDA No. 93.136			390,514
AIDS Education and Training Centers	3H4AH000670602	93.145	(428)
AIDS Education and Training Centers	5H4AHA00067-09-00	93.145	(17,124)
AIDS Education and Training Centers	6 H4HA000671308	93.145	2,122,440
Total CFDA No. 93.145			2,104,888
Human Genome Research	5R01HG005119-04	93.172	3,111
Human Genome Research	5R01HG007508-03	93.172	205,080
Human Genome Research	1U54HG00391801	93.172	(73,764)
Pass-through Brigham And Womens Hospital	109737	93.172	135,857
Pass-through University Of North Carolina	5033705	93.172	94,855
Total CFDA No. 93.172			365,139
Research Related to Deafness and Communication Disorders	5F31DC011987-03REV	93.173	12,665
Research Related to Deafness and Communication Disorders	5F31DC012225-03	93.173	586
Research Related to Deafness and Communication Disorders	5R01DC005213-11	93.173	85,004
Research Related to Deafness and Communication Disorders	5R01DC007423-05REVIS	93.173	2,718
Research Related to Deafness and Communication Disorders	5R01DC010204-05	93.173	418,837
Research Related to Deafness and Communication Disorders	5R33DC010476-05	93.173	(6,416)
Research Related to Deafness and Communication Disorders	5F32DC012702-03	93.173	50,869
Research Related to Deafness and Communication Disorders	5R01DC006483-10 REV	93.173	225,213
Research Related to Deafness and Communication Disorders	5R01DC008343-10	93.173	374,643
Research Related to Deafness and Communication Disorders	5R01DC005017-10	93.173	(7,119)
Pass-through Georgia State University	SP00011574-03	93.173	1,888
Pass-through Vanderbilt University	VUMC33635	93.173	(163)
Pass-through Vanderbilt University	VUMC33635/5R01DC0043	93.173	5,471
Total CFDA No. 93.173			1,164,196
Nursing Workforce Diversity	5 D19HP269730200	93.178	253,503
Total CFDA No. 93.178			253,503
Immunization Research, Demonstration, Public Information and Education_Training and Clinical Skills Improvement Projects			
Training and Clinical Skills Improvement Projects	5U01IP000413-04 REV	93.185	235,533
Total CFDA No. 93.185			235,533
Research and Training in Complementary and Alternative Medicine	5R01AT007052-04	93.213	407,470
Research and Training in Complementary and Alternative Medicine	5R21AT004208-03	93.213	171

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Research and Training in Complementary and Alternative Medicine	5R21AT007090-02	93.213	\$ 156,216
Research and Training in Complementary and Alternative Medicine	3R21AT004220-03S1	93.213	(513)
Research and Training in Complementary and Alternative Medicine	5R21AT004509-03REVIS	93.213	(628)
Pass-through Massachusetts General Hospital	U01AT000613	93.213	11,558
Pass-through University Of Arizona	54783	93.213	(1,575)
Pass-through University Of Arizona	69020	93.213	(5,729)
Total CFDA No. 93.213			566,970
Research on Healthcare Costs, Quality and Outcomes	1R03HS022595-01REVIS	93.226	32,992
Research on Healthcare Costs, Quality and Outcomes	1R03HS023403-01REVIS	93.226	52,838
Research on Healthcare Costs, Quality and Outcomes	1R36HS022206-01	93.226	6,475
Research on Healthcare Costs, Quality and Outcomes	4R00HS022431-03	93.226	156,918
Research on Healthcare Costs, Quality and Outcomes	4R24HS022059-03	93.226	321,783
Research on Healthcare Costs, Quality and Outcomes	5R03HS021789-02	93.226	20,140
Research on Healthcare Costs, Quality and Outcomes	5R21HS021797-02REVIS	93.226	59,200
Pass-through Georgia State University	SP00011579-02	93.226	5,303
Pass-through Kaiser Foundation Research Health Plan	8276-5R01HS021492-02	93.226	(401)
Total CFDA No. 93.226			655,248
Mental Health Research Grants	1 R21 MH086727-01A1	93.242	(354)
Mental Health Research Grants	1R01MH100318-01A1	93.242	112,867
Mental Health Research Grants	1R21MH106716-01	93.242	50,347
Mental Health Research Grants	3U01MH081988-05S2	93.242	39,795
Mental Health Research Grants	5P50MH05892209	93.242	2,035
Mental Health Research Grants	5P50MH077083-05	93.242	(44,351)
Mental Health Research Grants	5R01MH050268-15	93.242	9,979
Mental Health Research Grants	5R01MH068791-10REVIS	93.242	170,049
Mental Health Research Grants	5R01MH06988604	93.242	2,104
Mental Health Research Grants	5R01MH070437-10REVIS	93.242	508,805
Mental Health Research Grants	5R01MH07055304	93.242	393
Mental Health Research Grants	5R01MH070880-05	93.242	833
Mental Health Research Grants	5R01MH07153104	93.242	117
Mental Health Research Grants	5R01MH072908-10	93.242	439,427
Mental Health Research Grants	5R01MH073719-04	93.242	(15,213)
Mental Health Research Grants	5R01MH078002-05	93.242	420
Mental Health Research Grants	5R01MH078100-05	93.242	1,816
Mental Health Research Grants	5R01MH07877503	93.242	(31,936)
Mental Health Research Grants	5R01MH079100-05	93.242	82
Mental Health Research Grants	5R01MH079448-03	93.242	2,261
Mental Health Research Grants	5R01MH080330-05REV	93.242	280,464
Mental Health Research Grants	5R01MH081148-05	93.242	285,088
Mental Health Research Grants	5R01MH082819-05	93.242	4,082
Mental Health Research Grants	5R01MH082833-04 REV	93.242	131,125
Mental Health Research Grants	5R01MH083712-05REVIS	93.242	398,956
Mental Health Research Grants	5R01MH085600-05	93.242	23,757
Mental Health Research Grants	5R01MH085617-09	93.242	34,044
Mental Health Research Grants	5R01MH090584-05	93.242	522,028
Mental Health Research Grants	5R01MH092284-05	93.242	620,624
Mental Health Research Grants	5R01MH092902-04	93.242	2,132
Mental Health Research Grants	5R01MH099211-03	93.242	411,458
Mental Health Research Grants	5R01MH100122-03	93.242	598,963
Mental Health Research Grants	5R01MH100467-03	93.242	620,779
Mental Health Research Grants	5R01MH102690-02	93.242	861,646
Mental Health Research Grants	5R21MH07686902	93.242	(11,963)
Mental Health Research Grants	5R21MH08204602	93.242	2,003
Mental Health Research Grants	5R21MH084722-02	93.242	(24)
Mental Health Research Grants	5R21MH094525-02REVIS	93.242	26,925
Mental Health Research Grants	5R21MH103187-02	93.242	200,636
Mental Health Research Grants	5R33MH086947-05	93.242	29
Mental Health Research Grants	5U19MH069056-10REVIS	93.242	554,723
Mental Health Research Grants	7R01MH06676703	93.242	1,783
Mental Health Research Grants	1 F31 MH105238-01 RE	93.242	28,692
Mental Health Research Grants	1K08MH105754-01	93.242	117,468
Mental Health Research Grants	1K18MH105098-01	93.242	71,715
Mental Health Research Grants	1R01MH104534-01A1	93.242	351,470
Mental Health Research Grants	1R01MH104632-01A1	93.242	224,256
Mental Health Research Grants	1R01MH107305-01	93.242	76,092
Mental Health Research Grants	1R21MH105816-01A1	93.242	22,541
Mental Health Research Grants	1R21MH105897-01	93.242	92,793
Mental Health Research Grants	1R34MH106368-01A1	93.242	18,529
Mental Health Research Grants	2R56MH071537-11A1	93.242	1,717
Mental Health Research Grants	3R01MH094757-04S1	93.242	361,533
Mental Health Research Grants	4R00MH102355-03	93.242	63,496
Mental Health Research Grants	5F31MH097412-03REV	93.242	17,208
Mental Health Research Grants	5F31MH102165-02	93.242	29,011
Mental Health Research Grants	5F31MH102911-02 REV1	93.242	40,797
Mental Health Research Grants	5F31MH102956-02	93.242	42,990
Mental Health Research Grants	5F31MH105237-02	93.242	41,508
Mental Health Research Grants	5F31MH106298-02	93.242	39,330
Mental Health Research Grants	5F32MH101976-02	93.242	57,795
Mental Health Research Grants	5F32MH102890-02	93.242	55,925
Mental Health Research Grants	5K01MH085806-04	93.242	51
Mental Health Research Grants	5K23MH095679-03	93.242	174,053
Mental Health Research Grants	5K23MH096042-04	93.242	149,614
Mental Health Research Grants	5K23MH101380-02	93.242	109,910
Mental Health Research Grants	5K24MH075867-08	93.242	113,020
Mental Health Research Grants	5P50MH100023-03S1	93.242	2,031,011
Mental Health Research Grants	5P50MH100029-04	93.242	2,670,452
Mental Health Research Grants	5R01MH058846-16REVIS	93.242	387,364
Mental Health Research Grants	5R01MH069852-10	93.242	435,305
Mental Health Research Grants	5R01MH071537-10REVIS	93.242	148,965
Mental Health Research Grants	5R01MH073719-06	93.242	658,042
Mental Health Research Grants	5R01MH079448-05	93.242	334,009
Mental Health Research Grants	5R01MH083727-05	93.242	23,923
Mental Health Research Grants	5R01MH087604-05	93.242	167,901

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Mental Health Research Grants	5R01MH095503-04REVIS	93.242	\$ 580,586
Mental Health Research Grants	5R01MH096764-04	93.242	300,234
Mental Health Research Grants	5R01MH096983-04	93.242	482,247
Mental Health Research Grants	5R01MH099021-04	93.242	694,833
Mental Health Research Grants	5R01MH100390-02REVIS	93.242	513,896
Mental Health Research Grants	5R01MH100999-03	93.242	686,847
Mental Health Research Grants	5R01MH101477-03	93.242	363,365
Mental Health Research Grants	5R01MH105561-02	93.242	200,851
Mental Health Research Grants	5R01MH10917-02	93.242	609,657
Mental Health Research Grants	5R03MH100273-02	93.242	27,164
Mental Health Research Grants	5R21 MH097187-02 REV	93.242	(45)
Mental Health Research Grants	5R21MH098212-02	93.242	28,288
Mental Health Research Grants	5R21MH100670-02	93.242	60,870
Mental Health Research Grants	5R21MH101492-02	93.242	165,720
Mental Health Research Grants	5R21MH102191-02	93.242	188,052
Mental Health Research Grants	5R21MH102677-02S1	93.242	149,612
Mental Health Research Grants	5R21MH105353-02	93.242	141,354
Mental Health Research Grants	5R25MH101079-02	93.242	31,969
Mental Health Research Grants	5R34MH097790-03	93.242	220,048
Mental Health Research Grants	5U01MH081988-07	93.242	310,636
Mental Health Research Grants	5U01MH101720-02REVIS	93.242	1,481,773
Mental Health Research Grants	7R01MH083707-03REVIS	93.242	125,027
Pass-through Boston College	51007481-01	93.242	53,098
Pass-through Bowdoin College	2011_003	93.242	226,220
Pass-through Case Western Reserve University	RES509294	93.242	138,585
Pass-through Case Western Reserve University	RES5509294	93.242	159,237
Pass-through Cincinnati Childrens Hospital	134471	93.242	69,842
Pass-through Dartmouth College	1404	93.242	21,444
Pass-through Feinstein Institute For Medical Research	507010EU Am 1	93.242	27,253
Pass-through Florida State University	R01764	93.242	66,735
Pass-through George Washington University	11-M96, AMND4	93.242	(1,996)
Pass-through Georgia State University	SP00011261-01	93.242	36,424
Pass-through Georgia State University	SP00011261-02	93.242	35,106
Pass-through Georgia State University	SP0010889	93.242	(1,091)
Pass-through Johns Hopkins University	2000146603/AMEND3	93.242	(86)
Pass-through Kaiser Permanente	KFRI COSTCTR 9818B	93.242	(4,823)
Pass-through Morehouse School of Medicine	1R25MH071735-04	93.242	(378)
Pass-through Mount Sinai School of Medicine	0255-4713-4609	93.242	450
Pass-through Mount Sinai School of Medicine	0255-6211-4609	93.242	19,122
Pass-through Palo Alto Institute for Research and Education	CL00001-04	93.242	125,439
Pass-through Rhode Island Hospital	701-1963/AMND 1	93.242	224
Pass-through University of Alabama Birmingham	000506211-004	93.242	48,887
Pass-through University of California Los Angeles	2000GR4488	93.242	665,751
Pass-through University of Florida	UF07092/P50MH072850	93.242	(39,981)
Pass-through University of Iowa	W000711453	93.242	18,130
Pass-through University of Miami	663542	93.242	11,747
Pass-through University of Miami	M160785	93.242	13,784
Pass-through University of Michigan	3002786766	93.242	(5,835)
Pass-through University of Minnesota	A00285201	93.242	(3,338)
Pass-through University of Pittsburgh	0032045 (124593-1)	93.242	50,256
Pass-through University of South Carolina	14-2468	93.242	294,982
Pass-through University of South Carolina	15-2800	93.242	21,369
Pass-through University of South Florida	6144-1113-00-A	93.242	28,237
Pass-through University of Southern California	H50884/AMND2	93.242	50,000
Pass-through University of Washington	755980	93.242	20,007
Pass-through University of Wisconsin-Madison	337K481	93.242	46,530
Pass-through University of Wisconsin-Madison	409K065	93.242	14,150
Total CFDA No. 93.242			25,545,685
Substance Abuse and Mental Health Services_Projects of Regional and National Significance			
Pass-through Mercer University	420642-EU-02	93.243	9,990
Total CFDA No. 93.243			9,990
Public Health Training Centers Grant Program	5 UB6HP27875-02-00	93.249	566,986
Public Health Training Centers Grant Program	UB6HP20199-04-01	93.249	15,210
Total CFDA No. 93.249			582,196
Geriatric Academic Career Awards	5K01HP20509-04	93.250	70,716
Total CFDA No. 93.250			70,716
Family Planning_Personnel Training	6FPPTPA0400120301	93.260	137
Total CFDA No. 93.260			137
Occupational Safety and Health Program	1R01OH010745-01	93.262	33,910
Occupational Safety and Health Program	5R01OH10657-02	93.262	516,049
Occupational Safety and Health Program	5T03OH008609-10	93.262	(9,747)
Occupational Safety and Health Program	5T03OH008609-11	93.262	134,686
Total CFDA No. 93.262			674,898
Complex Humanitarian Emergency and War-Related Injury Public Health Activities	1T01GH001185-02	93.269	5,109
Complex Humanitarian Emergency and War-Related Injury Public Health Activities	5T01GH001185-02	93.269	140,224
Total CFDA No. 93.269			145,333
Alcohol National Research Service Awards for Research Training	1F32AA019880-01	93.272	(434)
Alcohol National Research Service Awards for Research Training	5T32AA013528-10	93.272	(6,735)
Total CFDA No. 93.272			(7,169)
Alcohol Research Programs	5F32AA022058-03	93.273	51,026
Alcohol Research Programs	5K08AA021404-04	93.273	199,270
Alcohol Research Programs	5K99A021803-02	93.273	111,182
Alcohol Research Programs	5R01AA017627-05	93.273	132,928
Alcohol Research Programs	5R01AA021411-03	93.273	266,860
Alcohol Research Programs	5R01AA016348-05	93.273	1,894
Alcohol Research Programs	5R01AA018096-05	93.273	544,953

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Alcohol Research Programs	5R33AA019582-05	93.273	18,678
Alcohol Research Programs	5K05AA021143-04	93.273	193,742
Pass-through Childrens Hospital of Los Angeles	5U01AA017122-07	93.273	78,454
Pass-through Pacific Institute For Res And Evaluation	P60AA006282	93.273	60,720
Pass-through San Diego State University Research Fdm	53311J P1650 7802212	93.273	110,868
Pass-through University of California Los Angeles	2000 G KG925	93.273	(844)
Pass-through University of California Los Angeles	2000 G RN421	93.273	25,766
Pass-through University of California San Diego	10313752-005	93.273	156,409
Pass-through University of California San Diego	33099608-002	93.273	59,408
Pass-through University Of Colorado	FY15.580.001 AMD 3	93.273	4,684
Total CFDA No. 93.273			2,015,998
Drug Abuse and Addiction Research Programs	5R03CA183016-02	93.279	68,855
Drug Abuse and Addiction Research Programs	5K24A1114444-02	93.279	159,410
Drug Abuse and Addiction Research Programs	1R01DA038453-01A1	93.279	150,209
Drug Abuse and Addiction Research Programs	3R01DA016434-10S1REV	93.279	216,760
Drug Abuse and Addiction Research Programs	5F31DA033091-03REVIS	93.279	22,054
Drug Abuse and Addiction Research Programs	5R01DA012514-15	93.279	275,227
Drug Abuse and Addiction Research Programs	5R01DA015162-07	93.279	966
Drug Abuse and Addiction Research Programs	5R01DA018294-04	93.279	581
Drug Abuse and Addiction Research Programs	5R01DA02011603	93.279	212
Drug Abuse and Addiction Research Programs	5R01DA025494-05	93.279	104,664
Drug Abuse and Addiction Research Programs	5R01DA027535-05	93.279	203,232
Drug Abuse and Addiction Research Programs	5R01DA029513-04	93.279	188,125
Drug Abuse and Addiction Research Programs	5R03DA036737-02	93.279	68,193
Drug Abuse and Addiction Research Programs	3U01DA036233-03S1	93.279	656,462
Drug Abuse and Addiction Research Programs	5 R01 DA035101-03	93.279	530,658
Drug Abuse and Addiction Research Programs	5F31DA036316-02	93.279	28,062
Drug Abuse and Addiction Research Programs	5F31DA036348-02	93.279	47,004
Drug Abuse and Addiction Research Programs	5F31DA037652-02	93.279	42,562
Drug Abuse and Addiction Research Programs	5K05DA031246-04	93.279	121,365
Drug Abuse and Addiction Research Programs	5R01DA030996-05	93.279	388,868
Drug Abuse and Addiction Research Programs	5R01DA037568-02	93.279	714,967
Drug Abuse and Addiction Research Programs	5R01DA038196-02	93.279	452,178
Drug Abuse and Addiction Research Programs	5R01DA038588-02	93.279	551,538
Drug Abuse and Addiction Research Programs	5R03DA034867-02	93.279	66,335
Drug Abuse and Addiction Research Programs	5R21DA033478-02REVIS	93.279	115,300
Drug Abuse and Addiction Research Programs	5R21DA034232-02 REV	93.279	109,250
Drug Abuse and Addiction Research Programs	5R21DA034808-02	93.279	156,527
Drug Abuse and Addiction Research Programs	5R34DA035728-02	93.279	326,136
Drug Abuse and Addiction Research Programs	5R37DA010344-19	93.279	471,939
Drug Abuse and Addiction Research Programs	5R90DA033462-05	93.279	177,584
Drug Abuse and Addiction Research Programs	5T90DA032466-05	93.279	175,479
Pass-through Beth Israel Deaconess Medical Center	1R01DA0356707-01	93.279	42,214
Pass-through Boston Medical Center	0356301	93.279	46,891
Pass-through Columbia University	1(GG008261-03)	93.279	694,404
Pass-through Medical University of South Carolina	MUSC11-020	93.279	(1,323)
Pass-through National Development and Research Institutes	R01DA013336.P0000446	93.279	2,829
Pass-through Northwestern University	60032445 EU-A03	93.279	99,411
Pass-through Northwestern University	60035189 EU	93.279	56,831
Pass-through Texas Tech University	21F088-01	93.279	43,855
Pass-through University of California San Francisco	6739SC	93.279	1,267
Pass-through University of Georgia	RR376-006/4785656	93.279	21,068
Pass-through University of Georgia	RR376-411/4945356	93.279	24,777
Pass-through University of Georgia	RR540-160/4941946	93.279	122,774
Pass-through University of Houston	R13-0071/R01DA034739	93.279	5,880
Pass-through University of Miami	66159L/R01DA01761204	93.279	49
Pass-through University of Miami	CTN0049	93.279	217,623
Pass-through University of Pittsburgh	5R01DA01891005/00052	93.279	(133)
Pass-through Vanderbilt University	VUMC 36512-4	93.279	26,732
Total CFDA No. 93.279			7,995,851
Mental Health Research Career/Scientist Development Awards	5 K01 MH085506-05	93.281	23,271
Mental Health Research Career/Scientist Development Awards	5K02MH064692-10	93.281	555
Mental Health Research Career/Scientist Development Awards	5K01MH095823-04	93.281	189,573
Mental Health Research Career/Scientist Development Awards	5K23MH091254-05	93.281	55,273
Mental Health Research Career/Scientist Development Awards	5K24MH076955-07	93.281	24,975
Total CFDA No. 93.281			293,647
Mental Health National Research Service Awards for Research Training	5F31MH097331-03	93.282	29,551
Mental Health National Research Service Awards for Research Training	5T32MH087977-05	93.282	17
Mental Health National Research Service Awards for Research Training	5F30MH095491-04	93.282	35,638
Mental Health National Research Service Awards for Research Training	5F31MH090729-03	93.282	722
Mental Health National Research Service Awards for Research Training	5F31MH095266-03	93.282	22,286
Mental Health National Research Service Awards for Research Training	5F31MH097397-03	93.282	12,896
Pass-through University of California Los Angeles	2000-S-RJ108	93.282	162,540
Total CFDA No. 93.282			263,653
Centers for Disease Control and Prevention Investigations and Technical Assistance	3U90TP42425604W1	93.283	261
Centers for Disease Control and Prevention Investigations and Technical Assistance	7U01DD00003904	93.283	135
Pass-through Georgia Department of Community Health	40500-036-13110270	93.283	(510)
Pass-through Georgia Department of Community Health	41900-036-10100072	93.283	(16,996)
Pass-through Georgia Dept of Public Health	40500-036-15110270	93.283	567,874
Pass-through Natl Fragile X Foundation	Longitudinal Data Co	93.283	532
Pass-through University of California Los Angeles	06105/U01CI00035302	93.283	(2,274)
Pass-through University of California Los Angeles	07178/U01CI00035303	93.283	(10,879)
Total CFDA No. 93.283			538,143
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R21EB016662-02	93.286	146,227
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R21EB019068-02	93.286	194,341
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R01EB00200913	93.286	54
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R01EB014266-04	93.286	113,125
Pass-through Georgia Institute of Technology	RA746-G1	93.286	570
Pass-through Georgia Institute of Technology	RB224-G1	93.286	311,922

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Pass-through Georgia Institute of Technology	RB224-G2	93.286	\$ 38,191
Pass-through Georgia Institute of Technology	RB224-S4	93.286	66,217
Pass-through Georgia Institute of Technology	RF188-G1	93.286	17,757
Pass-through Georgia State University	SP00013490-01	93.286	91,962
Pass-through University of California San Francisco	Subaward 8354sc	93.286	105,314
Pass-through University of Texas Southwestern	GMO 120705	93.286	117,792
Total CFDA No. 93.286			1,203,472
Minority Health and Health Disparities Research	1R01MD009746-01	93.307	33,535
Minority Health and Health Disparities Research	1R01MD010290-01	93.307	4,975
Minority Health and Health Disparities Research	5 R01 MD009064-02	93.307	445,012
Minority Health and Health Disparities Research	5R24MD008077-03REVIS	93.307	250,869
Minority Health and Health Disparities Research	5R01MD004117-05REVIS	93.307	11
Minority Health and Health Disparities Research	5R01MD008966-02	93.307	360,529
Pass-through Morehouse School of Medicine	TCCPP005	93.307	42,964
Pass-through Oregon Law Center	5R24MD002798-08	93.307	11,548
Pass-through Oregon Law Center	R24MD002798	93.307	30,685
Total CFDA No. 93.307			1,180,128
Trans-NIH Research Support	1R21CA185932-01	93.310	144,261
Trans-NIH Research Support	1DP2A112242-01	93.310	628,585
Trans-NIH Research Support	1DP5OD019892-01	93.310	367,023
Trans-NIH Research Support	5DP5OD012198-03	93.310	390,000
Trans-NIH Research Support	5DP7OD018424-02	93.310	450,428
Trans-NIH Research Support	5R01CA163256-05	93.310	1,540,211
Pass-through Broad Institute	5230122-550000603	93.310	40,485
Pass-through Georgia Institute Of Technology	NIH 1DP2 OD 007433-0	93.310	5,450
Pass-through Northeastern University	500177/P1104287 MOD1	93.310	859
Pass-through Pennsylvania State University	5114-EU-NIBIB-9785	93.310	11,994
Pass-through University of Michigan	3000691492-RPT	93.310	58,258
Pass-through University of North Carolina Chapel Hill	5-33722	93.310	(1,356)
Pass-through Xavier University of Louisiana	OSP-15-21173-00G	93.310	1,661
Total CFDA No. 93.310			3,637,859
National Center for Advancing Translational Sciences	5KL2TR000455-09	93.350	731,440
National Center for Advancing Translational Sciences	5TL1TR000456-09	93.350	191,873
National Center for Advancing Translational Sciences	5UL1TR000454-08REVIS	93.350	4,879,093
Pass-through University of Pittsburgh	9010570	93.350	323,643
Total CFDA No. 93.350			6,126,049
Research Infrastructure Programs	3R24OD010930-09S1	93.351	192,979
Research Infrastructure Programs	5R24OD010947-13	93.351	276,328
Research Infrastructure Programs	1 R21 OD020182-01	93.351	57,372
Research Infrastructure Programs	1S10OD016244-01	93.351	359
Research Infrastructure Programs	1S10OD016413-01	93.351	494,952
Research Infrastructure Programs	1S10OD018006-01	93.351	600,000
Research Infrastructure Programs	2R24OD010930-10A1	93.351	485,754
Research Infrastructure Programs	2R24OD010947-14	93.351	225,141
Research Infrastructure Programs	5R24OD010445-03	93.351	792,262
Research Infrastructure Programs	5U24OD011023-13	93.351	1,720,884
Total CFDA No. 93.351			4,846,031
Construction Support	1C06OD018248-01Revis	93.352	17,074
Total CFDA No. 93.352			17,074
Advanced Nursing Education Traineeships	5 a10hp271840200	93.358	342,196
Total CFDA No. 93.358			342,196
Nurse Education, Practice and Retention Grants	5UD7HP25046-03-00	93.359	476,208
Nurse Education, Practice and Retention Grants	5 UD7HP26046-03-00	93.359	32,096
Nurse Education, Practice and Retention Grants	6 UDYHP26046-02-01	93.359	483,899
Total CFDA No. 93.359			992,203
Nursing Research	5K01NR012779-03	93.361	8,129
Nursing Research	5P01NR011587-05	93.361	19,367
Nursing Research	5R01NR012021-05	93.361	135,272
Nursing Research	5R01NR014054-4	93.361	505,752
Nursing Research	5T32NR012715-04	93.361	358,670
Nursing Research	1F31NR015010-02	93.361	41,326
Nursing Research	1F31NR015180-01A1	93.361	31,082
Nursing Research	1F31NR015400-01A1	93.361	5,837
Nursing Research	1R01NR014973-01&01RV	93.361	60,109
Nursing Research	5 K99 NR014587-02	93.361	98,037
Nursing Research	5F31NR014609-02	93.361	51,235
Nursing Research	5F31NR014611-02REVIS	93.361	41,653
Nursing Research	5K01NR014673-03	93.361	104,257
Nursing Research	5P30NR014134-04	93.361	456,034
Nursing Research	5R01NR011278-4	93.361	(223)
Nursing Research	5R01NR012419-02REVIS	93.361	31,949
Nursing Research	5R01NR013700-03	93.361	634,647
Nursing Research	5R01NR014800-03	93.361	529,414
Nursing Research	5R01NR014886-02	93.361	403,022
Nursing Research	5R0NR012923-04	93.361	590,783
Nursing Research	1215007	93.361	123,767
Pass-through Dana Farber Cancer Institute	M15A11961(A10049)	93.361	92,346
Pass-through Yale University			
Total CFDA No. 93.361			4,322,465
National Center for Research Resources	3P51OD011132-55S1	93.389	11,012,201
National Center for Research Resources	8R01OD011094-04	93.389	(21,415)
National Center for Research Resources	3R24R018827-07S1	93.389	(8,283)
National Center for Research Resources	3UL1RR02500802S1	93.389	13,050
National Center for Research Resources	5K01CA10407905	93.389	648
National Center for Research Resources	5KL2RR025009-05REVIS	93.389	9,063

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
National Center for Research Resources	5R24RR01698808	93.389	\$ 8,173
National Center for Research Resources	5R24RR01882704	93.389	266
National Center for Research Resources	5UL1RR025008-05REVIS	93.389	40,121
National Center for Research Resources	8U24OD011023-10REVIS	93.389	(194)
Pass-through Baylor College Of Medicine	101897535	93.389	12,596
Pass-through Morehouse School of Medicine	UL1TR000454	93.389	3,000
Total CFDA No. 93.389			11,069,226
Cancer Cause and Prevention Research	1R21CA198455-01	93.393	32,881
Cancer Cause and Prevention Research	2R01CA095318-11A1	93.393	59,037
Cancer Cause and Prevention Research	5 R03 CA183006-02REV	93.393	54,309
Cancer Cause and Prevention Research	5 R21 CA149350-02	93.393	1,614
Cancer Cause and Prevention Research	5R01CA077337-14	93.393	206,077
Cancer Cause and Prevention Research	5R01CA095318-10 REVI	93.393	134,609
Cancer Cause and Prevention Research	5R01CA098239-09	93.393	133,641
Cancer Cause and Prevention Research	5R01CA179424-02	93.393	214,800
Cancer Cause and Prevention Research	5R03CA159369-02REVIS	93.393	1,400
Cancer Cause and Prevention Research	5R03CA171663-02	93.393	63,462
Cancer Cause and Prevention Research	5R03CA173770-02REVIS	93.393	72,333
Cancer Cause and Prevention Research	5R21CA158686-02	93.393	101,156
Cancer Cause and Prevention Research	5R21CA182752-02	93.393	152,306
Cancer Cause and Prevention Research	R03 CA184578-02	93.393	112,446
Cancer Cause and Prevention Research	2U10EY013272-11A1	93.393	508,785
Cancer Cause and Prevention Research	2R56CA114456-04	93.393	(2,989)
Cancer Cause and Prevention Research	3R01CA166825-03S1	93.393	561,459
Cancer Cause and Prevention Research	3R01CA178999-03S1	93.393	392,743
Cancer Cause and Prevention Research	5R01CA057327-20	93.393	(860)
Cancer Cause and Prevention Research	5R01CA09531805	93.393	1,247
Cancer Cause and Prevention Research	5R01CA105116-11	93.393	180,760
Cancer Cause and Prevention Research	5R01CA106826-09 REV	93.393	16
Cancer Cause and Prevention Research	5R01CA11445603	93.393	(13,801)
Cancer Cause and Prevention Research	5R01CA11679503	93.393	162
Cancer Cause and Prevention Research	5R01CA11787204	93.393	321
Cancer Cause and Prevention Research	5R01CA120288-05	93.393	2,002
Cancer Cause and Prevention Research	5R01CA132065-05 REV	93.393	36,853
Cancer Cause and Prevention Research	5R01CA136534-05	93.393	72,686
Cancer Cause and Prevention Research	5R01CA136716-04 REV	93.393	2,553
Cancer Cause and Prevention Research	5R01CA140515-05 REV	93.393	104,411
Cancer Cause and Prevention Research	5R01CA149107-05	93.393	104,335
Cancer Cause and Prevention Research	5R01CA151521-05	93.393	137,129
Cancer Cause and Prevention Research	5U01CA154282-05	93.393	1,392,895
Cancer Cause and Prevention Research	7R01NS060830-05	93.393	(790)
Pass-through Boston University	450001596	93.393	4,328
Pass-through Georgia Institute Of Technology	R0026-G1	93.393	28,832
Pass-through Harvard University	114926-5060413	93.393	29,875
Pass-through Mayo Clinic	64159622	93.393	613
Pass-through Tufts University School of Medicine	R21CA178296	93.393	41,568
Pass-through University of Texas Health Sciences Ctr	0009073A	93.393	56,250
Pass-through University of Michigan	02/3002587224/AMND#2	93.393	449,354
Pass-through University of Minnesota	N003436201	93.393	16,170
Pass-through University Of North Carolina Chapel Hill	5-30889	93.393	(373)
Pass-through University Of North Carolina Chapel Hill	5-33529	93.393	189,044
Pass-through University Of North Carolina Chapel Hill	5-33530	93.393	107,782
Pass-through University of Pennsylvania	564216	93.393	44,519
Pass-through University of Southern California	57925363	93.393	14,754
Total CFDA No. 93.393			5,802,704
Cancer Detection and Diagnosis Research	1R01CA181171-01A1	93.394	38,983
Cancer Detection and Diagnosis Research	1U24CA194362-01	93.394	15,812
Cancer Detection and Diagnosis Research	5 U01 CA 168930-04	93.394	169,652
Cancer Detection and Diagnosis Research	5R01CA154846-05	93.394	479,430
Cancer Detection and Diagnosis Research	5R01CA163746-04	93.394	281,048
Cancer Detection and Diagnosis Research	5R01CA169188-04	93.394	526,816
Cancer Detection and Diagnosis Research	5R01CA169937-03	93.394	351,546
Cancer Detection and Diagnosis Research	5R01CA176659-03	93.394	463,213
Cancer Detection and Diagnosis Research	5R21CA176684-02	93.394	150,689
Cancer Detection and Diagnosis Research	5R21CA182661-02	93.394	175,357
Cancer Detection and Diagnosis Research	5R21CA186169-02	93.394	338,238
Cancer Detection and Diagnosis Research	5R33CA161873-02	93.394	91,113
Cancer Detection and Diagnosis Research	5U01CA113913-10 rev	93.394	743,585
Cancer Detection and Diagnosis Research	5U01CA151802-05	93.394	293,196
Cancer Detection and Diagnosis Research	5U01CA173227-03	93.394	619,052
Cancer Detection and Diagnosis Research	5R01CA121320-06	93.394	153,517
Cancer Detection and Diagnosis Research	5R01CA156775-05REVIS	93.394	161,380
Cancer Detection and Diagnosis Research	5U01CA151810-05 REVI	93.394	487,727
Cancer Detection and Diagnosis Research	5U01CA168449-04	93.394	693,357
Pass-through Dartmouth College	R219	93.394	5,559
Pass-through Georgia Institute Of Technology	RC050-G1	93.394	(393)
Pass-through Johns Hopkins University	2001355031	93.394	17,513
Pass-through State University of New York - Stony Brook	69669-1121154-2	93.394	68,571
Pass-through Van Andel Institute	EMORY-BH-10-40234-1	93.394	56,134
Pass-through Van Andel Institute	V1377-S2-1	93.394	20,151
Pass-through Wake Forest University	WFUHS 56744	93.394	7,633
Pass-through Washington University	WU-15-76 PO#2922479Y	93.394	114,044
Total CFDA No. 93.394			6,522,923
Cancer Treatment Research	1 R21 CA185882-01A1	93.395	96,082
Cancer Treatment Research	1R01CA186918-01A1	93.395	121,896
Cancer Treatment Research	1R13CA192670-01	93.395	22,310
Cancer Treatment Research	3R01CA176001-02S1	93.395	357,282
Cancer Treatment Research	5R01CA118450-10	93.395	191,864
Cancer Treatment Research	5R01CA157754-04S2	93.395	255,909
Cancer Treatment Research	5R01CA160522-04	93.395	239,221
Cancer Treatment Research	5R01CA165306-04	93.395	423,239
Cancer Treatment Research	5R01CA180805-03	93.395	480,193



**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Cancer Treatment Research	5R01CA186129-02	93.395	255,205
Cancer Treatment Research	5R01CA188523-02	93.395	463,926
Cancer Treatment Research	5R21CA155511-02	93.395	630
Cancer Treatment Research	5U10CA180864-02	93.395	664,019
Cancer Treatment Research	5U10CA180950-02	93.395	508,439
Cancer Treatment Research	R21CA140766-03	93.395	490
Cancer Treatment Research	1R21CA139035-02	93.395	60
Cancer Treatment Research	3P01CA116676-05S2	93.395	(1,790)
Cancer Treatment Research	5R01CA116804-05	93.395	(40,513)
Cancer Treatment Research	5R01CA123490-05REV	93.395	(356)
Cancer Treatment Research	5R01CA129424-04 REV	93.395	353
Cancer Treatment Research	5R01CA129968-05REVIS	93.395	101
Cancer Treatment Research	5R01CA143107-06 REV1	93.395	250,089
Cancer Treatment Research	5R01CA154129-05	93.395	517,280
Cancer Treatment Research	510635	93.395	19,565
Pass-through Albert Einstein College of Medicine	1016 U10CA021661	93.395	(59)
Pass-through Amer College Of Radiology	1198	93.395	16,233
Pass-through Amer College Of Radiology	RTOG 0825	93.395	(56,735)
Pass-through Brigham and Womens Hospital	ACOSOG Z4099/RTOG 10	93.395	5,644
Pass-through Brigham and Womens Hospital	CALGB140503/U10CA760	93.395	10,672
Pass-through City of Hope	50023.1914965.669499	93.395	11,606
Pass-through Duke University	220Z4032/U10CA076001	93.395	5,017
Pass-through Ecog-Acrin Medical Research Foundation	U10CA180820-02	93.395	27,332
Pass-through Ecog-Acrin Medical Research Foundation	1UG1CA189828-01-EMRY	93.395	50,831
Pass-through Fred Hutchinson Cancer Research Center	0000804235	93.395	3,460
Pass-through Frontier Science And Technology Res Fdn	ECOG 1505	93.395	5,191
Pass-through Frontier Science And Technology Res Fdn	CT Phase 3	93.395	(19)
Pass-through Frontier Science And Technology Res Fdn	E5103	93.395	782
Pass-through Frontier Science And Technology Res Fdn	E3612ECOG23	93.395	(30)
Pass-through Frontier Science And Technology Res Fdn	ECOG MASTER AGREEMEN	93.395	(15)
Pass-through Frontier Science And Technology Res Fdn	PSAWCIEM00	93.395	(113)
Pass-through Frontier Science And Technology Res Fdn	S1007	93.395	500
Pass-through Frontier Science And Technology Res Fdn	THCO37SR-05	93.395	13,067
Pass-through Georgia Center for Oncology Res and Edu	GOG-0218	93.395	(2,234)
Pass-through Georgia State University	SP00011812-01	93.395	104,752
Pass-through Georgia State University	SP11051-01	93.395	6,385
Pass-through Medical College of Wisconsin	R01CA184798	93.395	89
Pass-through Ohio State University	60032891/AMND1	93.395	(69)
Pass-through Roswell Park Cancer Institute	NIH-NCI	93.395	11,872
Pass-through St Jude Childrens Research Hospital	111287200-7583702	93.395	2,161
Pass-through St Jude Childrens Research Hospital	111335050-7539300	93.395	829
Pass-through University of Arizona	KFS 301220	93.395	8,808
Pass-through University of Minnesota	PO02139202	93.395	3,263
Total CFDA No. 93.395			5,054,714
Cancer Biology Research	2R01CA1405015-06A1	93.396	12,215
Cancer Biology Research	3R01CA163722-03S1	93.396	243,530
Cancer Biology Research	5R01CA171189-03	93.396	385,046
Cancer Biology Research	5R01CA172392-03	93.396	302,562
Cancer Biology Research	5R01CA174786-02	93.396	278,514
Cancer Biology Research	5R01CA175316-02	93.396	387,187
Cancer Biology Research	5R01CA183594-02	93.396	214,894
Cancer Biology Research	5R21CA181754-02	93.396	187,279
Cancer Biology Research	5R01CA08419711	93.396	(46,546)
Cancer Biology Research	5R01CA123368-10	93.396	207,708
Cancer Biology Research	5R01CA123490-08	93.396	211,903
Cancer Biology Research	5R01CA127119-05	93.396	2,632
Cancer Biology Research	5R01CA140571-05	93.396	243,101
Cancer Biology Research	5R01CA142858-05	93.396	304,020
Pass-through University Of Medicine And Dentistry Of	8086	93.396	45,855
Total CFDA No. 93.396			2,979,900
Cancer Centers Support Grants	5P30CA138292-07S1	93.397	1,647,850
Cancer Centers Support Grants	3P30CA138292-04	93.397	(34,200)
Cancer Centers Support Grants	5P50CA128613-05REVIS	93.397	(9,049)
Pass-through Johns Hopkins University	2001785619	93.397	12,860
Total CFDA No. 93.397			1,617,461
Cancer Research Manpower	1 F31 CA189772-01	93.398	38,862
Cancer Research Manpower	1F31CA196181-01	93.398	23,487
Cancer Research Manpower	1F32CA189633-01	93.398	28,005
Cancer Research Manpower	5F31CA165632-03	93.398	19,451
Cancer Research Manpower	5F31CA168272-02	93.398	147
Cancer Research Manpower	5F31CA168321-03REV	93.398	20,426
Cancer Research Manpower	5F31CA180319-02	93.398	45,347
Cancer Research Manpower	5F31CA180511-02	93.398	38,920
Cancer Research Manpower	5F31CA183365-02	93.398	28,162
Cancer Research Manpower	5F31CA186511-02	93.398	43,399
Cancer Research Manpower	5F31CA186676-02	93.398	40,966
Cancer Research Manpower	5F31CA189672-02	93.398	42,676
Cancer Research Manpower	5F32CA168112-02	93.398	(2,829)
Cancer Research Manpower	5F32CA183215-02	93.398	61,662
Cancer Research Manpower	5K08CA143902-06	93.398	134,131
Cancer Research Manpower	5K23CA164015-05	93.398	159,300
Cancer Research Manpower	5K25CA181503-02	93.398	102,834
Cancer Research Manpower	5T32CA160040-03	93.398	225,571
Cancer Research Manpower	5F30CA177156-03	93.398	47,098
Cancer Research Manpower	5K07CA139114-05	93.398	109,410
Pass-through Health Research Roswell Park	HR#11601/55-0933-06	93.398	50,741
Total CFDA No. 93.398			1,257,766
Cancer Control	5P50CA128301-05REVIS	93.399	37,453
Cancer Control	5U54CA119338-05	93.399	(42,988)
Pass-through Frontier Science And Technology Res Fdn	#PRVC28FK-00	93.399	4,906

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Pass-through M D Anderson Cancer Center	288834/98415151	93.399	\$ (6,358)
Total CFDA No. 93.399			(6,987)
ARRA Grants for Training in Primary Care Medicine and Dentistry Training and Enhancement	1D5FHP20667-01-00	93.403	272,174
Total CFDA No. 93.403			272,174
Refugee and Entrant Assistance_Wilson/Fish Program			
Pass-through Georgia State University	SP00010891-02	93.583	12,025
Total CFDA No. 93.583			12,025
Health Care Innovation Awards	1C1CMS331041-03-01	93.610	3,507,415
Total CFDA No. 93.610			3,507,415
Children's Justice Grants to States			
Pass-through Georgia Department of Human Resources	42700-040-0000004749	93.643	48
Total CFDA No. 93.643			48
Social Services Block Grant			
Pass-through Georgia Department of Human Services	42700-373-0000034541	93.667	24,924
Total CFDA No. 93.667			24,924
Trans-NIH Recovery Act Research Support	3U19AI057266-06S2	93.701	349
Trans-NIH Recovery Act Research Support	5R01AI084834-02	93.701	1,673
Trans-NIH Recovery Act Research Support	5R01DA025045-02	93.701	(17)
Trans-NIH Recovery Act Research Support	5R01MH082813-02REVIS	93.701	(6,683)
Pass-through Georgia Institute Of Technology	S7045-G3/R01AR056694	93.701	(1,213)
Pass-through Morehouse School Of Medicine	R25R017964-S2	93.701	(6,059)
Pass-through National Childhood Cancer Foundation	5927-1003	93.701	19,238
Pass-through University Of Alabama Birmingham	000426901-001	93.701	79,156
Pass-through Wistar Institute	24402-04-319	93.701	121
Total CFDA No. 93.701			86,565
ARRA - Comparative Effectiveness Research - AHRQ:			
Pass-through Amer College Of Radiology	R01HS019403	93.715	4,626
Total CFDA No. 93.715			4,626
PPHF 2013 - Cooperative Agreement to Support Navigators in Federally-facilitated and State Partnership Exchanges			
Pass-through Grady Memorial Hospital	S1401	93.750	36,148
Pass-through Grady Memorial Hospital	S201414	93.750	35,773
Total CFDA No. 93.750			71,921
Medical Assistance Program:			
Pass-through Georgia Department of Behavioral Health	44100-907-0000056259	93.778	298,124
Pass-through Ohio State University	60049141	93.778	80,590
Pass-through University Of South Florida	5820-1161-00-U	93.778	12,164
Total CFDA No. 93.778			390,878
Cardiovascular Diseases Research	1F32HL124974-01A1	93.837	19,310
Cardiovascular Diseases Research	1K08HL124292-01A1	93.837	59,133
Cardiovascular Diseases Research	1R01HL127759-01A1	93.837	38,989
Cardiovascular Diseases Research	1R34HL122557-01A1	93.837	48,873
Cardiovascular Diseases Research	1R56HL124380-01	93.837	308,314
Cardiovascular Diseases Research	1R56HL125062-01	93.837	550,131
Cardiovascular Diseases Research	1R56HL126558-01	93.837	700,462
Cardiovascular Diseases Research	2P01HL095070-06A1	93.837	114,837
Cardiovascular Diseases Research	4R00HL119567-03	93.837	23,917
Cardiovascular Diseases Research	5F30HL110447-04	93.837	26,748
Cardiovascular Diseases Research	5F30HL118954-02	93.837	23,701
Cardiovascular Diseases Research	5F30HL122065-02	93.837	32,951
Cardiovascular Diseases Research	5K08HL119592-02	93.837	161,454
Cardiovascular Diseases Research	5K99HL119567-02	93.837	158,392
Cardiovascular Diseases Research	5P01HL095070-05	93.837	494,321
Cardiovascular Diseases Research	5R01HL079040-09	93.837	192,479
Cardiovascular Diseases Research	5R01HL109413-03	93.837	828,312
Cardiovascular Diseases Research	5R01HL109559-04	93.837	55,493
Cardiovascular Diseases Research	5R01HL113167-03	93.837	496,424
Cardiovascular Diseases Research	5R01HL119291-03	93.837	305,776
Cardiovascular Diseases Research	5R01HL119798-03	93.837	411,768
Cardiovascular Diseases Research	5R21HL118454-02	93.837	173,391
Cardiovascular Diseases Research	5R21HL123928-02	93.837	195,665
Cardiovascular Diseases Research	5R34HL117351-02REVIS	93.837	383,568
Cardiovascular Diseases Research	5T15HL098122-06	93.837	282,231
Cardiovascular Diseases Research	5T32HL007745-22	93.837	524,305
Cardiovascular Diseases Research	5U01HL105561-04	93.837	1,095,737
Cardiovascular Diseases Research	5U01HL117721-03	93.837	1,762,408
Cardiovascular Diseases Research	5U10HL110302-04Rev	93.837	368,667
Cardiovascular Diseases Research	5U54HL112309-04	93.837	2,290,139
Cardiovascular Diseases Research	7R01HL111646-04	93.837	95,698
Cardiovascular Diseases Research	7R01HL122392-03	93.837	19,316
Cardiovascular Diseases Research	7R34HL108761-04	93.837	42,094
Cardiovascular Diseases Research	1R01HL125246-01A1	93.837	9,979
Cardiovascular Diseases Research	2R56HL09506305A1	93.837	34
Cardiovascular Diseases Research	3R01HL05979810S1	93.837	1,039
Cardiovascular Diseases Research	5K23HL098744-05	93.837	104,595
Cardiovascular Diseases Research	5K23HL103842-05	93.837	152,471
Cardiovascular Diseases Research	5K23HL105785-05	93.837	170,906
Cardiovascular Diseases Research	5K23HL105892-05	93.837	98,301
Cardiovascular Diseases Research	5K24HL077506-10	93.837	91,101
Cardiovascular Diseases Research	5P01HL07520905	93.837	2,419
Cardiovascular Diseases Research	5P01HL101398-05 Revi	93.837	1,420,284
Cardiovascular Diseases Research	5P20HL113451-04	93.837	1,701,287
Cardiovascular Diseases Research	5R01HL058863-15	93.837	371,851
Cardiovascular Diseases Research	5R01HL060728-11	93.837	37
Cardiovascular Diseases Research	5R01HL07053105	93.837	(36,749)
Cardiovascular Diseases Research	5R01HL084471-06	93.837	47,161

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Cardiovascular Diseases Research	5R01HL088488-05	93.837	\$ 57,345
Cardiovascular Diseases Research	5R01HL090601-05	93.837	34,836
Cardiovascular Diseases Research	5R01HL090851-05	93.837	121
Cardiovascular Diseases Research	5R01HL092981-05REVIS	93.837	670,085
Cardiovascular Diseases Research	5R01HL094527-04 REV	93.837	34,544
Cardiovascular Diseases Research	5R01HL095479-04S1	93.837	1,269
Cardiovascular Diseases Research	5R01HL096970-05	93.837	159,688
Cardiovascular Diseases Research	5R01HL098481-05REVIS	93.837	141,013
Cardiovascular Diseases Research	5R21HL109979-02 REV	93.837	45,273
Cardiovascular Diseases Research	5R21HL110044-02	93.837	805
Cardiovascular Diseases Research	5R37HL038206-29	93.837	376,833
Cardiovascular Diseases Research	5T32HL007745-20	93.837	22
Cardiovascular Diseases Research	5U10HL109781-05	93.837	236,019
Cardiovascular Diseases Research	7K01HL092591-06	93.837	95,370
Cardiovascular Diseases Research	5R01HL08872604	93.837	9,300
Pass-through Atlanta Research and Educational Fdn	M15022	93.837	68,053
Pass-through Atlanta Research and Educational Fdn	M15009	93.837	32,131
Pass-through Baylor Research Institute	41010141103_AMD#3	93.837	(4,901)
Pass-through Beth Israel Deaconess Medical Center	SUBAWARD 0102442	93.837	(546)
Pass-through Boston Children's Hospital	RSTFD0000596371	93.837	10,386
Pass-through Cedars Sinai Medical Center	0000903313	93.837	1,597
Pass-through Children's Hospital Medical Center	109317	93.837	950
Pass-through Children's Hospital of Philadelphia	FP11498-19-02	93.837	4,486
Pass-through Cornell University	14091258-03	93.837	32,550
Pass-through Duke Clinical Research Institute	UTOHL084904	93.837	4,350
Pass-through Duke University	193603	93.837	35,938
Pass-through Duke University	ATHENA	93.837	2,424
Pass-through Duke University	RED ROSE-AHF	93.837	37,090
Pass-through Duke University	ROSE-AHF	93.837	20,905
Pass-through Duke University	U10HL084904	93.837	11,178
Pass-through Duke University	U1HL084904	93.837	11,215
Pass-through Frontier Science and Technology Res Fdn	PSAWCIEM00	93.837	(17)
Pass-through Georgia Health Sciences University	25603-1	93.837	285
Pass-through Johns Hopkins	1R24HL085534301/2005	93.837	(31)
Pass-through Johns Hopkins	2001185468	93.837	290,867
Pass-through Massachusetts General Hospital	5U01HL23336-02	93.837	3,121
Pass-through Medical College of Wisconsin	5R01HL119747-02	93.837	2,454
Pass-through Medical University of South Carolina	PO#181411 MUSC14-066	93.837	47,220
Pass-through Morehouse School of Medicine	003-Emory-350080-02	93.837	4,859
Pass-through Mount Sinai School Of Medicine	0255-3106-4605	93.837	25,288
Pass-through Mount Sinai School Of Medicine	5U01HL088942-08	93.837	2,961
Pass-through Mount Sinai School Of Medicine	8664-30255-9034-4609	93.837	59,623
Pass-through Natl Jewish Health	20200052108	93.837	25,708
Pass-through New England Research Institutes	U10HL068270	93.837	47,395
Pass-through New England Research Institutes	NIH U10HL068270	93.837	5,874
Pass-through New England Research Institutes	U01HL68270	93.837	(3,413)
Pass-through New England Research Institutes	U10HL068270	93.837	7,152
Pass-through New York University	U01HL105907	93.837	6,934
Pass-through Oregon Health and Science University	1002919-EU	93.837	40,982
Pass-through University of California Davis	201401440-01	93.837	363,599
Pass-through University of California San Diego	43486128	93.837	183,692
Pass-through University of California San Francisco	8043SC-137090	93.837	34,477
Pass-through University of Florida	UF12001	93.837	17,055
Pass-through University of Florida	UF12056	93.837	1,064
Pass-through University of Florida	UFDSPO0010263	93.837	57,637
Pass-through University of Florida	UFDSPO0010763	93.837	5,197
Pass-through University of Georgia	RR168-681/5054796	93.837	12,596
Pass-through University of Georgia	RR376-352/4945936	93.837	18,334
Pass-through University of Michigan	U01HL094345	93.837	1,898
Pass-through University of Rochester	5-29746	93.837	62,047
Pass-through Vanderbilt University	VUMC43988	93.837	50,403
Pass-through Virginia Commonwealth University	PT107848-SC104184	93.837	144,483
Pass-through Wake Forest University	WFUHS 110947	93.837	13,799
Pass-through Wake Forest University	WFUHS 114135	93.837	959,173
Pass-through Washington University	WU-13-267	93.837	984
Pass-through Weill Cornell Medical College	14121850-03	93.837	14,879
Pass-through Yale University	nih nhbi	93.837	10,889
Total CFDA No. 93.837			21,069,517
Lung Diseases Research	5F31HL114386-02	93.838	31,550
Lung Diseases Research	5R01 HL116958-03	93.838	278,551
Lung Diseases Research	5R01HL102167-04 REV	93.838	156,719
Lung Diseases Research	5R01HL109362-04 REV	93.838	51,611
Lung Diseases Research	5R01HL113548-04	93.838	256,625
Lung Diseases Research	5R01HL125042-02	93.838	737,861
Lung Diseases Research	5T32HL076118-10 REV	93.838	175,132
Lung Diseases Research	5T32HL116271-03	93.838	256,849
Lung Diseases Research	1R01HL122559-01A1	93.838	328,105
Lung Diseases Research	5K08HL102258-05	93.838	90,127
Lung Diseases Research	5R01HL063306-09	93.838	898
Lung Diseases Research	5U01HL08043302	93.838	(55,224)
Pass-through Childrens Hopsital of Boston	74159	93.838	4,349
Pass-through Cincinnati Childrens Hospital	130640_AMDND 02	93.838	5,874
Pass-through Cleveland Clinic Foundation	5R01HL06917008	93.838	1,945
Pass-through Johns Hopkins University	2001443924	93.838	83,069
Pass-through Morehouse School of Medicine	COPDgene/R01HL089897	93.838	9,811
Pass-through Seattle Children's Research Institute	11028SUB	93.838	292
Pass-through University Of Washington	723385/AMND5	93.838	(1,112)
Pass-through Vanderbilt University	VUMC40923/AMD2	93.838	33,850
Pass-through Wake Forest University	WFUHS 115916	93.838	99,446
Total CFDA No. 93.838			2,546,328
Blood Diseases and Resources Research	2P01HL086773-06A1	93.839	169,569
Blood Diseases and Resources Research	5R01HL082808-09- REV	93.839	242,295
Blood Diseases and Resources Research	5R01HL095479-06	93.839	500,726

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Blood Diseases and Resources Research	5R21HL117640-02	93.839	\$ 102,306
Blood Diseases and Resources Research	5R21HL117705-02	93.839	52,691
Blood Diseases and Resources Research	7R01HL117061-04	93.839	294,580
Blood Diseases and Resources Research	1P01HL086773-01A1REV	93.839	(3,784)
Blood Diseases and Resources Research	5K08HL102262-05	93.839	82,222
Blood Diseases and Resources Research	5R01HL092179-05 REV	93.839	123,130
Blood Diseases and Resources Research	5R01HL121264-02	93.839	351,695
Blood Diseases and Resources Research	5R21HL09126802	93.839	1,055
Blood Diseases and Resources Research	5T32HL069769-12	93.839	114,751
Blood Diseases and Resources Research	5U01HL072248-10REV	93.839	(10,640)
Pass-through Bloodcenter of Wisconsin	0263-81148	93.839	24,558
Pass-through Bloodcenter of Wisconsin	0268-81148	93.839	1,583
Pass-through Childrens Hospital Medical Center	R01HL095647	93.839	256,146
Pass-through Medical College of Wisconsin	2P01HL081588-06	93.839	(114)
Pass-through Natl Marrow Donor Program	CSPR0102	93.839	6,570
Pass-through Natl Marrow Donor Program	U01HL69294	93.839	(9,993)
Pass-through New England Research Institutes	U01HL072268	93.839	204,745
Pass-through New England Research Institutes	U01HL072268/SITE 006	93.839	(19,252)
Pass-through Oklahoma Medical Research Foundation	0183-10	93.839	524,892
Pass-through St Jude Childrens Research Hospital	111270051-7402372	93.839	(1,231)
Pass-through University of Alabama Birmingham	000502659-002	93.839	11,793
Pass-through University Of Iowa	1001322422	93.839	10,021
Pass-through University of Medicine and Dentistry Of New Jersey	1R01HL07395801	93.839	1,206
Pass-through University Of North Carolina Chapel Hill	5032283	93.839	145,272
Pass-through University Of Pittsburgh	0040317 (124034-1)	93.839	18,985
Pass-through Washington University	WU-14-107	93.839	(1,240)
Total CFDA No. 93.839			3,194,537
Arthritis, Musculoskeletal and Skin Diseases Research	1F31AR067645-01	93.846	24,259
Arthritis, Musculoskeletal and Skin Diseases Research	2R01AR048266-12	93.846	354,257
Arthritis, Musculoskeletal and Skin Diseases Research	5K01AR061453-04	93.846	92,850
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR047901-12	93.846	291,384
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR048615-14	93.846	289,962
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR054625-09	93.846	294,886
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR061267-04	93.846	265,572
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR062483-04	93.846	326,732
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR064307-02	93.846	382,500
Arthritis, Musculoskeletal and Skin Diseases Research	5R21AR066920-02	93.846	113,745
Arthritis, Musculoskeletal and Skin Diseases Research	5U01AR067169-02	93.846	98,727
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR04252715	93.846	252
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR047314-10	93.846	2,332
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR048266-10REVIS	93.846	(9,694)
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR050501-12	93.846	394,122
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR052133-05	93.846	1,781
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR05273004	93.846	66
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR056090-03	93.846	132
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR059364-05	93.846	255,834
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR060268-04	93.846	283,630
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR060893-04	93.846	224,356
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR061987-05	93.846	330,337
Pass-through Case Western Reserve University	RES508509	93.846	(296)
Pass-through Children's Research Institute	30000333-05	93.846	4,064
Pass-through Cincinnati Childrens Hospital	106355	93.846	4,262
Pass-through Georgia Institute of Technology	RD128-G1	93.846	35,280
Pass-through University Of Georgia	RR093-401/4708851	93.846	65,658
Pass-through University Of Maryland	20395-Z0579001	93.846	291,082
Pass-through University Of North Carolina	5030786	93.846	72,135
Total CFDA No. 93.846			4,490,207
Diabetes, Digestive, and Kidney Diseases Extramural Research	1DP3DK094346-01 REV	93.847	1,276,438
Diabetes, Digestive, and Kidney Diseases Extramural Research	1F31DK107229-01	93.847	9,044
Diabetes, Digestive, and Kidney Diseases Extramural Research	1R13DK102348-01	93.847	(1,748)
Diabetes, Digestive, and Kidney Diseases Extramural Research	1R13DK103532-01	93.847	36
Diabetes, Digestive, and Kidney Diseases Extramural Research	1R13DK105792-01	93.847	16,000
Diabetes, Digestive, and Kidney Diseases Extramural Research	2R01DK041707-19A1 RE	93.847	333,125
Diabetes, Digestive, and Kidney Diseases Extramural Research	2R01DK055679-16	93.847	106,385
Diabetes, Digestive, and Kidney Diseases Extramural Research	2R01DK074731-04A1	93.847	20,596
Diabetes, Digestive, and Kidney Diseases Extramural Research	2R01DK079392-10A1	93.847	243,664
Diabetes, Digestive, and Kidney Diseases Extramural Research	2R01DK080684-06A1	93.847	12,835
Diabetes, Digestive, and Kidney Diseases Extramural Research	2R56DK054154-15	93.847	39,373
Diabetes, Digestive, and Kidney Diseases Extramural Research	5 F30 DK097904-03	93.847	26,526
Diabetes, Digestive, and Kidney Diseases Extramural Research	5 R01 DK072564-20REV	93.847	46,225
Diabetes, Digestive, and Kidney Diseases Extramural Research	5 U01 DK056956-14	93.847	214,894
Diabetes, Digestive, and Kidney Diseases Extramural Research	5F30DK098928-02	93.847	45,096
Diabetes, Digestive, and Kidney Diseases Extramural Research	5F30DK100097-03	93.847	35,775
Diabetes, Digestive, and Kidney Diseases Extramural Research	5F32DK101163-02	93.847	56,920
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K01DK087763-05	93.847	113,344
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K01DK099617-02	93.847	114,766
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K01DK102851-02	93.847	102,226
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K08DK091506-04	93.847	250,406
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K24DK096574-09	93.847	140,757
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK046493-13	93.847	191,199
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK059380-13	93.847	304,967
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK059888-14	93.847	111,885
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK061379-13 REVI	93.847	15,441
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK061418-13	93.847	314,565
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK062092-12	93.847	358,939
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK071597-09	93.847	340,408
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK079713-09	93.847	426,867
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK083356-04 REV	93.847	22,437
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK089763-04	93.847	236,603
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK095610-04	93.847	321,021
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK095750-04	93.847	333,968
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK096983-03	93.847	404,488
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK100582-02	93.847	247,304

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R03DK096157-02	93.847	85,618
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R03DK097457-02	93.847	59,544
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R21DK098558-02	93.847	201,601
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R21DK099716-02	93.847	83,548
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R25DK101390-02S1	93.847	99,779
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R37 DK038842-27	93.847	319,247
Diabetes, Digestive, and Kidney Diseases Extramural Research	5T32DK007734-19	93.847	174,885
Diabetes, Digestive, and Kidney Diseases Extramural Research	5T32DK007771-15	93.847	189,546
Diabetes, Digestive, and Kidney Diseases Extramural Research	7R01DK092722-04	93.847	366,696
Diabetes, Digestive, and Kidney Diseases Extramural Research	3R01DK085097-05S1	93.847	356,908
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K01DK082733-05	93.847	28
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K08DK079176-05	93.847	311
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K08DK083056-04	93.847	808
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K23DK07071505	93.847	1,867
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K23DK080953-05	93.847	62
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK047987-22	93.847	358,200
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK054514-14	93.847	43
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK055679-15 REV	93.847	(62)
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK056239-14	93.847	485,163
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK056481-10	93.847	87
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK05766511	93.847	1,249
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK067110-07	93.847	(639)
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK072372-08Revis	93.847	(2,000)
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK075016-05	93.847	70,301
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK079392-09	93.847	1,451
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK079713-05	93.847	24
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK080684-05	93.847	76,809
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK087694-05	93.847	704,208
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK087838-05	93.847	206,344
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK089828-04	93.847	180,539
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK091780-04	93.847	230,677
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK098231-03	93.847	454,188
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK098391-02REVIS	93.847	406,817
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R03DK101870-02	93.847	41,295
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R21DK089369-02	93.847	50,739
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R37DK037963-25	93.847	(258)
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R37DK057665-16	93.847	422,670
Diabetes, Digestive, and Kidney Diseases Extramural Research	5T32DK007298-30	93.847	(1,392)
Diabetes, Digestive, and Kidney Diseases Extramural Research	5T32DK007298-35 REVI	93.847	190,537
Diabetes, Digestive, and Kidney Diseases Extramural Research	5T32DK007656-25S1	93.847	281,341
Diabetes, Digestive, and Kidney Diseases Extramural Research	5T32DK007734-15 REV	93.847	2,691
Diabetes, Digestive, and Kidney Diseases Extramural Research	5U01DK062408-12REV	93.847	326,010
Diabetes, Digestive, and Kidney Diseases Extramural Research	5U01DK062470-10REV	93.847	153,290
Diabetes, Digestive, and Kidney Diseases Extramural Research	5U01DK062470-12REV	93.847	326,429
Diabetes, Digestive, and Kidney Diseases Extramural Research	R37DK038842-24	93.847	(1,725)
Pass-through Atlanta Research and Education Fdn	M14045	93.847	56,321
Pass-through Atlanta Research and Education Fdn	M1510	93.847	46,003
Pass-through Brigham and Womens Hospital	111977	93.847	9,300
Pass-through Connecticut Childrens Medical Center	14-179296-04	93.847	311,814
Pass-through Connecticut Childrens Medical Center	1U01DK095745	93.847	86
Pass-through George Washington University	U01 -DK061230-09	93.847	6,570
Pass-through Georgia Institute of Technology	1R01DK076801-01A1	93.847	3,493
Pass-through Georgia State University	SP00010712 Amd 3	93.847	13,716
Pass-through Jaeb Center for Health Research	Protocol P	93.847	(54)
Pass-through Joslin Diabetes Center	1987203-14/AMND#1	93.847	222,515
Pass-through Mayo Clinic	63595870	93.847	98,844
Pass-through Mayo Clinic	R01DK079856-03/AMND1	93.847	(8,479)
Pass-through Research Institute at Nationwide Childrens	5UM1DK100866-02	93.847	765
Pass-through University of Alabama Birmingham	000500528-002	93.847	14,513
Pass-through University of California San Francisco	105871	93.847	1,604
Pass-through University of Colorado Denver	FY14.220.031	93.847	1,184
Pass-through University of Iowa	1001305395	93.847	5,821
Pass-through University of Michigan	3001819808	93.847	24,264
Pass-through University of Michigan	3002987307	93.847	7,288
Pass-through University of Pittsburgh	0019927 124826-8A	93.847	149,749
Pass-through University of Texas Southwestern	/ nmGMO-140903	93.847	62,828
Pass-through University of Wisconsin-Madison	361K620	93.847	5,254
Pass-through Virginia Commonwealth University	PD303567-SC105312	93.847	278,868
Pass-through Virginia Commonwealth University	PT103996-SC104345	93.847	63,613
Total CFDA No. 93.847			15,114,189
Digestive Diseases and Nutrition Research	5R01DK06728504	93.848	367
Digestive Diseases and Nutrition Research	5R03DK07539202	93.848	96
Digestive Diseases and Nutrition Research	5R03DK07661302	93.848	20
Total CFDA No. 93.848			483
Kidney Diseases, Urology and Hematology Research	5R21DK08043102	93.849	256
Pass-through Childrens Mercy Hospital	060003/AMENDMENT5	93.849	18,781
Total CFDA No. 93.849			19,037
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS071518-05	93.853	259,043
Extramural Research Programs in the Neurosciences and Neurological Disorders	1 R03 NS091699-01	93.853	18,224
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F31NS086130-01A1REV	93.853	45,803
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F31NS089242-01A1	93.853	16,389
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F31NS092437-01	93.853	10,268
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F32NS083205-01A1 RE	93.853	17,816
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F32NS092342-01 REVI	93.853	20,080
Extramural Research Programs in the Neurosciences and Neurological Disorders	1K99NS087104-01REVIS	93.853	29,205
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R01NS087142-01A1	93.853	124,720
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R01NS088528-01A1	93.853	278,397
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R01NS090319-01A1	93.853	23,768
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R01NS091749-01A1	93.853	77,833
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R01NS093016-01	93.853	54,865
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R01NS093362-01REVIS	93.853	34,918
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS089080-01A1	93.853	118,996

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS091630-01	93.853	\$ 30,083
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS091986-01	93.853	62,336
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS093550-01	93.853	12,289
Extramural Research Programs in the Neurosciences and Neurological Disorders	2P30NS055077-06A1	93.853	2,274
Extramural Research Programs in the Neurosciences and Neurological Disorders	2R01NS036654-17	93.853	546
Extramural Research Programs in the Neurosciences and Neurological Disorders	2U54NS065701-06 REVI	93.853	483,148
Extramural Research Programs in the Neurosciences and Neurological Disorders	3P50NS071669-05S1	93.853	1,370,233
Extramural Research Programs in the Neurosciences and Neurological Disorders	3R01NS084844-02S1 RE	93.853	241,078
Extramural Research Programs in the Neurosciences and Neurological Disorders	5 F31 NS089406-02	93.853	41,797
Extramural Research Programs in the Neurosciences and Neurological Disorders	5 F31NS081828-03REVI	93.853	31,153
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS081830-03	93.853	29,323
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS084730-03	93.853	29,288
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS084739-03	93.853	32,351
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS086370-02	93.853	39,933
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS08713-02	93.853	27,859
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F32NS070572-03REVIS	93.853	17,812
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F32NS078873-02	93.853	5,207
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F32NS080589-03	93.853	46,851
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F32NS087915-02	93.853	46,366
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K23NS083748-02	93.853	137,831
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K99NS082379-02	93.853	60,338
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R00NS065974-05	93.853	155,681
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS037112-15	93.853	460,723
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS045962-08	93.853	12,591
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS047357-11	93.853	335,430
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS057190-09	93.853	279,408
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS061070-10	93.853	428,040
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS073994-05	93.853	470,335
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS077982-04	93.853	574,128
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS078095-04	93.853	469,886
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS079268-04	93.853	378,468
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS079625-04	93.853	(56,898)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS079858-03	93.853	252,325
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS083386-03	93.853	358,783
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS084744-02	93.853	482,054
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS085006-03	93.853	390,621
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS085568-02	93.853	341,238
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS088413-02	93.853	595,479
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS088748-02	93.853	400,016
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS089694-02	93.853	143,672
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS074169-02	93.853	376
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS075338-02	93.853	4,026
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS077905-01REVIS	93.853	(12)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS079948-02REVIS	93.853	41,776
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS081461-02	93.853	(108)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS081606-02	93.853	200,434
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS082546-02	93.853	235,381
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS082680-02	93.853	192,966
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS083026-02	93.853	91,206
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS084229-02	93.853	323,124
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS084358-02	93.853	189,506
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS085382-02	93.853	263,659
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS085553-02	93.853	181,078
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS088503-02	93.853	265,528
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS091038-02	93.853	210,444
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R25NS065739-07REV	93.853	12,677
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R31NS086174-02	93.853	41,130
Extramural Research Programs in the Neurosciences and Neurological Disorders	5T32NS007480-15	93.853	255,837
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U01NS038455-14REVIS	93.853	2,654,407
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U10NS059032-09	93.853	282,475
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U10NS086607-03	93.853	324,049
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U18NS082143-02revis	93.853	3,048
Extramural Research Programs in the Neurosciences and Neurological Disorders	7R21NS074559-03	93.853	1,077
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F32NS087775-01A1	93.853	7,724
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS072810-02	93.853	1,177
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS087488-01A1	93.853	12,433
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS094136-01	93.853	131,913
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R56NS070879-01	93.853	32,252
Extramural Research Programs in the Neurosciences and Neurological Disorders	2R56NS03711210A1	93.853	15
Extramural Research Programs in the Neurosciences and Neurological Disorders	3R01NS033592-15S1	93.853	42
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS074620-03	93.853	2,275
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F32NS05454202	93.853	(6,950)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F32NS086368-03	93.853	51,349
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K02NS070960-05	93.853	97,273
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K08NS053454-05	93.853	558
Extramural Research Programs in the Neurosciences and Neurological Disorders	5KD8NS087121-02	93.853	103,260
Extramural Research Programs in the Neurosciences and Neurological Disorders	5P30NS055077-05	93.853	2,431
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS03045419	93.853	145
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS036232-16 REVI	93.853	324,271
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS037112-13	93.853	54
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS037948-16REVIS	93.853	1,598
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS038455-10 REV	93.853	50,082
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS041669-14	93.853	428,628
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS042599-08	93.853	715
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS04286708	93.853	2,333
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS045627-10	93.853	135,247
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS04757503	93.853	54
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS04825406	93.853	97
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS04947804	93.853	1,055
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS051630-10	93.853	596,283
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS055179-05	93.853	197
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS056097-05 REV	93.853	1,034
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS058710-04	93.853	43,802
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS060680-05REVIS	93.853	6,423
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS062073-05 REV	93.853	69

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS062097-05	93.853	\$ 213,813
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS062358-05REVIS	93.853	126
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS064162-04	93.853	104,359
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS064991-04	93.853	1,552
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS065187-04	93.853	1,703
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS065371-07	93.853	383,893
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS065949-05 REV	93.853	134,048
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS065992-04	93.853	286,746
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS067201-05	93.853	111,736
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS068464-04 REV	93.853	5,315
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS070526-05	93.853	188,644
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS071074-05	93.853	283,006
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS071867-05	93.853	222,999
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS072221-04	93.853	151,960
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS072394	93.853	338,204
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS072467-05	93.853	70,490
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS076775-04	93.853	436,204
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS079331-03REV	93.853	438,275
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS085387-02	93.853	245,005
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS06134902	93.853	110
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS063029-02	93.853	1,268
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS072712-02	93.853	1,254
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS084163-02	93.853	46,040
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS084647-02REV	93.853	205,904
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS084870-02	93.853	236,453
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U01NS058158-09	93.853	592,285
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U01NS062676-03	93.853	87,657
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U01NS062778-05REVIS	93.853	1,873,465
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U10NS053379-05 REV	93.853	4,848
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U10NS053379-07	93.853	3,927
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U10NS073666-05	93.853	207,211
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U54NS065701-05 REVI	93.853	407,319
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS072422-02	93.853	57,856
Pass-through Agnes Scott College	02530-YER-1	93.853	(87,699)
Pass-through Duke University	09NIH1078	93.853	10,410
Pass-through Duke University	13-NIH-1001	93.853	4,535
Pass-through Duke University	2033807	93.853	53,505
Pass-through Georgia Institute of Technology	RC836-G1	93.853	55,482
Pass-through Health Research	Gut Microbiome	93.853	(8,814)
Pass-through Johns Hopkins University	2001976905	93.853	117,390
Pass-through Massachusetts General Hospital	221606	93.853	7,102
Pass-through Massachusetts General Hospital	5U01NS04964005/ALS S	93.853	9,561
Pass-through Massachusetts General Hospital	5U01NS05259203	93.853	16,346
Pass-through Massachusetts General Hospital	U01NS077366-01	93.853	27,098
Pass-through Medical College of Wisconsin	PO# 1292659	93.853	30,480
Pass-through Medical University of South Carolina	MUSC08-041/AMND6	93.853	200,390
Pass-through Medical University of South Carolina	MUSC08094/U01NS0587	93.853	5,075
Pass-through Northwestern University	STEADY-PD	93.853	10,707
Pass-through Stanford University	60137320-51128-C	93.853	143,277
Pass-through Univ of Texas Health Sciences Center	AGREEMENT12615538	93.853	555
Pass-through University of California Irvine	12-811	93.853	1,302
Pass-through University of California Irvine	2009-2115	93.853	69
Pass-through University of Cincinnati	006288	93.853	(129)
Pass-through University of Cincinnati	COEUS 006883-010 PN	93.853	395,278
Pass-through University Of Melbourne	TA17404_EU	93.853	97,795
Pass-through University of Miami	662706 / PO# MR98032	93.853	71,446
Pass-through University of Michigan	111993-SHN	93.853	127,063
Pass-through University of Michigan	3001413083-PNT	93.853	81,680
Pass-through University of Michigan	3002268352	93.853	5,233
Pass-through University of Michigan	P0157550/361009-0543	93.853	1,633
Pass-through University of Michigan	SUBK00002373-ATACHII	93.853	10,290
Pass-through University of Michigan	SUBK00004094-ESETT	93.853	17,717
Pass-through University of North Carolina	5100029	93.853	161,349
Pass-through University of South Carolina	040895#5/2R01NS03899	93.853	1,348
Pass-through University of Southern California	32949287	93.853	9,427
Pass-through University of Southern California	55440607	93.853	27,507
Pass-through University of Southern California	H50438/H49894	93.853	2,702
Pass-through University Of Washington Seattle	700159/5R01NS0575670	93.853	920
Pass-through University Of Washington Seattle	747848	93.853	61,284
Pass-through University Of Wisconsin-Madison	613K476	93.853	9,241
Pass-through Wright State University	AMDT#3/5R01NS0493240	93.853	(4,193)
Pass-through Wright State University	P01NS057228	93.853	258,096
Total CFDA No. 93.853			27,428,459
Allergy, Immunology and Transplantation Research	1F31A118558-01	93.855	23,744
Allergy, Immunology and Transplantation Research	1K23A1108335-03	93.855	177,838
Allergy, Immunology and Transplantation Research	1R01A1110113-01A1	93.855	342,696
Allergy, Immunology and Transplantation Research	1R01A1110482-01A1	93.855	371,072
Allergy, Immunology and Transplantation Research	1R01A1110680-01A1	93.855	80,182
Allergy, Immunology and Transplantation Research	1R01A1113883-01	93.855	750,657
Allergy, Immunology and Transplantation Research	1R01A1116379-01A1	93.855	392,797
Allergy, Immunology and Transplantation Research	1R01A1116933-01A1	93.855	9,991
Allergy, Immunology and Transplantation Research	1R01A1118853-01	93.855	128,947
Allergy, Immunology and Transplantation Research	1R13A1112459-01	93.855	1,000,000
Allergy, Immunology and Transplantation Research	1R21A1094402-01A1	93.855	34,116
Allergy, Immunology and Transplantation Research	1R21A1109601-02	93.855	190,882
Allergy, Immunology and Transplantation Research	1R21A1113385-01A1	93.855	51,300
Allergy, Immunology and Transplantation Research	1R21A1115018-01	93.855	125,514
Allergy, Immunology and Transplantation Research	1R21A1115183-01	93.855	70,026
Allergy, Immunology and Transplantation Research	1R21A1116361-01A1	93.855	33,017
Allergy, Immunology and Transplantation Research	1R21A1117162-01	93.855	3,947
Allergy, Immunology and Transplantation Research	1R21A1118542-01	93.855	39,393
Allergy, Immunology and Transplantation Research	1R56A1095712-01A1	93.855	73,941
Allergy, Immunology and Transplantation Research	1R56A1103382-01A1	93.855	593,227
Allergy, Immunology and Transplantation Research	1R56A1109526-01	93.855	382,673

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Allergy, Immunology and Transplantation Research	1R56A1110516-01	93.855	\$ 187,820
Allergy, Immunology and Transplantation Research	1R56A1117851-01	93.855	22,888
Allergy, Immunology and Transplantation Research	1U01A1115651-01	93.855	46,830
Allergy, Immunology and Transplantation Research	1U19A1117891-01	93.855	156,616
Allergy, Immunology and Transplantation Research	2R01 A1088025-06	93.855	147,926
Allergy, Immunology and Transplantation Research	2R01A1064060-11A1	93.855	88,516
Allergy, Immunology and Transplantation Research	2R01A1065429-11	93.855	240,322
Allergy, Immunology and Transplantation Research	2R56A1061031-06A1	93.855	(565)
Allergy, Immunology and Transplantation Research	2R56A1074417-04A1	93.855	277
Allergy, Immunology and Transplantation Research	2U19A1090023-06	93.855	129,224
Allergy, Immunology and Transplantation Research	3R01A1049781-13S1	93.855	577,763
Allergy, Immunology and Transplantation Research	3R01A1104699-03	93.855	477,768
Allergy, Immunology and Transplantation Research	3T32A1074492-06S1	93.855	261,543
Allergy, Immunology and Transplantation Research	4R33A1104278-03	93.855	78,137
Allergy, Immunology and Transplantation Research	4R37A1021150-30	93.855	89,776
Allergy, Immunology and Transplantation Research	4R37A1049660-12	93.855	314,148
Allergy, Immunology and Transplantation Research	5 F31 A1112261-02	93.855	42,546
Allergy, Immunology and Transplantation Research	5 R01 A1093881-04	93.855	283,450
Allergy, Immunology and Transplantation Research	5 R01 A111907-02	93.855	482,890
Allergy, Immunology and Transplantation Research	5 R03 A1109194-02	93.855	124,769
Allergy, Immunology and Transplantation Research	5 R21 A1116200-02	93.855	278,995
Allergy, Immunology and Transplantation Research	5 R37 A1048638-15	93.855	415,957
Allergy, Immunology and Transplantation Research	5F31A1114250-02	93.855	41,974
Allergy, Immunology and Transplantation Research	5K23A1103044-03	93.855	182,075
Allergy, Immunology and Transplantation Research	5K23A1114407-02	93.855	158,992
Allergy, Immunology and Transplantation Research	5K23A1116388-02	93.855	131,983
Allergy, Immunology and Transplantation Research	5P30A1050409-17REVIS	93.855	2,260,584
Allergy, Immunology and Transplantation Research	5R01A1090840-04	93.855	2,620
Allergy, Immunology and Transplantation Research	5R01A1028731-25	93.855	464,936
Allergy, Immunology and Transplantation Research	5R01A1030048-24	93.855	318,010
Allergy, Immunology and Transplantation Research	5R01A1053668-15	93.855	440,434
Allergy, Immunology and Transplantation Research	5R01A1058057-11	93.855	130,761
Allergy, Immunology and Transplantation Research	5R01A1058706-13	93.855	711,255
Allergy, Immunology and Transplantation Research	5R01A1058828-10	93.855	357,772
Allergy, Immunology and Transplantation Research	5R01A1064462-09	93.855	347,305
Allergy, Immunology and Transplantation Research	5R01A1070101-09	93.855	172,136
Allergy, Immunology and Transplantation Research	5R01A1084808-06REVIS	93.855	253,099
Allergy, Immunology and Transplantation Research	5R01A1084836-05	93.855	97,146
Allergy, Immunology and Transplantation Research	5R01A1086133-04	93.855	1,596
Allergy, Immunology and Transplantation Research	5R01A1087465-05	93.855	590,774
Allergy, Immunology and Transplantation Research	5R01A1088025-05	93.855	199,257
Allergy, Immunology and Transplantation Research	5R01A1089349-06	93.855	578,689
Allergy, Immunology and Transplantation Research	5R01A1090797-04	93.855	63,723
Allergy, Immunology and Transplantation Research	5R01A1093406-05	93.855	676,069
Allergy, Immunology and Transplantation Research	5R01A1094575-04 REVI	93.855	628,515
Allergy, Immunology and Transplantation Research	5R01A1097423-02	93.855	(76)
Allergy, Immunology and Transplantation Research	5R01A1098628-04REVIS	93.855	1,475,280
Allergy, Immunology and Transplantation Research	5R01A1100110-04	93.855	597,703
Allergy, Immunology and Transplantation Research	5R01A1101047-04	93.855	576,505
Allergy, Immunology and Transplantation Research	5R01A1101982-02REV	93.855	411,283
Allergy, Immunology and Transplantation Research	5R01A1106715-03	93.855	187,957
Allergy, Immunology and Transplantation Research	5R01A1107960-02	93.855	627,467
Allergy, Immunology and Transplantation Research	5R01A1110334-03	93.855	787,237
Allergy, Immunology and Transplantation Research	5R01A1110474-02	93.855	238,323
Allergy, Immunology and Transplantation Research	5R01A1110701-02	93.855	397,425
Allergy, Immunology and Transplantation Research	5R01A1110720-02	93.855	459,112
Allergy, Immunology and Transplantation Research	5R01A1111557-02	93.855	617,092
Allergy, Immunology and Transplantation Research	5R01A1111851-02	93.855	422,695
Allergy, Immunology and Transplantation Research	5R01A1111863-02	93.855	782,900
Allergy, Immunology and Transplantation Research	5R01A1111948-02	93.855	603,823
Allergy, Immunology and Transplantation Research	5R01A1113021-02	93.855	322,650
Allergy, Immunology and Transplantation Research	5R03A1111396-02	93.855	88,531
Allergy, Immunology and Transplantation Research	5R21A1094449-02	93.855	154,735
Allergy, Immunology and Transplantation Research	5R21A1095718-02	93.855	80,113
Allergy, Immunology and Transplantation Research	5R21A1098581-02 REV	93.855	83,889
Allergy, Immunology and Transplantation Research	5R21A1098592-02	93.855	64,323
Allergy, Immunology and Transplantation Research	5R21A1098800-02	93.855	1,087
Allergy, Immunology and Transplantation Research	5R21A1101775-02	93.855	126,426
Allergy, Immunology and Transplantation Research	5R21A1102197-02	93.855	(108,212)
Allergy, Immunology and Transplantation Research	5R21A1103270-02	93.855	133,686
Allergy, Immunology and Transplantation Research	5R21A1103651-02	93.855	175,168
Allergy, Immunology and Transplantation Research	5R21A1104278-02REV	93.855	68,368
Allergy, Immunology and Transplantation Research	5R21A1106386-02	93.855	143,137
Allergy, Immunology and Transplantation Research	5R21A1111388-02	93.855	82,471
Allergy, Immunology and Transplantation Research	5R33A1098800-04	93.855	456,864
Allergy, Immunology and Transplantation Research	5R33A1102197-04	93.855	572,073
Allergy, Immunology and Transplantation Research	5R37A1040519-19	93.855	288,814
Allergy, Immunology and Transplantation Research	5R37A1049660-11	93.855	383,922
Allergy, Immunology and Transplantation Research	5R37A1066998-11	93.855	552,162
Allergy, Immunology and Transplantation Research	5R37A1112787-02	93.855	1,045,028
Allergy, Immunology and Transplantation Research	5T32 A1007610-15	93.855	258,644
Allergy, Immunology and Transplantation Research	5T32A1070081-09	93.855	173,005
Allergy, Immunology and Transplantation Research	5T32A1106699-02	93.855	114,792
Allergy, Immunology and Transplantation Research	5U019A1109633-02	93.855	2,630,180
Allergy, Immunology and Transplantation Research	5U01A108415-05	93.855	2,283,139
Allergy, Immunology and Transplantation Research	5U01A1090956-04	93.855	1,574
Allergy, Immunology and Transplantation Research	5U01A1103408-03 REV	93.855	2,777,176
Allergy, Immunology and Transplantation Research	5U19A1051731-14REVIS	93.855	2,873,834
Allergy, Immunology and Transplantation Research	5U19A1057266-10 REV	93.855	27,235
Allergy, Immunology and Transplantation Research	5U19A1057266-12REVIS	93.855	3,172,562
Allergy, Immunology and Transplantation Research	5U19A1090023-05	93.855	2,908,310
Allergy, Immunology and Transplantation Research	5U19A1110483-02	93.855	447,801
Allergy, Immunology and Transplantation Research	5U19A1111211-02REV	93.855	1,688,827
Allergy, Immunology and Transplantation Research	5UM1A1069418-09REVIS	93.855	2,068,581
Allergy, Immunology and Transplantation Research	7R01A1065429-10	93.855	363,595



**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Allergy, Immunology and Transplantation Research	R01 AI112723-01A1	93.855	\$ 105,678
Allergy, Immunology and Transplantation Research	1R21AI089093-02	93.855	2,123
Allergy, Immunology and Transplantation Research	1R56A1087673-01A1	93.855	393
Allergy, Immunology and Transplantation Research	1R56A1107295-01A1	93.855	184,492
Allergy, Immunology and Transplantation Research	1U19 AI096187-04	93.855	5,481,464
Allergy, Immunology and Transplantation Research	5K01AI087724-05	93.855	103,424
Allergy, Immunology and Transplantation Research	5K01AI091864-05	93.855	106,329
Allergy, Immunology and Transplantation Research	5K01AI103544-03	93.855	132,033
Allergy, Immunology and Transplantation Research	5K01AI106961-02	93.855	107,309
Allergy, Immunology and Transplantation Research	5P01AI080192-05	93.855	408,783
Allergy, Immunology and Transplantation Research	5P01AI088575-04 REV	93.855	1,022,803
Allergy, Immunology and Transplantation Research	5R01AI020211-29REVIS	93.855	86
Allergy, Immunology and Transplantation Research	5R01AI024710-23	93.855	1,972
Allergy, Immunology and Transplantation Research	5R01AI047498-13	93.855	311,223
Allergy, Immunology and Transplantation Research	5R01AI05433730	93.855	5,345
Allergy, Immunology and Transplantation Research	5R01AI05599605	93.855	457
Allergy, Immunology and Transplantation Research	5R01AI05601703	93.855	12,946
Allergy, Immunology and Transplantation Research	5R01AI058706-10	93.855	6,257
Allergy, Immunology and Transplantation Research	5R01AI064060-10	93.855	926,298
Allergy, Immunology and Transplantation Research	5R01AI06711014	93.855	8,638
Allergy, Immunology and Transplantation Research	5R01AI069148-03	93.855	(189)
Allergy, Immunology and Transplantation Research	5R01AI072435-06REVIS	93.855	1,489
Allergy, Immunology and Transplantation Research	5R01AI072435-10	93.855	387,500
Allergy, Immunology and Transplantation Research	5R01AI072462-05	93.855	22,118
Allergy, Immunology and Transplantation Research	5R01AI073830-05	93.855	7,845
Allergy, Immunology and Transplantation Research	5R01AI078773-05REVIS	93.855	116,490
Allergy, Immunology and Transplantation Research	5R01AI083366-05	93.855	219,615
Allergy, Immunology and Transplantation Research	5R01AI087798-05	93.855	278,523
Allergy, Immunology and Transplantation Research	5R01AI096879-04	93.855	503,747
Allergy, Immunology and Transplantation Research	5R01AI099000-04	93.855	396,463
Allergy, Immunology and Transplantation Research	5R21AI098028-03	93.855	174,003
Allergy, Immunology and Transplantation Research	5R21AI103653-02	93.855	226,372
Allergy, Immunology and Transplantation Research	5R37AI021150-29	93.855	275,016
Allergy, Immunology and Transplantation Research	5R37AI030048-19REVIS	93.855	6,774
Allergy, Immunology and Transplantation Research	5R37AI051231-11	93.855	(19,646)
Allergy, Immunology and Transplantation Research	5R37AI051231-14	93.855	774,744
Allergy, Immunology and Transplantation Research	5T32AI007470-15	93.855	5,901
Allergy, Immunology and Transplantation Research	5T32AI055404-10	93.855	136
Allergy, Immunology and Transplantation Research	5T32AI074492-05	93.855	6,095
Allergy, Immunology and Transplantation Research	5U01AI089317-03REVIS	93.855	2,322
Allergy, Immunology and Transplantation Research	SU19AI05726602	93.855	365
Allergy, Immunology and Transplantation Research	5UM1AI069418-07REVIS	93.855	(1,257)
Allergy, Immunology and Transplantation Research	P01AI078907-05	93.855	2,171,707
Pass-through Albert Einstein College of Medicine	PO# 154518	93.855	38,666
Pass-through Baylor Research Institute	41000411343	93.855	68,976
Pass-through Benaroya Research Institute At Virginia	FY141TN061	93.855	11,140
Pass-through Benaroya Research Institute At Virginia	FY151TN023	93.855	27,801
Pass-through Beth Israel Deaconess Medical Center	U19AI095985	93.855	299,991
Pass-through Boston University	4500001634	93.855	516,670
Pass-through Brandeis University	401862	93.855	224,701
Pass-through Brigham And Womens Hospital	109461	93.855	55,850
Pass-through Brigham And Womens Hospital	2UM1AI068636-08	93.855	273,680
Pass-through Brigham And Womens Hospital	5UM1AI068636-09	93.855	109,720
Pass-through Case Western Reserve University	RES509044	93.855	66,946
Pass-through Case Western Reserve University	RES509540	93.855	185,598
Pass-through Centre For The Aids Program	1R21AI115978-01	93.855	15,949
Pass-through Childrens Hospital And Res Ctr Oakland	12.8216.002	93.855	3,045
Pass-through Childrens Hospital Oakland	12.7845_Emory_3	93.855	208,822
Pass-through Childrens Hospital of Boston	517509	93.855	(22,367)
Pass-through Columbia University	4(GG006382-07)	93.855	29,590
Pass-through Dana Farber Cancer Institute	1034817	93.855	(377)
Pass-through Dana Farber Cancer Institute	1194804	93.855	198,042
Pass-through Duke University	2032942	93.855	979
Pass-through Duke University	2033045	93.855	23,517
Pass-through Duke University	Duke ID 2032979	93.855	2,222
Pass-through Feinstein Institute For Medical Research	R01AI1068759	93.855	10
Pass-through Fred Hutchinson Cancer Research Center	000790194	93.855	3,894
Pass-through Fred Hutchinson Cancer Research Center	0000818988	93.855	438,557
Pass-through George Washington University	12-M55	93.855	933
Pass-through Georgia Institute of Technology	E-25-T68-G2(R8602)	93.855	6,212
Pass-through Georgia Institute of Technology	RE606	93.855	(33,202)
Pass-through Georgia Institute of Technology	RE606-G2	93.855	108,885
Pass-through Georgia State University	SP00011121-01	93.855	81,310
Pass-through Georgia State University	SP00011162-01	93.855	74,445
Pass-through Georgia State University	SP00011272-02	93.855	110,847
Pass-through Georgia State University	SP00011671-02	93.855	68,329
Pass-through Harvard University	149639.5025086.1010	93.855	7,130
Pass-through Harvard University	149648.5035353.0002	93.855	66,046
Pass-through Harvard University	151163.5027281.0003	93.855	9,031
Pass-through Harvard University	152382.5087275.1108	93.855	318,258
Pass-through Henry M Jackson Foundation	PO-828074	93.855	76,920
Pass-through Henry M Jackson Foundation	Sub# 2503 PO# 823684	93.855	115,052
Pass-through Johns Hopkins University	2002351815	93.855	354,418
Pass-through Johns Hopkins University	PO# 2001007978	93.855	145,427
Pass-through Massachusetts General Hospital	223544	93.855	155,831
Pass-through Mayo Clinic	63484620	93.855	247,492
Pass-through Mayo Clinic	po 63807180	93.855	182,176
Pass-through Md Anderson	00001893	93.855	16,731
Pass-through Medical University of South Carolina	MUSC14-033 PO173143	93.855	10,221
Pass-through Mount Sinai School of Medicine	0254-3193-4609	93.855	377,020
Pass-through Mount Sinai School of Medicine	025513534609/5U01AI0	93.855	(2,680)
Pass-through Mount Sinai School of Medicine	0255-1359-4609	93.855	68,168
Pass-through Mount Sinai School of Medicine	25580714609	93.855	96,387
Pass-through Public Health Foundation of India	HHSN268200900026C	93.855	(26,584)
Pass-through Research Institute At Nationwide Children's Hospital	R01AI096882	93.855	241,480

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Pass-through Scripps Research Institute	5-50823	93.855	\$ 683,798
Pass-through Scripps Research Institute	5-50824	93.855	960,662
Pass-through Scripps Research Institute	PO #5-50822	93.855	69,064
Pass-through Seattle Childrens Hospital	11113SUB/IR21A111618	93.855	12,617
Pass-through Texas Agricultural And Mechanical Univ	99-S130670	93.855	23,334
Pass-through University of Alabama Birmingham	000338217-SP021-010	93.855	(38,168)
Pass-through University of Alabama Birmingham	000502889-SP007-001	93.855	219,640
Pass-through University of Alabama Birmingham	000503299-001	93.855	756
Pass-through University of Alabama Birmingham	000503356--SP013-004	93.855	165,624
Pass-through University of Alabama Birmingham	000505362-001	93.855	57,666
Pass-through University of Alabama Birmingham	5R01AI084772-05	93.855	8,465
Pass-through University of Alberta	1U01AI06519104	93.855	15,372
Pass-through University of California Berkeley	00007955-BB00039299	93.855	31,374
Pass-through University of California Davis	201303042-01	93.855	283,005
Pass-through University of California Davis	201403118-01	93.855	30,606
Pass-through University of California Davis	SUB 016341-02	93.855	(145)
Pass-through University of California San Francisco	5029SC/AMENDMENT2	93.855	593
Pass-through University of California San Francisco	7264sc - U01AI100807	93.855	22,010
Pass-through University of California San Francisco	8096sc	93.855	10,025
Pass-through University of California San Francisco	8503sc	93.855	272,152
Pass-through University of Georgia	RR374-101/4708622	93.855	62,030
Pass-through University of Georgia	RR57120289224772	93.855	10,327
Pass-through University of Houston	R-15-0005	93.855	99,130
Pass-through University of Michigan	3002590302	93.855	9,165
Pass-through University of Minnesota	N002877305	93.855	276,813
Pass-through University of North Carolina	5U54AI057157-11	93.855	7,081
Pass-through University of North Carolina Chapel Hill	NIH/5U19AI031496-23	93.855	(3,628)
Pass-through University of Pennsylvania	553645/R01AI084836	93.855	30,039
Pass-through University of Pennsylvania	562140	93.855	41,985
Pass-through University of Pennsylvania	566103	93.855	20,086
Pass-through University of Rochester	415888-G	93.855	(444)
Pass-through University of Texas Southwestern	150402	93.855	35,799
Pass-through University of Texas Southwestern	GMO-130601	93.855	4,494
Pass-through University of Washington Seattle	759203	93.855	282,189
Pass-through University of Wisconsin-Madison	298K012 / 581K523	93.855	274,558
Pass-through Vanderbilt University	VUMC 38503	93.855	343,924
Pass-through Vanderbilt University	VUMC 40875 / AMND 3	93.855	4,691
Pass-through Vanderbilt University	VUMC34383_AMD5	93.855	(268)
Pass-through Vanderbilt University	VUMC50821	93.855	107,221
Pass-through Washington University	WU-15-317/PO2923045Y	93.855	24,753
Total CFDA No. 93.855			77,422,963
Microbiology and Infectious Diseases Research			
Pass-through Dartmouth College	1266	93.856	334
Pass-through Dartmouth College	1644	93.856	48,903
Pass-through Dartmouth College	R106	93.856	46,259
Pass-through University of Alabama	002COMPANS/5U19AI028	93.856	1,256
Total CFDA No. 93.856			96,752
Biomedical Research and Research Training			
Biomedical Research and Research Training	1F31GM111047-01	93.859	31,562
Biomedical Research and Research Training	1F31GM113397-01A1	93.859	9,588
Biomedical Research and Research Training	1F32GM113570-01	93.859	32,417
Biomedical Research and Research Training	1R01GM112547-01REVIS	93.859	296,416
Biomedical Research and Research Training	1R01GM113228-01	93.859	9,955
Biomedical Research and Research Training	1R01GM114306-01	93.859	54,348
Biomedical Research and Research Training	1R01GM114612-01	93.859	48,437
Biomedical Research and Research Training	2R01GM090158-05A1	93.859	50,571
Biomedical Research and Research Training	2R01GM099142-05	93.859	92,095
Biomedical Research and Research Training	2T32GM008367-26	93.859	28,879
Biomedical Research and Research Training	3 T32 GM008490-23S1	93.859	365,386
Biomedical Research and Research Training	3R01GM035463-28S1	93.859	553,984
Biomedical Research and Research Training	3R01GM049245-22S1	93.859	396,734
Biomedical Research and Research Training	3R01GM097399-04S1	93.859	440,929
Biomedical Research and Research Training	3R01GM104540-03S1	93.859	267,198
Biomedical Research and Research Training	3T32GM008169-29S1	93.859	731,427
Biomedical Research and Research Training	5F31GM108351-02	93.859	27,275
Biomedical Research and Research Training	5F31GM112418-02	93.859	41,328
Biomedical Research and Research Training	5F32GM112517-02	93.859	48,950
Biomedical Research and Research Training	5K12GM000680-15	93.859	1,358,229
Biomedical Research and Research Training	5K99GM104158-02REVIS	93.859	27,525
Biomedical Research and Research Training	5P41GM103694-03	93.859	1,437,794
Biomedical Research and Research Training	5R01 GM105655-02	93.859	280,870
Biomedical Research and Research Training	5R01GM029433-29REVIS	93.859	24,940
Biomedical Research and Research Training	5R01GM047310-19	93.859	217,578
Biomedical Research and Research Training	5R01GM051173-30 REVI	93.859	415,808
Biomedical Research and Research Training	5R01GM054787-22	93.859	427,952
Biomedical Research and Research Training	5R01GM058728-15	93.859	102,505
Biomedical Research and Research Training	5R01GM072808-11	93.859	263,985
Biomedical Research and Research Training	5R01GM077569-07 REVI	93.859	388,775
Biomedical Research and Research Training	5R01GM083889-18	93.859	353,594
Biomedical Research and Research Training	5R01GM084070-07	93.859	250,232
Biomedical Research and Research Training	5R01GM084175-03	93.859	3,840
Biomedical Research and Research Training	5R01GM093294-04	93.859	(32,541)
Biomedical Research and Research Training	5R01GM099142-04REV	93.859	292,235
Biomedical Research and Research Training	5R01GM101040-03	93.859	159,772
Biomedical Research and Research Training	5R01GM104198-05	93.859	282,316
Biomedical Research and Research Training	5R01GM104323-03	93.859	251,661
Biomedical Research and Research Training	5R01GM105813-03	93.859	256,117
Biomedical Research and Research Training	5R01GM108838-02	93.859	212,344
Biomedical Research and Research Training	5R01GM109779-02	93.859	330,103
Biomedical Research and Research Training	5R01GM110000-02	93.859	318,103
Biomedical Research and Research Training	5R01GM110663-02	93.859	297,205
Biomedical Research and Research Training	5R01GM111027-19	93.859	385,140
Biomedical Research and Research Training	5R24GM098791-03	93.859	2,075
Biomedical Research and Research Training	5R25GM099644-03	93.859	849,421
Biomedical Research and Research Training	5R25GM102789-03 REVI	93.859	102,051

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Biomedical Research and Research Training	5T32GM008602-19	93.859	\$ 271,404
Biomedical Research and Research Training	5T32GM008605-20	93.859	314,267
Biomedical Research and Research Training	1F32GM112402-01 REV1	93.859	50,390
Biomedical Research and Research Training	2R01GM093278-06A1	93.859	214,908
Biomedical Research and Research Training	3 R01 GM091875-13S1	93.859	3,997
Biomedical Research and Research Training	3R01GM053640-18A1S1	93.859	359,779
Biomedical Research and Research Training	3R01GM069971-10S1	93.859	254,739
Biomedical Research and Research Training	5F31GM075426-03REV1S	93.859	(6,232)
Biomedical Research and Research Training	5K08GM110537-02	93.859	186,485
Biomedical Research and Research Training	5K12GM000680-10REV1S	93.859	8,934
Biomedical Research and Research Training	5R01GM035463-25	93.859	8,568
Biomedical Research and Research Training	5R01GM046331-21	93.859	3,044
Biomedical Research and Research Training	5R01GM047310-15	93.859	15
Biomedical Research and Research Training	5R01GM049245-20	93.859	413
Biomedical Research and Research Training	5R01GM060448-12	93.859	151,486
Biomedical Research and Research Training	5R01GM068680-07	93.859	(35,622)
Biomedical Research and Research Training	5R01GM068680-08	93.859	(1,705)
Biomedical Research and Research Training	5R01GM072808-09REV1S	93.859	11,638
Biomedical Research and Research Training	5R01GM080754-04 REV	93.859	22,745
Biomedical Research and Research Training	5R01GM082932-04	93.859	132
Biomedical Research and Research Training	5R01GM084070-05 REV	93.859	(1,068)
Biomedical Research and Research Training	5R01GM090158-04	93.859	(83,198)
Biomedical Research and Research Training	5R01GM091875-15	93.859	234,550
Biomedical Research and Research Training	5R01GM097331-04	93.859	481,714
Biomedical Research and Research Training	5R01GM100151-04 REV1	93.859	294,500
Biomedical Research and Research Training	5R01GM103613-03REV	93.859	157,072
Biomedical Research and Research Training	5R01GM108480-03	93.859	307,818
Biomedical Research and Research Training	5R01GM109501-03	93.859	374,091
Biomedical Research and Research Training	5R25GM089615-04	93.859	8,143
Biomedical Research and Research Training	5R37GM051173-27	93.859	518
Biomedical Research and Research Training	5T32GM008367-25	93.859	267,381
Biomedical Research and Research Training	5T32GM008490-20REVSD	93.859	307,494
Biomedical Research and Research Training	5T32GM008602-15	93.859	(54)
Biomedical Research and Research Training	5T32GM095442-05	93.859	279,591
Pass-through Albert Einstein College Of Medicine	31550L	93.859	208,416
Pass-through Albert Einstein College Of Medicine	31599E	93.859	359,317
Pass-through Duke University	13-NIH-1020	93.859	293,260
Pass-through Fred Hutchinson Cancer Research Center	215918	93.859	114,103
Pass-through Fred Hutchinson Cancer Research Center	PO 000802944	93.859	34,525
Pass-through Georgia Department of Human Resources	4.27931E+14	93.859	(44,240)
Pass-through Georgia Institute Of Technology	RA927-G2	93.859	50,851
Pass-through Georgia State University	SP0010548-03	93.859	68,715
Pass-through Ohio State University	6Q044032	93.859	5,420
Pass-through Rice University	R22071 Amendment 4	93.859	183,323
Pass-through Rosalind Franklin University	212970EU	93.859	25,625
Pass-through University Of Florida	UF09107	93.859	5,327
Pass-through University Of Florida	UFDFSP00010341	93.859	5,975
Pass-through University Of Florida	UR08111/U01GM074492	93.859	(2,107)
Pass-through University Of Georgia	RR166-500/4945226	93.859	69,045
Pass-through University Of Georgia	RR166-501/4708616	93.859	359,298
Pass-through University Of Georgia	RR166-501/4708617	93.859	248,549
Pass-through University Of Georgia	RR549-343/4785766	93.859	10,877
Pass-through University Of Minnesota	P003397401/AMND2	93.859	60,258
Pass-through University Of North Carolina Chapel Hill	5034567	93.859	22,721
Pass-through University Of Pittsburgh	0029564(124946-3)	93.859	42,302
Pass-through University Of Tennessee Hlth Science Ctr	GM10450Emory	93.859	(29)
Pass-through University Of Virginia	GC12025-142670	93.859	18,221
Total CFDA No. 93.859			19,374,797
Child Health and Human Development Extramural Research	1K23HD080837-01A1	93.865	21,168
Child Health and Human Development Extramural Research	1R01HD078131-01A1 RE	93.865	231,013
Child Health and Human Development Extramural Research	1R01HD082373-01	93.865	71,194
Child Health and Human Development Extramural Research	1R03HD081438-01A1	93.865	7,820
Child Health and Human Development Extramural Research	1R21HD079969-02	93.865	100,895
Child Health and Human Development Extramural Research	1R21HD080429-01A1	93.865	38,988
Child Health and Human Development Extramural Research	1R21HD084114-01 REV1	93.865	81,521
Child Health and Human Development Extramural Research	5F31HD070735-04	93.865	13,127
Child Health and Human Development Extramural Research	5F31HD079226-02	93.865	51,270
Child Health and Human Development Extramural Research	5K01HD079584-02	93.865	132,810
Child Health and Human Development Extramural Research	5K23HD069199-02	93.865	69,853
Child Health and Human Development Extramural Research	5K23HD078153-02	93.865	113,633
Child Health and Human Development Extramural Research	5R01HD072659-04	93.865	340,088
Child Health and Human Development Extramural Research	5R01HD074486-03	93.865	320,232
Child Health and Human Development Extramural Research	5R01HD075655-02REV1S	93.865	368,414
Child Health and Human Development Extramural Research	5R01HD081274-02	93.865	291,530
Child Health and Human Development Extramural Research	5R03HD074724-02	93.865	49,764
Child Health and Human Development Extramural Research	5R21HD066577-02REV	93.865	773
Child Health and Human Development Extramural Research	5R21HD074502-02	93.865	84,353
Child Health and Human Development Extramural Research	5R21HD075264-02	93.865	201,639
Child Health and Human Development Extramural Research	5R21HD075612-02	93.865	96,027
Child Health and Human Development Extramural Research	5R21HD078077-02	93.865	163,059
Child Health and Human Development Extramural Research	5R21HD078121-02	93.865	129,291
Child Health and Human Development Extramural Research	5R21HD078778-02	93.865	147,722
Child Health and Human Development Extramural Research	5R25HD079102-02REV1S	93.865	53,555
Child Health and Human Development Extramural Research	5T32HD071845-03	93.865	172,006
Child Health and Human Development Extramural Research	5U01HD066439-04	93.865	190,282
Child Health and Human Development Extramural Research	5SU10HD027851-25	93.865	231,233
Child Health and Human Development Extramural Research	5U54NS091859-02	93.865	1,589,161
Child Health and Human Development Extramural Research	1F31HD076617-01REV1S	93.865	34,858
Child Health and Human Development Extramural Research	1R03HD082436-01REV1S	93.865	14,818
Child Health and Human Development Extramural Research	2R21HD067906-02	93.865	53,308
Child Health and Human Development Extramural Research	2U10HD027851-21	93.865	32
Child Health and Human Development Extramural Research	3P01HD032571-19S1	93.865	1,336,092
Child Health and Human Development Extramural Research	5 R01 HD066059-05	93.865	619,372
Child Health and Human Development Extramural Research	5K01HD074726-03	93.865	116,021

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Child Health and Human Development Extramural Research	5K12HD072245-04REVIS	93.865	\$ 443,689
Child Health and Human Development Extramural Research	5R01HD038979-13	93.865	110,889
Child Health and Human Development Extramural Research	5R01HD043099-08	93.865	143,551
Child Health and Human Development Extramural Research	5R01HD046922-10	93.865	178,580
Child Health and Human Development Extramural Research	5R01HD056956-06	93.865	1,124
Child Health and Human Development Extramural Research	5R01HD059122-05REVIS	93.865	80,502
Child Health and Human Development Extramural Research	5R01HD071982-03	93.865	561,122
Child Health and Human Development Extramural Research	5R01HD075784-02	93.865	531,600
Child Health and Human Development Extramural Research	5R01HD077623-03	93.865	1,036,030
Child Health and Human Development Extramural Research	5R03HD076368-02	93.865	44,639
Child Health and Human Development Extramural Research	5R21HD073033-02REVIS	93.865	126,859
Child Health and Human Development Extramural Research	5R21HD076387-02	93.865	151,928
Child Health and Human Development Extramural Research	5T32HD052460-05	93.865	220
Child Health and Human Development Extramural Research	5T32HD052460-10	93.865	276,656
Child Health and Human Development Extramural Research	HHSN2752008000024C	93.865	90,037
Child Health and Human Development Extramural Research	R01HD067359-04	93.865	251,368
Pass-through Boston University	4500001182 Amend 2	93.865	41,041
Pass-through Case Western Reserve University	RESS06273	93.865	72,612
Pass-through Georgia State University	SP00010461-3/5P01HDO	93.865	77,668
Pass-through Georgia State University	SP11537-1	93.865	135,428
Pass-through Georgia State University	SP11537-2	93.865	134,785
Pass-through Mount Sinai School of Medicine	0255-4421-4609	93.865	194,119
Pass-through New York University	PO#: M130002002	93.865	122,490
Pass-through Rehabilitation Institute of Chicago	ARM	93.865	5,924
Pass-through Rehabilitation Institute of Chicago	R24	93.865	15,188
Pass-through San Francisco State University	S12-0002/A3	93.865	76,077
Pass-through Sanford Health	SR-2014-15	93.865	3,750
Pass-through Univ of Massachusetts Medical School	WA00236690/RFS201509	93.865	433,373
Pass-through University of California Davis	201224693-01	93.865	113,110
Pass-through University of Michigan	3003518660	93.865	110,719
Pass-through University of Pennsylvania	560191	93.865	(200)
Pass-through University of Utah	2408022-06A	93.865	(5,325)
Pass-through University of Washington	757768	93.865	116,989
Pass-through Washington University	NIH 2K12HD055931-06	93.865	(21,387)
Pass-through Washington University	WU-13-134-MOD 4	93.865	138,413
Total CFDA No. 93.865			13,330,490
Aging Research	1R13AG047064-01	93.866	35,743
Aging Research	5P01AG026423-05 REV	93.866	2,429
Aging Research	5P50AG025688-10	93.866	1,215,456
Aging Research	5R01AG02539206	93.866	24
Aging Research	5R01AG02876903	93.866	639
Aging Research	5R21AG043885-02	93.866	198,014
Aging Research	KR01AG034126-05	93.866	157,872
Aging Research	1R01AG047408-01A1	93.866	56,719
Aging Research	1RF1AG047667-01	93.866	356,727
Aging Research	2P50AG025688-11REV	93.866	301,734
Aging Research	3U01AG046161-02S1	93.866	1,534,165
Aging Research	5F31AG048719-02	93.866	39,015
Aging Research	5F32AG041543-04	93.866	26,438
Aging Research	5K01AG042498-04	93.866	111,814
Aging Research	5K23AG042856-03	93.866	166,011
Aging Research	5K99/R00 AG032362	93.866	33,266
Aging Research	5R01AG019206-14	93.866	406,058
Aging Research	5R01AG023695-08	93.866	372,422
Aging Research	5R01AG038746-05	93.866	609,422
Aging Research	5R01AG040013-05	93.866	472,990
Aging Research	5R01AG042127-04	93.866	226,239
Aging Research	5R03AG042831-02	93.866	8,305
Aging Research	5R21AG042730-02	93.866	118,827
Aging Research	5R36AG043646-02	93.866	35,343
Aging Research	7R03AG042336-03	93.866	69,180
Pass-through Barrow Neurological Institute	1032114	93.866	130,629
Pass-through CDIC	1R43AG042237-01	93.866	2,920
Pass-through Columbia University	1(Acct. #5-34005)	93.866	(600)
Pass-through Georgia State University	SP00011273-01	93.866	92,729
Pass-through Georgia State University	SP00011514-01	93.866	9,465
Pass-through Mayo Clinic	5P50AG016574-15	93.866	(1,570)
Pass-through Medical University of South Carolina	MUSC14-075	93.866	3,866
Pass-through Rush University Medical Center	P01AG014449-15.AMD#6	93.866	191
Pass-through Rush University Medical Center	P01AG014449-16	93.866	(11,263)
Pass-through University of Alabama Birmingham	000410331-003	93.866	29,477
Pass-through University of California San Diego	ADC-033-NGF	93.866	6,989
Pass-through University of California San Diego	ADC-040-A4	93.866	55
Pass-through University of California San Diego	ADNI-2	93.866	19,418
Pass-through University of Louisville	051523Z02B	93.866	(345)
Pass-through University of Michigan	1R24AG045061-01A1 RE	93.866	238
Pass-through University of Pennsylvania	10762/00	93.866	46,800
Pass-through University of Pennsylvania	557704	93.866	65,953
Pass-through University of Pennsylvania	563249	93.866	19,378
Pass-through University of Washington	762181, BPO 2094	93.866	91,239
Pass-through University of Washington Seattle	721762	93.866	579
Pass-through Wake Forest University	WFUHS 110918 Hepburn	93.866	5,000
Pass-through Wake Forest University	WFUHS 110918 Neigh	93.866	569
Total CFDA No. 93.866			7,066,569
Vision Research	1F30EY025154-01REV	93.867	20,663
Vision Research	2R01EY004864-30A1	93.867	8,080
Vision Research	2R01EY016435-06A1	93.867	11,173
Vision Research	2T32EY007092-29	93.867	45,634
Vision Research	5K23EY019341-05	93.867	88,006
Vision Research	5K23EY021760-04	93.867	225,078
Vision Research	5R01EY014852-11	93.867	221,194
Vision Research	5R01EY016400-10	93.867	330,818
Vision Research	5R01EY016470-09	93.867	337,479

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Vision Research	5R01EY017841-07	93.867	\$ 387,994
Vision Research	5R01EY021592-03	93.867	318,417
Vision Research	2R01EY004864-32	93.867	457,773
Vision Research	5P30EY006360-25S1	93.867	(51,050)
Vision Research	5P30EY006360-30	93.867	679,852
Vision Research	5R01EY01244008	93.867	1,623
Vision Research	5R01EY012440-13	93.867	255,564
Vision Research	5R01EY014026-10	93.867	600,467
Vision Research	5R01EY016435-05REVIS	93.867	12,953
Vision Research	5R01EY01647004	93.867	(2,354)
Vision Research	5R01EY016997-04	93.867	39
Vision Research	5T32EY007092-28Revis	93.867	98,548
Vision Research	5U10EY013287-09	93.867	(28,214)
Vision Research	5U10EY013287-12REVIS	93.867	423,131
Pass-through Georgia Institute of Technology	R7747-G14	93.867	(5,467)
Pass-through Georgia Institute of Technology	R7747-G15	93.867	83,496
Pass-through Jaeb Center For Health Research	RE-302-S1	93.867	20,140
Pass-through Jaeb Center For Health Research	ATS18	93.867	10,553
Pass-through Jaeb Center For Health Research	EY12358	93.867	386
Pass-through Jaeb Center For Health Research	U10EY14231	93.867	3,034
Pass-through Johns Hopkins University	2000011277	93.867	14,399
Pass-through Johns Hopkins University	2000594943	93.867	48,001
Pass-through Johns Hopkins University	2001619544	93.867	59,654
Pass-through Morehouse School of Medicine	1R01EY022216-12	93.867	12,431
Pass-through Pennsylvania State University	SCORE2	93.867	2,163
Pass-through Rice University	R22564	93.867	40,478
Pass-through Stanford University	23913450-41077-A	93.867	(7,115)
Pass-through University of California San Francisco	8319sc	93.867	14,478
Pass-through University of Colorado	FY14.558.002	93.867	277,001
Pass-through University of Minnesota	S6406153101/SR01EY15	93.867	(2,806)
Pass-through University of Pennsylvania	000001	93.867	2,002
Pass-through University of Pennsylvania	1-U10-EY023530-01/CA	93.867	15,962
Pass-through University of Pennsylvania	553810	93.867	(8,855)
Pass-through University of Pennsylvania	560624	93.867	74,740
Pass-through University Of Texas Medical Branch	12-090AMD2	93.867	18,644
Pass-through Vanderbilt University	VUMC 41809	93.867	155,807
Pass-through Vanderbilt University	VUMC 42824	93.867	17,008
Total CFDA No. 93.867			5,289,002
Medical Library Assistance	5K22LM011576-03	93.879	198,085
Pass-through State University Of New York Stony Brook	67542-116467-2	93.879	31,056
Total CFDA No. 93.879			229,141
Grants for Training in Primary Care Medicine and Dentistry	5 D55HP232050400	93.884	189,549
Grants for Training in Primary Care Medicine and Dentistry	6 D57HP232440203	93.884	30,478
Total CFDA No. 93.884			220,027
Health Care and Other Facilities	7R21HL097226-02	93.887	9,502
Total CFDA No. 93.887			9,502
Alcohol Research Center Grants	5P50AA013757-10REVIS	93.891	102,385
Total CFDA No. 93.891			102,385
HIV Emergency Relief Project Grants			
Pass-through Fulton County	PO118155C98514B-BR-1	93.914	299,399
Total CFDA No. 93.914			299,399
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	6 H76HA07848-08-01	93.918	232,715
Total CFDA No. 93.918			232,715
HIV Demonstration, Research, Public and Professional Education Projects	5U01PS003322-04 REVI	93.941	140,494
HIV Demonstration, Research, Public and Professional Education Projects	5U01PS003322-04REV	93.941	153,056
Total CFDA No. 93.941			293,550
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	5U01DP003894-03	93.946	4,156
Total CFDA No. 93.946			4,156
Block Grants for Prevention and Treatment of Substance Abuse			
Pass-through Georgia Department of Behavioral Health	MSACD 44100-906-0000	93.959	886,738
Total CFDA No. 93.959			886,738
Public Health Traineeships	5A03HP011601500	93.964	(33,780)
Public Health Traineeships	5A03HP01160-16-00	93.964	33,780
Total CFDA No. 93.964			---
Geriatric Education Centers	6 UB4HP19215-05-01	93.969	636,775
Total CFDA No. 93.969			636,775
Family Planning_Service Delivery Improvement Research Grants	5 FPRPA006056-03-00	93.974	137,704
Family Planning_Service Delivery Improvement Research Grants	6FPRPA006056-02-02	93.974	3,054
Total CFDA No. 93.974			140,758
Preventive Health Services_Sexually Transmitted Diseases Research, Demonstrations, and Public Information and Education Grants			
Pass-through Kaiser Foundation Research Health Plan	GR08429-EU-01	93.978	15,257
Total CFDA No. 93.978			15,257
International Research and Research Training	1R21TW009535-01	93.989	162,710
International Research and Research Training	2D43TW007124-11	93.989	66,939
International Research and Research Training	3D43TW005746-10S1	93.989	(259)
International Research and Research Training	3R24TW009545-02S1	93.989	14,064
International Research and Research Training	4R00TW008043-05	93.989	38
International Research and Research Training	5D43TW001042-15REVIS	93.989	169,371
International Research and Research Training	5D43TW007124-10	93.989	63,517
International Research and Research Training	5D43TW009127-03	93.989	113,927
International Research and Research Training	5D43TW009135-04	93.989	306,542
International Research and Research Training	5K01TW009664-03	93.989	122,975
Pass-through Aga Khan University	2D43TW007585	93.989	17,315
Pass-through Vanderbilt University	mVUMC 40185	93.989	75,913
Pass-through Vanderbilt University	VUMC41430	93.989	1,929
Total CFDA No. 93.989			1,114,981

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Maternal and Child Health Services Block Grant to the States			
Pass-through Georgia Department of Human Resources	4279309090557	93.994	\$ (1,942)
Total CFDA No. 93.994			(1,942)
Contract	200-2011-41278	93.RD	511,535
Contract	200-2012-51279	93.RD	111,498
Contract	200-2014-M-59415	93.RD	77,359
Contract	HHSN261201000025C	93.RD	(1,556)
Contract	HHSN261201300015I	93.RD	2,288,854
Contract	HHSN261201300331P	93.RD	10,130
Contract	HHSN268201400169P	93.RD	65,649
Contract	226HHSN272201400004C	93.RD	4,006,688
Contract	HHSN272200800005C	93.RD	872,489
Contract	HHSN272201200031C	93.RD	3,747,855
Contract	HHSN272201300006C	93.RD	2,345,268
Contract	HHSN272201300018	93.RD	299,471
Contract	HHSN272201500008C	93.RD	99,805
Contract	HHSN275201400017C	93.RD	24,664
Contract	N01-AI-25456	93.RD	54,800
Contract	N01DK75004/HHSN26720	93.RD	1,067
Contract	200200200676	93.RD	(1,441)
Contract	200-2008-24753/0001	93.RD	(261,555)
Contract	200-2012-51332	93.RD	222,545
Contract	200-2014-M-58528	93.RD	374,297
Contract	200-2014-M-59732	93.RD	47,342
Contract	200-2014-M-61117	93.RD	84,559
Contract	200-2015-61471Mod1	93.RD	392,260
Contract	HHSH258201300008C	93.RD	47,061
Contract	HHSN272200800005C	93.RD	1,226,466
Contract	HHSN272201300018	93.RD	444,775
Contract	HHSN272201300018I/HH	93.RD	(8,234)
Contract	HHSN272201300018I	93.RD	48,253
Contract	HHSN275201400162P	93.RD	8,876
Contract	HHSN275201400450P	93.RD	8,463
Pass-through Assoc Of Schools Of Public Health	S5033-3/5	93.RD	1,625,979
Pass-through Assoc State Territorial Health Official	83-12312 (#336)	93.RD	45,000
Pass-through Atlanta Research And Education Fdm	AREF M14051	93.RD	234,666
Pass-through Atlanta Research And Education Fdm	SHI1B5	93.RD	25,252
Pass-through Atlanta Research And Education Fdm	40500-036-14130867	93.RD	6,886
Pass-through Benaroya Research Institute At Virginia	FY15ITN125	93.RD	20,521
Pass-through CDC Foundation	FACT	93.RD	14,474
Pass-through Childrens Healthcare of Atlanta	U01CA180886	93.RD	89,469
Pass-through Childrens Healthcare of Atlanta	637000-1216-01	93.RD	44,935
Pass-through Children'S Hospital of Philadelphia	961476-RSUB	93.RD	270
Pass-through Childrens Mercy Hospital	13-0027	93.RD	9,504
Pass-through Cobb County	20-2012	93.RD	5,179
Pass-through Colorado Department of Public Health & Environment	PO# FHLA20150000000	93.RD	22,000
Pass-through Dartmouth College	1272	93.RD	58,051
Pass-through Duke University	MOD.2/NO1A150019	93.RD	25
Pass-through Duke University	201316	93.RD	1,201
Pass-through Feinstein Institute For Medical Research	HHSN-271-2009-00019C	93.RD	13
Pass-through Franklin And Marshall College	CHIMPS GI PARASITES	93.RD	2,997
Pass-through Fred Hutchinson Cancer Research Center	0000828757	93.RD	33,481
Pass-through Frontier Science And Technology Res Fdm	E2408: BVR VS. BR	93.RD	(449)
Pass-through Frontier Science And Technology Res Fdm	ECOG MASTER AGREEMENT	93.RD	489
Pass-through Frontier Science And Technology Res Fdm	PSAWCIEM00	93.RD	(965)
Pass-through Frontier Science And Technology Res Fdm	PSAWCIEM00 E1609	93.RD	(9,440)
Pass-through Georgia Center For Oncology Res And Edu	PSAWIEM00	93.RD	(110)
Pass-through Georgia Department Of Community Health	Master Clinical Res.	93.RD	223
Pass-through Georgia Department Of Community Health	2011056	93.RD	204,832
Pass-through Georgia Department Of Community Health	40500-039-13110288	93.RD	(1,653)
Pass-through Georgia Dept Of Public Health	40500-032-13120764	93.RD	(14)
Pass-through Georgia Institute Of Technology	RB307-S1/AMND4	93.RD	1,562,602
Pass-through Grady Memorial Hospital	S201413	93.RD	65,671
Pass-through H Lee Moffitt Cancer Center And Res Inst	10143989901EMORY1578	93.RD	3,679
Pass-through H Lee Moffitt Cancer Center And Res Inst	10-14398-99-01-EMORY	93.RD	(1,102)
Pass-through H Lee Moffitt Cancer Center And Res Inst	10143989901EMORY1543	93.RD	53,201
Pass-through H Lee Moffitt Cancer Center And Res Inst	10-16385-99-01-01	93.RD	7,592
Pass-through H Lee Moffitt Cancer Center And Res Inst	20-24398-99-01-EMORY	93.RD	10,998
Pass-through H Lee Moffitt Cancer Center And Res Inst	HHSN261200622008C	93.RD	(16)
Pass-through H Lee Moffitt Cancer Center And Res Inst	NCI 8784	93.RD	68
Pass-through Harvard University	70001429247	93.RD	1,800
Pass-through Johns Hopkins University	ABTC0904	93.RD	(18)
Pass-through Johns Hopkins University	W81XWH-09-20108	93.RD	3,149
Pass-through Johns Hopkins University	W8XWH-10-2-0090/METR	93.RD	6,366
Pass-through Kaiser Foundation Research Health Plan	003/200-2012-53583	93.RD	1,863
Pass-through Leidos Biomedical Research	13xs019	93.RD	274,926
Pass-through Leidos Biomedical Research	14X138	93.RD	166,887
Pass-through Leidos Biomedical Research	29XS132 TO25 MOD06	93.RD	423,012
Pass-through Leidos Biomedical Research	29XS132T024MOD 07	93.RD	292,446
Pass-through Leidos Biomedical Research	29XS132T08MOD12	93.RD	400,547
Pass-through Leidos Biomedical Research	13XS066STO2	93.RD	2,861
Pass-through Leidos Biomedical Research	15X071	93.RD	6,617
Pass-through Massachusetts General Hospital	Subaward # 225183	93.RD	37,429
Pass-through Massachusetts General Hospital	HHSF232201400115C	93.RD	7,739
Pass-through Massachusetts General Hospital	RAPID	93.RD	79,565
Pass-through Massachusetts General Hospital	Subcontract # 225532	93.RD	13,879

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
Pass-through Minneapolis Medical Research Foundation	HSH250201000018C	93.RD S	14,525
Pass-through Morehouse School of Medicine	HHSN272200700031C	93.RD	7,611
Pass-through Morehouse School of Medicine	HHSN272200700031C	93.RD	9,860
Pass-through Natl Initiative For Children'S Healthcar	WISCH Project	93.RD	(4,974)
Pass-through Natl Jewish Medical And Research Center	ATOPIC DERMATTITIS	93.RD	297,869
Pass-through Natl Marrow Donor Program	BMT CTN 0801	93.RD	1,422
Pass-through Natl Marrow Donor Program	RIDER0402/PO14829	93.RD	(420)
Pass-through New England Research Institutes	HHSN268201200001I	93.RD	6,137
Pass-through Office of The Child Advocate	CDC/OCA	93.RD	(2,974)
Pass-through Organization of Teratology Information Services	Mother To Baby	93.RD	41,287
Pass-through Pennsylvania State University	EMU 109086	93.RD	5,526
Pass-through Research Services	200-2013-57341	93.RD	17,578
Pass-through Research Support Services Inc	200-2013-57341ORDER2	93.RD	27,338
Pass-through Research Triangle Institute	HD036790	93.RD	457,027
Pass-through Saic Frederick	11st1030	93.RD	(42,086)
Pass-through Saic Frederick	13xs019	93.RD	(122)
Pass-through Scripps Research Institute	552291	93.RD	151,495
Pass-through Sloan Kettering Institute	PO#BD517193	93.RD	9,810
Pass-through St Luke Roosevelt Hospital Center	OMG	93.RD	881
Pass-through Tennessee Technological University	BL55436275	93.RD	5,264
Pass-through Univ of Texas Health Sciences Ctr	157061	93.RD	156,000
Pass-through University of Alabama Birmingham	000406291-010	93.RD	(15,885)
Pass-through University of Alabama Birmingham	000500918-010/HHSN2	93.RD	13,201
Pass-through University of Alabama Birmingham	000406291-010	93.RD	28,926
Pass-through University of Alabama Birmingham	41610	93.RD	2,668
Pass-through University of California San Francisco	1009001 N01-AI-15416	93.RD	(58,360)
Pass-through University of California San Francisco	106731/N01-AI-15416	93.RD	(7,653)
Pass-through University of California San Francisco	109041 N01-AI-15416	93.RD	4,427
Pass-through University of California San Francisco	3123SCAMEND9/N01AI15	93.RD	(4,095)
Pass-through University of California San Francisco	556XXX-26226	93.RD	(162,332)
Pass-through University of California San Francisco	ITN1000700SC/N01AI15	93.RD	(749,871)
Pass-through University of California San Francisco	N01-AI-15416	93.RD	47,276
Pass-through University of Florida	UF13119	93.RD	(3,049)
Pass-through University of Florida	UFDSP00010272	93.RD	49,130
Pass-through University of Florida	UFDSP00010040	93.RD	46,067
Pass-through University of Michigan	3002784115 /HHSN268201100026C	93.RD	16,276
Pass-through University of Pennsylvania	2941655	93.RD	4,381
Pass-through University of Pittsburgh	0024031-1	93.RD	15,491
Pass-through University of South Florida	Oral Insulin--TrialN	93.RD	435
Pass-through University of South Florida	TrialNet Clinic Agmt	93.RD	78,276
Pass-through University of Texas Southwestern	GMO 120703	93.RD	47,145
Pass-through University of Texas Southwestern	GMO601018/N01HB07159	93.RD	38,367
Pass-through University of Washington Saint Louis	WU-14-179/PO2923076X	93.RD	36,929
Pass-through University of Wisconsin-Madison	603K691	93.RD	16,390
Pass-through Utah State University	10069005	93.RD	206,033
Pass-through Vanderbilt University	VUMC 40512	93.RD	1,238
Pass-through Wake Forest University	WFUHS330216/330218	93.RD	217,477
Pass-through Washington University	WU-11-159-MOD-3	93.RD	(83,283)
Pass-through Weill Cornell Medical College	9040431	93.RD	465,774
Total CFDA No. 93.RD			<u>24,414,253</u>
U.S. Department of Health and Human Services Total			<u>338,319,651</u>
U.S. Agency for International Development:			
USAID Foreign Assistance for Programs Overseas	AID-OAA-F-13-00083	98.001	103,977
Pass-through Colorado State University	G9650-19-Amend 4	98.001	123,640
Pass-through Colorado State University	G-9650-3	98.001	(172)
Pass-through University Of California San Diego	45032328	98.001	48,617
Pass-through University Of Reading	Scaling up climate svc	98.001	24,383
Pass-through University Research Corporation	FY 14-G08-6990	98.001	116,246
Pass-through International Aids Vaccine Initiative	1934	98.001	334,973
Pass-through International Aids Vaccine Initiative	Annual sow 1929	98.001	426,653
Pass-through International Aids Vaccine Initiative	Annual sow 2166	98.001	786,436
Pass-through International Aids Vaccine Initiative	Annual sow 2175	98.001	694,070
Pass-through International Aids Vaccine Initiative	Annual sow 2176	98.001	863,458
Pass-through International Aids Vaccine Initiative	IAVI Atlanta 2010	98.001	19
Pass-through International Aids Vaccine Initiative	IAVI Rwanda 2014	98.001	171,921
Total CFDA No. 98.001			<u>3,694,221</u>
U.S. Agency for International Development Total			<u>3,694,221</u>
Total Research and Development Cluster			<u>368,247,073</u>

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
U.S. Department of Defense:			
Basic and Applied Scientific Research			
Pass-through National Marrow Donor Program	AGREE #12693/18027	12.300	\$ 695,740
Total CFDA No. 12.300			<u>695,740</u>
Military Medical Research and Development			
Pass-through Geneva Foundation	W81XWH-15-1-0154	12.420	16,673
Pass-through Joan and Sanford J Weill Medical College	S-1313-01-MOD 4	12.420	31,402
Pass-through University Of California San Francisco	09010049-11081437	12.420	5,450
Pass-through University Of Cincinnati	8599sc	12.420	13,170
Total CFDA No. 12.420	007108	12.420	<u>68</u>
Total CFDA No. 12.420			<u>66,763</u>
Uniformed Services University Medical Research Projects			
Pass-through Duke University	3837309	12.750	911,004
Pass-through Henry M Jackson Foundation	2407/795400	12.750	322,372
Pass-through Henry M Jackson Foundation	2490 – PO# 825668	12.750	60,867
Pass-through Henry M Jackson Foundation	PO830097 – 2604	12.750	288,945
Total CFDA No. 12.750			<u>1,583,188</u>
U.S. Department of Defense Total			<u>2,345,691</u>
U.S. Department of State:			
Academic Exchange Programs – Humphrey Fellowship Program			
Pass-through Institute of International Education	2013-2014	19.010	(36)
Pass-through Institute of International Education	S-ECAGD-14-CA-1037	19.010	27,494
U.S. Department of State Total			<u>27,458</u>
National Endowment for The Humanities:			
Promotion of the Humanities_Division of Preservation and Access			
Total CFDA No. 45.149	PT-50202-11	45.149	52,808
Total CFDA No. 45.149			<u>52,808</u>
Promotion of the Humanities_Professional Development			
Promotion of the Humanities_Professional Development	EH-50395-13	45.163	19,845
Promotion of the Humanities_Professional Development	FV-50359-13	45.163	1,208
Total CFDA No. 45.163			<u>21,053</u>
Museums for America			
Pass-through Institute of Museum and Library Services	RE-01-07-0009-07	45.301	(7,446)
Total CFDA No. 45.301			<u>(7,446)</u>
National Endowment for The Humanities Total			<u>66,415</u>
National Science Foundation:			
Mathematical and Physical Sciences			
Pass-through Georgia Institute of Technology	RB011-G8, AMND 4	47.049	34,889
Pass-through University Of California Los Angeles	0757 G RA022	47.049	209,323
Total CFDA No. 47.049			<u>244,212</u>
Biological Sciences			
Pass-through Longwood University	DBI-1346549	47.074	45,148
Pass-through Longwood University	215001-03	47.074	13,930
Total CFDA No. 47.074			<u>59,078</u>
Social, Behavioral, and Economic Sciences			
Pass-through Rutgers University	5341	47.075	42,913
Total CFDA No. 47.075			<u>42,913</u>
National Science Foundation Total			<u>346,203</u>
U.S. Department of Education:			
Special Education – State Personnel Development			
Pass-through Metropolitan Regional Educational Service	MRESA Teacher Prep	84.323	2,549
Total CFDA No. 84.323			<u>2,549</u>
U.S. Department of Education Total			<u>2,549</u>
National Archives and Records Administration:			
National Historical Publications and Records Grants			
Total CFDA No. 89.003	NAR13-RH-50063-13	89.003	37,806
Total CFDA No. 89.003			<u>37,806</u>
National Archives and Records Administration Total			<u>37,806</u>
U.S. Department of Health and Human Services:			
Global AIDS			
Global AIDS	3U2GPS001904-05S1	93.067	229,010
Global AIDS	5U2GPS001839-05REV	93.067	320,223
Total CFDA No. 93.067			<u>549,233</u>
Birth Defects and Developmental Disabilities – Prevention and Surveillance			
Birth Defects and Developmental Disabilities – Prevention and Surveillance	5U50DD001027-03	93.073	2,410
Birth Defects and Developmental Disabilities – Prevention and Surveillance	5U50DD001027-03REV1S	93.073	486,575
Total CFDA No. 93.073			<u>488,985</u>
Prevention of Disease, Disability, and Death by Infectious Diseases			
Prevention of Disease, Disability, and Death by Infectious Diseases	5U38PS004646-02	93.084	637,095
Total CFDA No. 93.084			<u>637,095</u>
Maternal and Child Health Federal Consolidated Programs			
Pass-through Amer Thrombosis and Hemostasis Network	5 H46MC24090-03-00	93.110	461,769
Pass-through Hemophilia Of Georgia	NHPCC-1-01	93.110	40,590
Pass-through Hemophilia Of Georgia	5 H30 MC 24046-03-00	93.110	52,500
Total CFDA No. 93.110			<u>554,859</u>
Project Grants and Cooperative Agreements for Tuberculosis Control Programs			
Pass-through Georgia Dept Of Public Health	40500-046-14100210	93.116	20,760
Total CFDA No. 93.116			<u>20,760</u>
Community Programs to Improve Minority Health Grant Program			
Pass-through Amer College of Rheumatology	1CPIMP141065-01-00	93.137	35,356
Pass-through Lupus Research Institute	1CPIMP141065-01-00	93.137	2,088
Total CFDA No. 93.137			<u>37,444</u>



**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number or other I.D. number	Federal expenditures
AIDS Education and Training Centers Pass-through Addis Ababa University	T84HA21124-02-00	93.145	\$ 17,922
Total CFDA No. 93.145			<u>17,922</u>
Health Program for Toxic Substances and Disease Registry Pass-through Amer Academy of Pediatrics	771100-EUSM	93.161	79,682
Pass-through Assoc of Occupational and Env Clinics	1U61TS000118	93.161	21,400
Total CFDA No. 93.161			<u>101,082</u>
Disabilities Prevention Pass-through Georgia State University	SP00011716-01	93.184	117,960
Pass-through Hemophilia of Georgia	2U27DD000862-04	93.184	38,250
Total CFDA No. 93.184			<u>156,210</u>
Substance Abuse and Mental Health Services, Projects of Regional and National Significance Pass-through Childrens Healthcare of Atlanta	1U79SM061214-01	93.243	39,642
Pass-through Highland Rivers Community Service Board	1H79SM061070-01	93.243	37,549
Total CFDA No. 93.243			<u>77,191</u>
Rapid Expansion of Antiretroviral Therapy Programs for HIV-Infected Persons in Selected Countries in Africa and the Caribbean Under the President's Emergency Plan for AIDS Relief Pass-through Addis Ababa University	T84HA21124-05-00	93.266	76,119
Total CFDA No. 93.266			<u>76,119</u>
Centers for Disease Control and Prevention, Investigations and Technical Assistance Centers for Disease Control and Prevention, Investigations and Technical Assistance	5U01DP005119-02	93.283	908,959
Centers for Disease Control and Prevention, Investigations and Technical Assistance	5U38HK00001503	93.283	12,964
Centers for Disease Control and Prevention, Investigations and Technical Assistance	5U50DD00002902	93.283	24
Pass-through Amer Thrombosis And Hemostasis Network	ATHN2011002-HTC6-3	93.283	7,175
Pass-through Assoc. of American Medical Colleges	MM-1148-10/10	93.283	426
Pass-through Atlanta Research And Education Fdm	AREF MOU M15006	93.283	84,580
Pass-through Atlanta Research And Education Fdm	M15007	93.283	325,027
Pass-through Georgia Center For Oncology Res and Edu	1U58DP003794-01	93.283	5,481
Pass-through Georgia Department of Human Resources	427930808115399	93.283	(901)
Pass-through Georgia Dept Of Public Health	40500-036-14100293	93.283	54,960
Pass-through Morehouse School Of Medicine	U01CT000312	93.283	845
Pass-through Olive View UCLA Medical Center	11-03	93.283	(4,928)
Total CFDA No. 93.283			<u>1,394,612</u>
National State Based Tobacco Control Programs Pass-through Kansas Department of Health & Environment	DP15-1509	93.305	16,571
Total CFDA No. 93.305			<u>16,571</u>
Mobilization for Health: National Prevention Partnership Awards Pass-through Center for Black Women's Wellness	PAWOS000020-01-00	93.311	39,841
Total CFDA No. 93.311			<u>39,841</u>
Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Se	1U19GH001583-01	93.318	289,346
Total CFDA No. 93.318			<u>289,346</u>
Cancer Centers Support Grants	5P50CA128613-05REVIS	93.397	(30,865)
Total CFDA No. 93.397			<u>(30,865)</u>
Cancer Control Pass-through University Of Medicine And Dentistry Of New Jersey	8006 - P0768511	93.399	45,150
Total CFDA No. 93.399			<u>45,150</u>
NON-ACA/PPHF—Building Capacity of the Public Health System to Improve Population Health through National Nonprofit Organizations Pass-through Assoc State Territorial Health Official	63-10722REQUISITION	93.424	205,775
Total CFDA No. 93.424			<u>205,775</u>
PPHF: State Nutrition, Physical Activity, and Obesity Programs – financed in part by PPHF Pass-through South Dakota Department of Health	15SC090715	93.548	21,841
Total CFDA No. 93.548			<u>21,841</u>
Children's Justice Grants to States Pass-through Georgia Department of Human Services	42700-040-0000029413	93.643	96,906
Total CFDA No. 93.643			<u>96,906</u>
Child Abuse and Neglect State Grants Pass-through Georgia Department of Human Services	427-040C-R1458056625	93.669	65,332
Total CFDA No. 93.669			<u>65,332</u>
Prevention Public Health Fund: Viral Hepatitis Prevention	1U51PS003909-01REV	93.736	68,969
Total CFDA No. 93.736			<u>68,969</u>
Medical Assistance Program Pass-through Georgia Department of Behavioral Health	44100-906-0000062709	93.778	117,133
Total CFDA No. 93.778			<u>117,133</u>
Preventive Health and Health Services Block Grant Pass-through Michigan Department of Public Health	National Diabetes Pr	93.911	7,558
Total CFDA No. 93.911			<u>7,558</u>
HIV Emergency Relief Project Grants Pass-through Fulton County	PO11814SC94085B-TR/V	93.914	394,783
Total CFDA No. 93.914			<u>394,783</u>
HIV Care Formula Grants Pass-through Fulton County	PO11811SC79205BTR1-1	93.917	(21,422)
Pass-through Fulton County	PO11813SC89167B-BR	93.917	(3,478)
Total CFDA No. 93.917			<u>(24,900)</u>

**EMORY UNIVERSITY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended August 31, 2015

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>Federal CFDA number or other I.D. number</u>	<u>Federal expenditures</u>
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	4H76HA078480901	93.918	\$ 384,994
Total CFDA No. 93.918			<u>384,994</u>
Assistance Programs for Chronic Disease Prevention and Control			
Pass-through Tennessee Department of Health	34352-06215	93.945	11,949
Total CFDA No. 93.945			<u>11,949</u>
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	5 U01 DP003894-04	93.946	202,956
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	5U01DP003894-03	93.946	312,165
Total CFDA No. 93.946			<u>515,121</u>
Preventive Health Services_Sexually Transmitted Diseases Control Grants	5 H25PS004311-02REV	93.977	159,579
Total CFDA No. 93.977			<u>159,579</u>
U.S. Department of Health And Human Services Total			<u>6,496,595</u>
Corporation for National and Community Service:			
AmeriCorps			
Pass-through Jumpstart	CFDA-94.006-JS-SITE	94.006	(3,198)
Corporation for National and Community Service Total			<u>(3,198)</u>
Total Expenditures of Federal Awards			<u>\$ 521,972,805</u>

See accompanying notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards.

**SCHEDULE OF CASH RECEIPTS AND EXPENDITURES OF  
STATE OF GEORGIA AWARDS**

**EMORY UNIVERSITY**

Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards  
Year ended August 31, 2015

State of Georgia contract number	State of Georgia Agency	Program title	Cash receipts	Expenditures
427930909042699	GEORGIA DEPARTMENT OF HUMAN RESOURCES	FETAL ALCOHOL AND DRUG SCREENING PROJECT: MATERNAL SUBS	\$ —	(44,240)
427930808115399	GEORGIA DEPARTMENT OF HUMAN RESOURCES	THE GEORGIA LUPUS REGISTRY	—	(901)
4279309090557	GEORGIA DEPARTMENT OF HUMAN RESOURCES	DHR CONTRACT FOR EMORY CYSTIC FIBROSIS CENTER	—	(1,942)
41900-036-10100072	GEORGIA DEPARTMENT OF COMMUNITY HEALTH		77,295	(16,996)
MSACD 44100-906-0000	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH		541,738	872,428
42700-040-0000004749	GEORGIA DEPARTMENT OF HUMAN RESOURCES	Summer Child Advocacy Program	—	48
40500-036-13110270	GEORGIA DEPARTMENT OF COMMUNITY HEALTH		—	(510)
2011056	GEORGIA DEPARTMENT OF COMMUNITY HEALTH		197,486	204,832
0240500-032-13120764	GEORGIA DEPT OF PUBLIC HEALTH	CRC Program Evaluation	38,147	(14)
40500-039-13110288	GEORGIA DEPARTMENT OF COMMUNITY HEALTH	FOLLOW-UP OF NEWBORNS WITH SCREEN POSITIVE RESULTS FOR METABOLIC AND ENDOCRINE DIS	56,638	(1,653)
MRESA Teacher Prep	METROPOLITAN REGIONAL EDUCATIONAL SERVIC	Collaboration on Teacher Preparation Between Walden Early Childhood Center and Ge	13,108	2,549
427-040C-R1458056625	GEORGIA DEPARTMENT OF HUMAN SERVICES	External Review – Div of Family and Children Services, GA DHS	71,026	65,332
40500-046-14100210	GEORGIA DEPT OF PUBLIC HEALTH	GEORGIA DEPARTMENT OF COMMUNITY HEALTH – BLUMBURG	53,921	20,760
42700-040-0000029413	GEORGIA DEPARTMENT OF HUMAN SERVICES	2015 Summer Child Advocacy Program	25,941	96,906
40500-036-14100293	GEORGIA DEPT OF PUBLIC HEALTH	GEORGIA COVERDELL ACUTE STROKE REGISTRY	56,577	54,960
40500-036-15110270	GEORGIA DEPT OF PUBLIC HEALTH	Federal Funds – Proj 1 – Operation of the Statewide	472,206	567,874
44100-907-0000056259	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	Fetal Alcohol Clinic: Emory Neurodevelopment Exposure Clinic – NonFederal (State)	285,002	298,124
42700-373-0000034541	GEORGIA DEPARTMENT OF HUMAN SERVICES	Cross Training DAS	17,500	24,924
44100-906-0000062709	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	Improving Community-Based Infrastructure	—	117,133
4050004615151505	GEORGIA DEPT OF PUBLIC HEALTH	2015 – Contract #40500-046-15151505	26,960	23,574
			<u>\$ 1,933,546</u>	<u>2,283,188</u>

See accompanying notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards.

**EMORY UNIVERSITY**

Notes to Supplementary Schedules of Expenditures of Federal Awards and  
Cash Receipts and Expenditures of State of Georgia Awards

August 31, 2015

**(1) Summary of Significant Accounting Policies**

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Emory University (the University) and is presented on the accrual basis of accounting. The information in the Schedule is presented in accordance with the requirements of OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Therefore, some amounts presented in the Schedule may differ from amounts presented in, or used in the preparation of, the consolidated financial statements.

The accompanying schedule of cash receipts and expenditures of State of Georgia awards includes expenditures incurred (i.e., on an accrual basis) by the University and grant revenues received from State of Georgia agencies under various state contracts.

Negative balances represent programs with unfunded expenditures prior to normal closeout procedures, which were subsequently transferred to unrestricted cost centers.

**(2) Pass-Through Funding**

The University passes through certain federal awards to subrecipient organizations. Such subrecipients are responsible for compliance with the applicable provisions of the grants and contracts governing the underlying federal awards. Federal awards passed through to subrecipients by the University during 2015 are as follows:

<u>Federal program</u>	<u>Number</u>	<u>Amount</u>
Research and Development Cluster	Various	\$ 52,550,944

**(3) Noncash Federal Assistance**

Most federal financial assistance is in the form of cash awards. However, there are a number of federal programs that do not involve cash transactions with the University. These noncash transactions in which the University obtains other assistance are the Federal Direct Student Loan Program (FDSLPL) and revolving loan programs, such as the Federal Perkins Loan Program.

**EMORY UNIVERSITY**

Notes to Supplementary Schedules of Expenditures of Federal Awards and  
Cash Receipts and Expenditures of State of Georgia Awards

August 31, 2015

The loans advanced and related expenditures are as follows for the various student loan programs:

	<b>CFDA number</b>	<b>Amount</b>
Federal Direct Student Loan Programs:		
Student loans advanced:	84.268	
Subsidized Stafford Loan Program		\$ 9,794,286
Unsubsidized Stafford Loan Program		73,193,979
Total Direct Stafford Loan Program		82,988,265
Federal Direct PLUS Loan Program		34,859,953
Total Direct Student Loan Programs		\$ 117,848,218
Federal Perkins Loan Program	84.038	\$ 3,329,531

The Federal Perkins Loan Program is administered directly by the University and balances and transactions relating to this program are included in the University’s consolidated financial statements. Federal Perkins loans outstanding at August 31, 2015 totaled approximately \$13,580,371.

The University is responsible for the performance of certain administrative duties with respect to the FDSLPLP loan program. It is not practicable to determine the balance of loans outstanding to students and former students of the University under this program as of August 31, 2015. These loans are not included in the University’s consolidated financial statements.

**(4) Matching**

Under the Federal Supplemental Educational Opportunity Grant (FSEOG) program, the University matched \$197,969 in funds awarded to students for the year ended August 31, 2015 in addition to the federal share of expenditures included in the Schedule.

Under the Federal Work Study (FWS) program, the University matched \$495,713 in total compensation to students for the year ended August 31, 2015 in addition to the federal share of expenditures included in the Schedule.

**OMB CIRCULAR A-133 REPORTS**



**KPMG LLP**  
Suite 2000  
303 Peachtree Street, N.E.  
Atlanta, GA 30308-3210

**Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards***

The Board of Trustees  
Emory University:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Emory University and subsidiaries (Emory University), which comprise the consolidated statement of financial position as of August 31, 2015, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated December 18, 2015.

**Internal Control Over Financial Reporting**

In planning and performing our audit of the consolidated financial statements, we considered Emory University's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of Emory University's internal control. Accordingly, we do not express an opinion on the effectiveness of Emory University's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.





### **Compliance and Other Matters**

As part of obtaining reasonable assurance about whether Emory University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

### **Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Emory University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Emory University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

**KPMG LLP**

December 18, 2015



KPMG LLP  
Suite 2000  
303 Peachtree Street, N.E.  
Atlanta, GA 30308-3210

## **Independent Auditors' Report on Compliance for Each Major Program; Report on Internal Control Over Compliance; and Report on Schedules of Expenditures of Federal Awards Required by OMB Circular A-133**

Board of Trustees  
Emory University:

### **Report on Compliance for Each Major Federal Program**

We have audited Emory University's compliance with the types of compliance requirements described in the *OMB Circular A-133 Compliance Supplement* that could have a direct and material effect on each of Emory University's major federal programs for the year ended August 31, 2015. Emory University's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

#### ***Management Responsibility***

Management is responsible for compliance with the requirements of laws, regulations, contracts, and grants applicable to its federal programs.

#### ***Auditors' Responsibility***

Our responsibility is to express an opinion on compliance for each of Emory University's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Those standards and OMB Circular A-133 require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Emory University's compliance with those requirements and performing such other procedures as we consider necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of Emory University's compliance.

#### ***Opinion on Each Major Federal Program***

In our opinion, Emory University complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended August 31, 2015.

### **Report on Internal Control Over Compliance**

Management of Emory University is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing



our audit of compliance, we considered Emory University's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with OMB Circular A-133, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Emory University's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of OMB Circular A-133. Accordingly, this report is not suitable for any other purpose.

#### **Report on Schedule of Expenditures of Federal Awards Required by OMB Circular A-133 and the Schedule of Cash Receipts and Expenditures of State of Georgia Awards**

We have audited the consolidated financial statements of Emory University as of and for the year ended August 31, 2015, and have issued our report thereon dated December 18, 2015, which contained an unmodified opinion on those consolidated financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards and schedule of cash receipts and expenditures of State of Georgia awards are presented for purposes of additional analysis as required by OMB Circular A-133 and the State of Georgia, respectively, and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards and the schedule of cash receipts and expenditures of State of Georgia awards are fairly stated in all material respects in relation to the consolidated financial statements as a whole.

**KPMG LLP**

February 29, 2016

**EMORY UNIVERSITY**

Schedule of Findings and Questioned Costs

August 31, 2015

**(1) Summary of Auditors' Results**

- (a) The type of report issued on the consolidated financial statements: **Unmodified opinion**
- (b) Significant deficiencies in internal control were disclosed by the audit of the Financial Statements: **None reported** Material weaknesses: **No**
- (c) Noncompliance which is material to the financial statements: **No**
- (d) Significant deficiencies in internal control over major programs: **None reported** Material weaknesses: **No**
- (e) The type of report issued on compliance for major programs: **Unmodified opinion**
- (f) Any audit findings which are required to be reported under Section 0.510(a) of OMB Circular A-133: **None reported**
- (g) Major programs: Student Financial Assistance Cluster (various CFDA numbers); Research and Development Cluster (various CFDA numbers)
- (h) Dollar threshold used to distinguish between Type A and Type B programs: **\$3,000,000**
- (i) Auditee qualified as a low-risk auditee under Section 0.530 of OMB Circular A-133: **Yes**

**(2) Findings Relating to the Consolidated Financial Statements Reported in Accordance with *Government Auditing Standards***

There were no findings relating to the consolidated financial statements for the year ended August 31, 2015.

**(3) Findings and Questioned Costs Relating to Federal Awards**

There were no findings relating to the federal awards for the year ended August 31, 2015.